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Summary
In the past 30 years the prevalence of obesity has almost trebled resulting in an 
increased incidence of type 2 diabetes mellitus (T2DM) and other co-morbidities. 
Visceral adipose tissue is believed to play a vital role in these conditions, but underlying 
mechanisms remain unclear. A close association exists between obesity, diabetes and 
oxidative stress, resulting in increased reactive oxygen species formation.
The experiments in this thesis address this by searching for possible biochemical 
changes which may be specific for the onset of obesity related T2DM, as well as looking 
for genetic alterations at molecular and gene expression levels. This thesis also 
explored various techniques such as polymerase chain reaction (PCR), colorimetric 
assays and real-time RT-PCR. The aim was to investigate the role of adipose tissue in 
obesity and T2DM, focusing on markers of oxidative stress and gene expression in 
human visceral adipose tissue from subjects categorised as lean, obese and obese with 
T2DM. This cross-sectional study measured two markers of oxidative stress, two 
markers of DNA damage, gene expression analysis and identification of genes 
associated with T2DM and obesity. Specific gene sequencing was carried out on the 
glutathione reductase gene to determine possible gene variants.
Results showed a paradoxical decrease in adipose markers of oxidative stress in 
subjects with obesity and T2DM. There appeared to be a protective mechanism in these 
subjects, displaying reduced levels of oxidative stress compared to other groups. This 
could be due to a significant proportion of these subjects being on ACE inhibitor and 
statin therapy, which may be confounding results and minimising the effects of the 
oxidative burden. Additionally, the same subjects showed an increased expression 
of the glutathione reductase gene. It is difficult to conclude if the decreased levels of 
oxidative stress in these subjects were a result of the increased glutathione reductase 
expression in the visceral adipose tissue or if there remains an unseen factor 
influencing the dramatic expression change seen in this group of subjects. No 
glutathione reductase gene variants were identified in these samples.
This analysis highlighted that within this sample set, the impact of oxidative stress is 
in fact reversible as the antioxidant capacity in these subjects is evident, and in 
combination with correct drug therapy it may be possible to combat oxidative 
burden and reduce the subsequent damage inflicted upon the cells.
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CHAPTER ONE 
GENERAL INTRODUCTION
l
Type 2 diabetes (T2DM) and obesity are very common chronic inflammatory 
conditions. Whilst obesity is associated with T2DM, not all obese subjects develop 
diabetes. Susceptibility to T2DM is likely to be the result of combined genetic and 
environmental factors and it is probable that gene-environment interactions play a 
major influence in the progression from simple obesity to obesity with glucose 
dysregulation. This is supported by the observation that groups of similar genetic 
backgrounds exposed to particular environments have an increase in the prevalence 
of T2DM. This may explain why lifestyle intervention alone may not help a 
proportion of these high-risk subjects. Impaired glucose regulation is not universal 
amongst those with obesity. Possible reasons for this include differing proportions 
of visceral fat, and levels of adipokines and inflammatory markers (implicated in 
insulin resistance) which may influence (3-cell function. This thesis will discuss the 
pro-inflammatory and pro-oxidant phenotype associated with morbid obesity and 
examine its contribution to the risk of T2DM.
1.1 Oxidative stress
Oxidative stress is free radical-mediated damage caused by reactive oxygen species 
(ROS) (Stephens et al, 2006). ROS are molecules that have one or more unpaired 
electrons within the outer shell of their structure thus making them highly reactive 
(Turrens, 2003). Oxidative stress occurs as a result of an overproduction of ROS, and 
even though they are produced naturally, their overproduction combined with an 
insufficient antioxidant defence, can have severe pathological consequences such as 
the onset of coronary heart disease (CHD), diabetes and cancer (Flekac et al, 2008;
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Stephens et al, 2009). Excessive levels of ROS have the ability to cause oxidative 
DNA damage (Salpea et al, 2009) and alter both a molecule's function and structure 
causing damage to tissue and resulting in overall dysfunction (Zalba et al, 2006). 
This overproduction can be further intensified by the addition of exogenous sources 
of ROS such as those found in cigarette smoke, which is a major risk factor involved 
in the onset of CHD (Stephens et al, 2008).
1.1.1 Pro-oxidants
There are different species of ROS, which arise from different sources and each 
having their individual effects within a cell. Table 1.2 gives examples of the main 
pro-oxidants. The effects of free radicals on macromolecules are controlled by a 
range of different endogenous and exogenous enzymatic and non-enzymatic 
antioxidant systems (Maritim et al, 2003).
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Table 1.1 Examples of oxidising agents
Radical Name Comments
*o 2- Superoxide anion Formed via the reduction of 0 2 during oxidative 
phosphorylation by the electron transport chain. 
Undergoes dismutation forming H20 2 or results in 
*OH formation via enzymatic catalysis
h 2o 2 Hydrogen peroxide Formed by the reduction of 0 2 or by dismutation of 
*0 2-. Soluble in lipids and able to diffuse across 
membranes
‘OH Hydroxyl radical Formed during peroxynitrite decomposition and the 
Fenton reaction. Damages most cellular components 
due to its highly reactive state
ROOH Organic
hydroperoxide
Formed via radical reactions with cellular 
components such as lipids and nucleobases
r o V r o o * Alkoxy/Peroxy
radicals
Formed via radical addition to double bonds or 
hydrogen abstraction in the presence of oxygen. 
Plays a role in lipid peroxidation
HOCI Hypochlorous acid Formed from H20 2by myeloperoxidase. Soluble in 
lipids and able to oxidise protein components such 
as amino groups, thiol groups and methionine due to 
its highly reactive state
ONOO' Peroxynitrite Formed via reactions between *0 2- and NO*. Soluble 
in lipids and highly reactive. Forms hydroxyl radicals 
and nitrogen dioxide via homolytic cleavage
1.1.2 Antioxidants
Endogenous anti-oxidative enzymes limit the burden of ROS by scavenging 
excessive oxidants (Lee and Choi, 2006). However, in diseases such as T2DM these 
scavenger enzymes are less effective as their defensive role is hampered by 
excessive oxidative stress (Flekac et al, 2008). Polymorphisms or genetic variations, 
which are single base DNA changes within a population, in antioxidant genes can
predispose to increased levels of oxidative stress, as a result of diminished enzyme 
activity, ultimately resulting in diabetes (Chistyakov et al, 2001). Also, exogenous 
antioxidants, such as dietary vitamin E have been found to play an anti-oxidant role 
and can decrease ROS levels; however these may have little effect if there is an 
excessive level of oxidative stress (Farbstein et al, 2013). The maintenance of a 
healthy level of cellular ROS plays an important role in endothelial health and 
availability of nitric oxide (NO), which itself is a pro-oxidant but also acts as an 
important cellular signalling molecule. It has been reported that oxidative stress 
induced endothelial dysfunction is associated with ageing and cardiovascular 
disease (CVD) (Sturgeon et al, 2010).
Different antioxidant systems are responsible for the maintenance of different 
oxidant levels. For example, H20 2 is formed during normal cell metabolism and is 
responsible for the generation of hydroxyl radicals resulting in cellular damage such 
as lipid peroxidation, protein oxidation and DNA damage and mutation (Diaz-Llera 
et al, 2000). The glutathione antioxidant system is responsible for the reduction of 
cellular H20 2 to oxygen and water (Sturgeon et al, 2010). In the case of this 
antioxidant system failing to maintain H20 2 levels then lipid peroxidation may be 
initiated.
1.1.3 Lipid peroxidation
Lipid peroxidation is the process in which lipids are degraded in environments of 
high oxidative burden. During this cellular process electrons are 'stolen' from lipids
by free radicals, particularly in cell membranes, resulting in cellular damage. 
Polyunsaturated fatty acids are more susceptable to lipid peroxidation due to their 
higher carbon double bond content. There are three stages that make up the lipid 
peroxidation process: initiation, propagation and termination. During the initiation 
stage, ROS such as hydroxyl fO H ) and hydroperoxyl (H 02) radicals, combine with 
hydrogen (H2) to produce water and fatty acid radicals. These radicals are highly 
unstable and react with oxygen producing a peroxyl fatty acid radical in the 
propagation stage of lipid peroxidation. The peroxyl fatty acid radical is an unstable 
molecule that in turn produces further fatty acid radicals and lipid peroxides. These 
radical reactions continue producing new fatty acid radicals each time. Termination 
occurs when a radical reacts with another radical producing a non-radical species. 
For this to occur there must be a high enough concentration of radicals to make the 
probability of two colliding more likely. As previously described (section 1.1.2) these 
radicals are 'scavenged' by antioxidant agents in order to terminate lipid 
peroxidation and therefore preserve the cellular membrane. Products of lipid 
peroxidation are considered important markers of oxidative damage in diabetes 
(Lyons, 1991; Armstrong and al-Awadi, 1991; Kakkar et al, 1995). Previous studies 
have found a decrease in antioxidant levels and an increase in lipid peroxidation 
products, such as F2-isoprostanes in patients with diabetes (Baynes, 1991; Gopaul et 
al, 1995; Patrono and Fitzgerald, 1997). F2-isoprostanes are an example of widely 
used plasma markers of oxidative stress. A clear association between oxidative 
stress and T2DM has been shown by measuring elevated levels of lipid peroxidation 
products (Griesmacher et al, 1995). Lipid peroxidation can be promoted by a
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combination of increased oxidative stress and decreased antioxidant levels or 
efficiencies (Manfredini et al, 2010). Furthermore, increased ROS production may 
be a result of inflammation. It has been seen in inflammatory diseases, such as 
asthma, that an overproduction of ROS by inflammatory cells may result in 
increased lipid peroxidation (Wood eta l, 2003).
1.2 Inflammation and the production of reactive oxygen species
Inflammation is a protective response to exposure to substances such as allergens, 
pollutants, bacteria and viruses, which may cause damage and infection. The 
inflammatory response, as summarised in Figure 1.1, is characterised by the 
production of proinflammatory cytokines including interleukin-5 (IL-5) and IL-8 and 
the activation of inflammatory cells, such as: mast cells, eosinophils, neutrophils 
and macrophages. This activation results in the production of ROS due to the cell's 
'respiratory burst', during which oxygen (0 2) is taken into the cell and ROS are 
released. During this 'burst' a number of pro-oxidant reactions occur resulting in the 
accumulation of ROS (Figure 1.1). If levels of ROS become high enough to 
overwhelm the antioxidant systems this results in lipid peroxidation (Wood et al, 
2003).
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Figure 1.1 Induction of oxidative stress and lipid peroxidation by 
inflammatory response
Acquired immune system
/— "4
Antigen
Activation of Th2 cells
Production of IL-5 
Recruitment of eosinophils
Innate immune system
Virus, Endotoxin, N02/  
Ozone chemicals
Activation of endothelial/ 
macrophage
Production of IL-8 
Recruitment of neutrophils
*  /  
Activation of inflammatory cells
Mediator release 
including cytokines <e‘ 
and ROS
I
Lipid peroxidation
ROS production (0 2*'; H20 2, *OH)
NADPH-oxidase
2 0 2 + NADPH ---------------- >  2 0 2* + NADP* + H+
2 0 2* + 2H*
SOD
H20 2 + 0 2
EPO/MPO
h 2o 2 + c i + h + ----------------->  H0CI + H20
HOCI + 0 , ->  ’ OH + cr + o,
Figure. 1.1 Mechanisms o f inflam m ation tha t result in lipid peroxidation. EPO:
eosinophil peroxidase; H2: hydrogen; H20 2: hydrogen peroxide; *0H: hydroxyl radical; IL: interleukin; 
MPO: myeloperoxidase; NADPH: reduced nicotinam ide-adenine dinucleotide phosphate; NADP: 
nicotinam ide-adenine dinucleotide phosphate; 0 2 : superoxide; SOD: superoxide dismutase; Th2: T- 
helper type-2 cells
Activated in flam m atory cells such as macrophages, which are present at high levels 
in adipose tissue (AT), have been associated w ith  the developm ent o f obesity and 
diabetes (Hotamisligil and Erbay, 2008). Increased inflam m ation observed in obesity 
is characterised by in flam m atory mediators in AT (Ye, 2009).
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1.3 Adipose tissue
AT is an active endocrine and paracrine organ that releases a large number of 
cytokines and bioactive mediators, which influence body weight and many 
homeostatic mechanisms including glucose homeostasis and insulin resistance (IR) 
(Van Gaal et al, 2006; Eldor et al, 2006). There are two types of adipose tissue; 
brown adipose tissue (BAT) and white adipose tissue (WAT), both of which store 
energy in the form of triglycerides but have different morphology, function and 
regulation and are both found in different anatomical locations.
1.3.1 Brown adipose tissue
BAT appears brown in colour due to vast vascularisation and cytochromes present 
in the large number of mitochondria (Figure 1.2). It releases energy as heat and is 
responsible for the regulation of body heat in newborn mammals and during 
hibernation. It is predominantly involved in non-shivering thermogenesis, which is a 
thermogenic function required by an organism to counteract heat loss associated 
with birth and atmospheric life (Lee et al, 2013). In most mammals BAT develops 
during the gestational period and is therefore prominent in newborns and the 
young, located primarily around arterial vessels and vital organs. The amount of BAT 
in a mammal is dependent on the amount of non-shiver thermogenesis required 
and corresponds to the balance between metabolic body mass (i.e. heat produced 
and heat lost). As most mammals age their heat lost per unit body weight is 
decreased and BAT becomes undistinguishable to WAT. Although, recent studies
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show human adults still have a large proportion of BAT w ith in  the thoracic area 
(Saito et al, 2009).
1.3.2 W hite adipose tissue
WAT is the main source o f energy in any mammal and is the most abundant fa tty  
tissue, accounting fo r approxim ately 50% o f an individual's body weight in severe 
obesity (Hahn and Novak, 1975). WAT cells are predom inantly developed a fte r b irth 
via adipose cell hypertrophy. This study w ill focus on WAT as the human AT samples 
are all from  adult patients.
Figure 1.2 Comparison of BAT and WAT
-  ^  v A  .*
• i  &  V * .S rt \  ■ * WI  ,  *  ’ ‘ . *  • ’ ’ t i 
V * • k V I  .
> i  * »
' v  • -•/?. w k i V .
\
\
Figure 1.2 Immunohistochemical image o f brown adipose tissue (left) and w hite adipose tissue 
(right) (adapted from  www.circ.ahajournals.org, accessed 16th April 2013)
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1.3.3 Structure and function
AT is predominantly made up of mature adipocytes. Adipocytes are a unique cell 
type as 95% of the total cell body consists of a lipid droplet (Trujillo et al, 2006) 
(Figure 1.2). The primary role of the lipid droplet is the storage of triglycerides, 
which are released via lipolysis adding to overall triglyceride levels produced by 
triglyceride synthesis. An adipose cell can vary vastly in size from approximately 25- 
200pm in diameter, which is determined by an increased storage of lipid resulting in 
overall cell size increase. The remaining 5% of the adipocyte capacity is responsible 
for the expression and release of endocrine and paracrine hormones, which are 
able to communicate with neighbouring adipose cells as well as acting as regulators 
of cellular processes in peripheral tissues (e.g. liver and nervous system) (Trujillo et 
al, 2006). AT also contains preadipocytes (undifferentiated adipocytes), endothelial 
cells, pericytes, tissue resident macrophage, monocytes, fibroblasts and is rich in 
blood vessels (Kowalska, 2007; Trujillo et al, 2006). Endothelial cells and pericytes 
have been observed to be crucial components in AT homeostasis allowing growth 
and development in AT (Claffey et al, 1992), whereas cell types such as monocytes 
and macrophages are responsible for the clearance of necrotic adipocytes 
particularly abundant in obesity (Cinti et al, 2005). These characteristics make it 
ideally suited for its function as an endocrine organ and the distribution of these cell 
types within AT has been found to differ depending on its localisation, such as tissue 
developed in different adipose depots (Prunet-Marcassus et al, 2006).
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1.3.4 Adipose depots
AT is located within specific depots within the body. There are considered to be 
three main depots of AT: (i) subcutaneous AT (layer under the skin), (ii) visceral AT 
(VAT) (around internal abdominal organs) and (iii) bone marrow. These depots have 
different biochemical functions, structure, composition and relationship with 
neighbouring organs (Trujillo et al, 2006). Recent studies focusing on differences in 
AT depots have described modest gene expression differences between depots 
although not enough to be employed as biomarkers for the specific depots (Gesta et 
al, 2006). Gesta et al suggested that adipocytes located in different depots have 
distinct developmental gene expression differences, which are thought to play a 
role in the distribution of AT and contribute the development of obesity and other 
metabolic disorders (Gesta et al, 2006). In abdominal visceral depots, often 
described as abdominal pads or omentum, there is a characteristically higher 
expression of interleukin-6 (IL-6) in comparison to subcutaneous depots (Huh et al, 
2012), as a result abdominal VAT is closely associated with IR, T2DM and CVD. 
Therefore, the focus of this work will concentrate on VAT.
1.3.5 Adipokines
As aforementioned, AT is an endocrine and paracrine organ that communicates 
with other organs and neighbouring tissues via local and systemic interactions 
mediated by adipose-specific cytokines, or protein factors called adipokines (Trujillo 
et al, 2006). AT has been found to be a source of pro-inflammatory cytokines such
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as IL-6 and tumour necrosis factor alpha (TNF-a) and anti-inflammatory factors such 
as adiponectin (Kowalska eta l, 2007) (Table 1.2).
Adipokines have been associated with atherosclerosis, inflammation, insulin 
resistance and oxidative stress (Eldor et al, 2006). An increase in oxidative stress is 
associated with adipokine dysfunction (Furukawa et al, 2013; Iyer et al, 2010). 
Obesity induces the expression of several adipokines and pro-inflammatory markers 
that contribute to cardiovascular risk in overweight and obese subjects (Van Gaal et 
al, 2006).
Table 1.2 Adipokines and their function
Adipokine Function References
Adiponectin AT secreted hormone. Role in glucose regulation 
and fatty acid oxidation. Associated with 
obesity, T2DM and CVD
Hui et al, 2011
Leptin AT secreted hormone. Role in appetite and 
metabolism. Controls energy intake and 
expenditure via central nervous system
Mantzoros et al, 2011
Resistin AT secreted factor. Responsible for increased 
levels of low-density lipoprotein (LDL). Plays a 
role in IR. Associated with obesity and T2DM 
and CVD
Jamaluddin eta l, 2011
Visfatin Cytokine involved in (3-cell maturation and 
inhibits neutrophil apoptosis, activates insulin 
receptors and lowers blood glucose and 
improves insulin sensitivity
Zhanget al, 2011
IL-6 Cytokine involved in pro and anti-inflammatory 
response as a mediator of acute phase 
inflammatory response during infection or 
trauma. Associated with diabetes and 
atherosclerosis
Hirano, 2010
TNF-a Cytokine involved in acute phase inflammatory 
response responsible for apoptotic cell death 
during inflammation
Marusic et al, 2012
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1.4 Obesity
Obesity is an excess of body fat, or AT, which is associated with an adverse effect on 
an individual's health. In the past 30 years the prevalence of obesity has almost 
trebled (Rennie and Jebb, 2005) resulting in an increased incidence of T2DM, CHD 
and other co-morbidities. Increased body fat (particularly VAT) is believed to play a 
vital role in these conditions in obese people, but many of the underlying 
mechanisms remain unclear. A close association exists between obesity, diabetes, 
inflammation and oxidative stress, which results in increased formation of ROS 
(Mathieu et al, 2009; Inge et al, 2010).
In recent decades the prevalence of obesity has increased rapidly in both developed 
and developing countries. In 1980, the UK statistics showed that 6% of the males 
and 8% of females were obese. However, by the year 2002 these numbers had 
increased to 23% and 25% respectively (Rennie and Jebb, 2005). In recent years this 
has continued to escalate to more than 55% of the UK population being classified as 
being overweight or obese. This high prevalence trend is also beginning to appear in 
children. In 2002, approximately 22% boys and 28% girls aged 2-15 were overweight 
or obese (Rennie and Jebb, 2005).
1.4.1 Body Mass Index
Body Mass Index (BMI) is a surrogate marker often used to define obesity. BMI is 
calculated using the following equation:-
14
BMI (kg /m 2) = weight (kg) /  [height (m )]2
The W orld Health Organisation (WHO) categorise individuals as underweight if they
have a BMI <18.5, healthy between 18.5-24.9, overw eight 25-29.9, obese >30 and
m orb id ly obese >40 (Figure 1.3).
Figure 1.3 Standard graph to calculate BMI
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BMI may not be accurate in the case o f large muscle mass as it does not consider
body build. BMI classification may d iffe r by ethnic group as there  are lower cu t-o ff
values fo r each class. A measure to  assess central obesity is waist circum ference or
waist circum ference: hip circumference ratio  (WHR). Central obesity can be defined
as a WHR ratio  o f >0.95 in males or >0.85 in females or waist circum ference of
>102cm and >88cm respectively in Caucasian subjects (W orld Health Organisation,
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2008). Waist circumference may be a more accurate measure of VAT than BMI as it 
provides information about the distribution of fat and allows risk assessment for 
CHD and associated conditions. An increase in BMI has been associated with 
increased mortality and is a principal component in the development of metabolic 
syndrome (Furukawa, 2013). In particular the distribution of adiposity has a 
significant impact of the risk of metabolic disorders, including diabetes (Kissebah, et 
al, 1982; Hartz et a;, 1983).
1.4.2 Fat distribution
The distribution of AT in obese subjects differs by gender (Bouchard et al, 1993). An 
increase in abdominal VAT is seen particularly in males, whereas females are more 
likely to have an increase in subcutaneous AT. Sex hormones have been shown to 
play a role in this process, particularly during the menopause when there is an 
increase in AT distribution within the abdomen (Toth et al, 2000). Obesity can be 
defined according to fat distribution, as the type of obesity may alter a patient's 
susceptibility to other co-morbidities. For example, patients with central obesity 
(predominantly abdominal) have an increased cardiovascular risk when compared 
to those with gluteo-femoral obesity (Ibrahim, 2010). Central obesity is due to an 
increase in intra-abdominal VAT deposits, which in itself can have numerous 
adverse effects on health. The distribution of adiposity, and therefore the type of 
obesity, is likely to be due to a number of factors including age, sex, environmental 
factors and genetic susceptibility.
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1.4.3 Environmental and genetic factors involved in obesity
The aetiology of obesity is complex and is a result of environmental factors such as 
excess calorie intake, a lack of physical activity and genetic factors. Modern lifestyle 
plays a massive role in obesity as people live more sedentary lifestyle compared to 
past generations. Also, a "normal" diet has become higher in calories than 
previously. The combination of a less active lifestyle and a diet of refined sugars and 
foods high in fat have contributed to the global increase in obesity. Studies have 
found that increased energy expenditure through exercise of 500kcal/week can 
significantly reduce the risk of obesity and related risk of T2DM (Helmrich et al, 
1991).
Even though there are genetic factors that can cause an individual to become obese 
such as the monogenic condition that causes leptin deficiency or resistance, genetic 
causes of obesity are not entirely understood, despite a family history often being 
present. To date, no significant progress has been made in identifying causative 
genes. Other monogenic conditions such as Prader-Willi syndrome and Lawrence- 
Moon-Biedl syndrome also can cause obesity (Farooqi and O'Rahilly, 2005). An 
increase in body fat has been closely associated with an increase in morbidity and 
mortality and obesity is associated with other co-morbidities such as hypertension, 
dyslipidaemia, CVD and T2DM (Poirier et al, 2006). Obesity is associated with the 
appearance of a chronic, low grade inflammatory state due to changes in function 
of adipocytes and macrophage within AT (Ross, 1999). During adipocyte dysfunction 
there is an increase in secretion of pro-inflammatory and pro-diabetic
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adipocytokines, accompanied by a decreased production of adiponectin. As 
adipocytes enlarge, increased levels of adipocyte-derived free fatty acids (FFA) are 
released which can stimulate the local macrophages to produce tumour necrosis 
factor alpha (TNFa). Saturated FFA bind to the toll-like receptor-4 (TLR-4) which is 
expressed on macrophages resulting in nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) activation. Macrophage-derived TNFa activates human 
adipocytes thereby enhancing the expression of various genes (e.g. IL-6). 
Macrophages are more prevalent in AT of obese subjects and increased 
macrophages are associated with increased insulin resistance (Hajer et al, 2008). 
Increased weight has also been associated with an increase in ROS production and 
systemic markers of oxidative stress (Keany, 2003). This increase in systemic 
oxidative stress plays a role in the dysregulation of adipokine production in AT 
(Furukawa, 2013). Differences in adipokine production can contribute to insulin 
resistance in obesity (Hotamisligil, 1993) and therefore may contribute to the 
development of T2DM.
1.5 Diabetes Mellitus
Diabetes Mellitus (DM) is a common complex carbohydrate metabolic disorder that 
is caused by genetic and environmental factors (Andrulionyte et al, 2004). Patients 
with diabetes have abnormally high levels of blood glucose due to insufficient 
insulin levels or activity. The two most common classes of diabetes are Type 1 
Diabetes Mellitus (T1DM) and T2DM.
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1.5.1 Blood glucose and insulin
In healthy individuals, insulin produced by (3-cells of the pancreas, stimulates 
glucose uptake from the bloodstream to be utilised for energy production and 
storage as glycogen in the liver, skeletal muscle and AT to be utilised later as an 
energy source. In patients with diabetes, the cell is unable to take up blood glucose 
due to abnormally low or absent insulin levels as seen in T1DM, or due to insulin 
resistance, seen in T2DM, leading to elevated blood glucose levels and associated 
complications.
1.5.2 Type 2 diabetes
Approximately 90% of people with diabetes have T2DM (Zimmet et al, 2001). It is a 
multi-factorial disease that usually occurs in older and/or obese people (Zimmet et 
al, 2001). Lifestyle factors such as physical inactivity and obesity have been 
associated with the development of the disease. T2DM is characterised by 
hyperglycaemia however, unlike T1DM ketoacidosis (high levels of ketone bodies in 
the blood) is typically absent. In the early stages of T2DM the disease can be 
managed by increased exercise and dietary modification, however as the duration 
of the disease increases, oral medication and/or insulin may be necessary. T2DM is 
caused by a combination of aetiologies: (i) insulin resistance, where insulin is 
present at normal or elevated levels but the individual is resistant to its action; (ii) 
(3-cell dysfunction, where the processing of proinsulin to insulin is impaired; and (iii) 
3-cell destruction.
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1.5.3 Insulin resistance
IR occurs when insulin is produced but is unable to be utilised effectively. IR leads to 
an increased requirement of insulin as muscle, fat and liver cells are unable to 
respond to insulin present at physiological levels and therefore are unable to take 
up glucose from the blood stream. As a result of this higher demand for insulin, 
pancreatic p-cells increase insulin production allowing blood glucose to be 
maintained at a healthy level. Over prolonged periods of IR, [3-cells become unable 
to maintain the production of insulin to meet the demand leading to the onset of 
T2DM (Capurso and Capurso, 2012). This occurs due to excess levels of blood 
glucose building up as insulin levels are reduced. IR has been associated with an 
increased BMI and a lack of physical activity, with studies showing that weight loss 
reduces IR, preventing or delaying the onset of T2DM (Poirier et al, 2006).
1.5.4 (3-cell dysfunction and destruction
p-cell dysfunction results in impaired insulin secretion and is considered to play a 
secondary role in the pathogenesis of T2DM after obesity and IR, although more 
recent studies suggest that it is associated with the development of obesity and IR 
(Shoelson et al, 2007). During |3-cell destruction islets fail to secrete insulin although 
they do secrete other markers, for example, the levels of pro-insulin secreted by 13- 
cells is increased along with the secretion of amyloid fibrils, which are normally 
secreted alongside insulin and have a toxic effect on islet cells. This leads to 
apoptotic cell death of the P-cells and the replacement of the islet by amyloid and 
ultimately diabetes, p-cell dysfunction, destruction and IR are a result of
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hyperglycaemic conditions, which in turn  results in fu rthe r hyperglycaemia leading 
to  the pathogenesis o f T2DM (Figure 1.4).
Figure 1.4 Hyperglycemic induction of IR, P-cell dysfunction and T2DM
Insulin Resistance
Hyperglycemia^ ^Hyperglycemia T2DM
3 -cell Dysfunction\
M ulti-factoria l m etabolic changes predom inantly related to  hyperglycaemia lead to 
damage and functional im pairm ent o f both large (macrovascular) and small 
(m icrovascular) blood vessels w ith in  the body resulting in concom itant conditions.
1.5.5 Co-morbidities
As previously mentioned T2DM is a heterogenous disease characterised by 
abnormal glucose tolerance, insulin dysregulation, dislipidaemia and in flam m ation 
which combined lead to  fu rthe r complications.
Macrovascular complications occur due to  damage o f blood vessels. CHD, 
peripheral vascular disease and stroke occur when there is hypoperfusion to  the 
heart, periphery and brain respectively, due to  atherosclerosis. Diabetes is 
considered a major risk factor fo r CHD (Flekac et al, 2008), which can u ltim ate ly  lead 
to  angina (chest pains), cardiac fa ilure  (shortness o f breath), and in worse cases
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myocardial infarction (heart attack). CHD is a multi-factorial disease that is the main 
cause of premature mortality and is associated with a 2-4 times greater morbidity in 
patients with T2DM compared to those without diabetes (Kawalska et al, 2007). 
This is due to mechanisms involved in the pathogenesis of the disease being 
induced by hyperglycaemia and resulting oxidative stress. High levels of oxidative 
stress have been observed in patients with CHD (Stephens et al, 2007), and ROS 
have been found to activate a number of biomolecular pathways that are 
associated with the pathogenesis of vascular disorders (Flekac et al, 2008).
Microvascular complications include retinopathy, nephropathy and neuropathy 
(Armstrong and al-Awadi, 1991), which affect the small vessels of the eye, kidney 
and nervous system respectively. Increased oxidative stress induced by 
hyperglycaemia plays a critical role in the pathogenesis of these diabetes 
complications (Mehta et al, 2006; Dronavalli et al, 2008). Diabetic retinopathy 
results in damage to the retina of the eye causing loss of sight and it is the most 
common cause of blindness within patients with diabetes. The development of 
retinopathy is highly dependent on duration and severity of hyperglycaemia in 
T2DM and has also been associated with the presence of hypertension and 
oxidative stress (van Reyk et al, 2003). Diabetic nephropathy is diabetes associated 
kidney disease effecting approximately 40% of patients with T2DM (Gross et al, 
2005). It is the single most common condition in patients with end stage renal 
failure, particularly in westernised countries (Ritz, 2006) and is characterised initially 
by microalbuminuria and proteinuria. The main risk factors for nephropathy, similar
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to other microvascular conditions are prolonged hyperglycaemia, untreated 
hypertension and genetic susceptibility (Gross et al, 2005). Diabetic neuropathy is 
the dysfunction of peripheral nerves. As seen in other microvascular complications, 
longevity of hyperglycaemia increases the risk of developing neuropathy as well as 
genetic susceptibility but to a lesser extent (van Dam, 2002). Oxidative stress has 
been surmised to play a role in peripheral nerve damage, which occurs in 
hyperglycaemia due to increased ROS, decreased nitric oxide and glutathione, and 
damage from advanced glycation end products (AGEs) (Boulton et al, 2005).
1.5.6 Oxidative stress in diabetes
Diabetes is associated with high levels of ROS due to hyperglycaemia (Kiritoshi et al, 
2003; Blasiak et al, 2004; Salpea et al, 2009) and is evident in subjects with poor 
glycaemic control (Shin et al, 2001). The oxidants produced by hyperglycaemia are 
pathogenic as they alter the structure of proteins and lipids causing deleterious 
vascular effects (Flekac et al, 2008). Pancreatic p-cells have been found to be 
particularly susceptible to ROS damage, suggesting that excessive ROS produced 
due to ongoing hyperglycaemia and/or obesity can cause p-cells to lose function 
and impaired insulin signalling resulting in the onset of T2DM (Stephens et al, 2009). 
Endogenous anti-oxidative enzymes attempt to control ROS levels by removing 
excessive oxidants (Lee et al, 2006). However, in DM these scavenger enzymes are 
less effective as their defensive role is hampered by excessive oxidative stress 
(Flekac et al, 2008). In addition, exogenous antioxidants, such as vitamins, can 
decrease ROS levels; however these may have little effect if there is excessive
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oxidative stress. Alterations in the genetic code of these anti-oxidant enzymes may 
reduce the overall expression, activity and efficiency of the enzymes to maintain 
levels of excess ROS.
1.6 Nucleic acids
Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) encode genetic information 
required for the development and functioning of all living organisms. Damage to 
these nucleic acid sequences, such as that induced by oxidative stress, may result in 
the increased or decreased expression of genes and overall dysfunction of cellular 
mechanisms. To understand the damage caused in an environment of oxidative 
stress understanding the structure and function of DNA and RNA is important.
DNA is a double stranded polymer made up of anti-parallel chains of nucleotide 
monomers in a double helix structure. Each nucleotide is made up of a sugar, base 
and phosphate group. There are four different types of base that make up DNA; 
adenine (A), guanine (G), cytosine (C) and thymine (T). These bases form the inside 
of the DNA double helix structure via hydrogen bonding of paired purine (A and G) 
and pyrimidine (C and T) bases, therefore an A base will only pair with T and G will 
only pair with C. The sequence of the bases within the nucleic acids determines the 
resulting proteins they code for. In the coding regions of these sequences, every 
three bases makes up a codon that is transcribed via RNA into amino acids, which 
are the building blocks for protein synthesis. Any alterations in the DNA sequence
may lead to a change in the resulting amino acid sequence effecting the overall 
function of the final protein.
RNA is single stranded structure, similar to DNA, with the main difference being an 
uracil (U) in RNA in place of the thymine (T) in DNA. Alterations in the sequence of 
DNA may not only occur due to oxidative damage but also in the process of DNA 
replication, resulting in an altered RNA sequence.
1.6.1 DNA replication
DNA replication allows biological inheritance of genetic material. Prior to dividing it 
is necessary for a cell to make copies of its DNA, which is carried out in a 5'-3' 
direction by a highly accurate DNA polymerase to ensure all daughter cells receive 
complete genetic information. This process is semi-conservative, meaning that each 
resulting cell will contain one copy of the parent strand of DNA and one copy of a 
new replicated strand.
DNA polymerase must have a template strand of DNA or RNA to replicate, along 
with a primer of complementary bases to the template. DNA polymerases are also 
able to proof-read the new DNA strand to ensure the correct bases have been 
inserted, in order to reduce the chance of error that may result in lost information 
within the daughter cells. Reverse exonuclease activity identifies incorrect bases, 
which are removed and replaced with the correct base. Errors formed during DNA 
replication that are not corrected lead to DNA damage within the daughter cells. A
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naturally occurring form of DNA damage associated with DNA replication is the 
shortening of telomere sequences to prevent the loss of coding sequences.
1.7 Telomeres
Telomeres are DNA repeat sequences found at the end of chromosomes that have a 
protective role against chromosomal deterioration and chromosomal fusion. These 
single stranded telomeric regions shorten during replication, which is a natural 
process to prevent the shortening of the genes located at the chromosome ends. If 
chromosome ends contained genes, their coding sequences would erode with each 
cell division causing mutations. Cells have developed a protective strategy by 
placing noncoding DNA repeat sequences, telomeric repeats, at the ends of 
chromosomes. The human non-coding repeat sequence is TTAGGG. During each cell 
division, the telomeric repeat sequence shortens and can therefore be 
representative of the cell's biological age (Astrup et al, 2010).
Within adult human somatic cells there is no active telomerase enzyme present to 
protect against the loss of repeat sequences, so approximately 100 base pairs of 
shortening occurs with every cell division. Due to the fact that in adult cells there is 
no replenishment of telomeric sequence the telomere acts as a time delay until the 
eventual loss of genetic code, resulting in the cessation of cell division. This 
replicative senescence appears to be a mechanism to ensure genomic stability by 
enforcing a limit to the number of divisions a cell can undertake before it becomes 
unstable and increases the likelihood of anomalies within the sequence (Houben et
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al, 2008). Telomere shortening has been associated with poor health and disease in 
conditions such as diabetes (Salpea et al, 2009). An estimated loss of approximately 
20bp is expected during replication but in reality 50-100bp have been found to be 
lost, which has been explained by shortening due to presence of free radicals.
1.8 DNA damage
DNA damage is a physical abnormality seen in DNA, including single-stranded and 
double-stranded breaks. If DNA damage is left uncorrected it can result in either the 
initiation of apoptosis or the prevention of further transcription. Oxidative stress 
causes DNA damage and although low level ROS are present at all times due to 
natural metabolic processes, in times of excess oxidative stress the cell is unable to 
repair background levels of damage. This may ultimately resulti in apoptosis or in 
very severe cases bypassing controlled cell death to the destruction of the cell. 
Endogenously produced ROS and replication errors result in different types of DNA 
damage, which are summarised in Table 1.3. Exogenous sources of damage include 
radiation (UV, x-rays, etc), hydrolysis, mutagenic chemicals and viruses (Helton & 
Chen, 2007). If damaged DNA is replicated, the sequence containing the error will 
be inherited by the daughter cell. Once errors are inherited the DNA modification 
cannot be corrected, except in rare cases of 'back mutation1 (gene conversion). The 
majority of damage caused to DNA is localised to the primary structure in the form 
of base modification. Modifications can affect the structure of DNA in the form of 
adducts or incorrect bonds.
As previously mentioned, oxidative stress has numerous associations with a variety 
of disease including diabetes, CVD and inflammatory diseases as well as aging 
(Rossner & Sram, 2012).
Table 1.3 Examples of endogenous types of DNA damage
Source Modification
Oxidation of bases 8-oxo-7,8-dihydroguanine (8-oxoG)
Alkylation of bases Methylation
Hydrolysis of bases deamination, depurination and depyrimidination
Adduct formation benzo[a]pyrene diolepoxide-dG adduct, aristolactam 1-dA 
adduct
Mismatch of bases Caused by errors in DNA replication, when a base is 
skipped or incorrectly inserted into the new DNA strand
An environment of high oxidative stress, such as that brought on by 
hyperglycaemia, is a major source of DNA damage such as the oxidation of bases 
and sugar phosphate binding sites (Blasiak et al, 2004). Alterations such as these are 
associated with cancer development in patients with diabetes due to their 
mutagenic effects and resulting DNA replication arrest (Palazzo et al, 2012). 
Lymphocytes are ideal markers of DNA damage and mutation as they circulate for 
many years through various organs accumulating DNA damage (Palazzo et al, 2012).
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1.9 Mutation types
A mutation is an inherited alteration within the genome or a result of un-repaired 
DNA damage. A mutation differs from DNA damage as a mutation is a change in the 
base sequence of the DNA and it is unable to be recognised by potential repair 
enzymes once a mutation becomes part of the sequence, and therefore cannot be 
repaired. Although there is a clear underlying difference between DNA damage and 
mutation, DNA damage often is the cause of DNA synthesis errors during replication 
or repair, which may ultimately cause mutation. There are a number of mutation 
types ranging from single base pair alterations to massive chromosomal 
abnormalities, all of which have the ability to alter the function of the gene product. 
If a mutation arises only in a somatic cell the mutant characteristics will affect only 
the individual in which the mutation occurs and will not be inherited by the next 
generation, known as a somatic mutation. A germ-line mutation is where the 
mutation is within a germ line cell and can be passed on to the next generation 
producing an individual with the mutation in both its somatic and germ-line cells. 
Diaz-Llera and colleagues (2000) noted that DNA mutation induced by ROS are 
commonly on a smaller scale such as point mutations, particularly base pair 
substitutions, insertions and deletions (Table 1.4).
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Table 1.4 Summary of point mutations caused by ROS
Mutation Description Example
Base pair substitution One base pair replaced by another.
Transition mutation -  purine/pyrimidine 
replaces same type. Transversion mutation 
- a purine replaces a pyrimidine or vice 
versa
Missense mutation
Nonsense mutation
Base pair insertion/ 
deletion
A base pair substitution causing a change in 
mRNA codon, resulting in amino acid 
change in final protein. May or may not 
result phenotypic alteration
A base pair substitution causing a change in 
mRNA codon from one amino acid to a stop 
codon, resulting in premature chain 
termination and incomplete protein
Base pair inserted into or deleted from 
sequence resulting in a base pair shift. May 
result in an alteration to amino acid codon 
sequence
A:T -> G:C 
or
A:T -> T:A
Insertion of 
different 
amino acid
Amino acid 
ATG (stop 
codon)
If DNA damage occurs cells utilise multiple DNA repair pathways to correct 
damaged DNA including nucleotide excision repair, mismatch repair, base excision 
repair, homologous recombination, and non-homologous end joining pathways 
(Helton and Chen, 2007). Impairment of these pathways results in unreliable repair 
of DNA damage that may lead to increased mutagenesis (Zhang et al, 2007).
1.10 Aims
Although 80% of patients with T2DM are obese, less than 10% of obese people have
diabetes (Beck-Nielsen and Hother-Niesen, 1996). The aim of this thesis was to
explore the role that AT plays in T2DM and obesity using hVAT obtained from
subjects undergoing abdominal surgery that were categorised as lean (L), obese (O)
30
and obese with T2DM (ODM). This cross-sectional study attempted to examine 
markers of oxidative stress and identify particular genes that may play a role in 
T2DM in obese subjects. The study was undertaken with the following objectives:-
1. Examine adipose markers of oxidative stress in subjects to determine the 
extent of oxidative burden within this sample set that may be attributed to 
obesity and/or diabetes.
2. Investigate differences in basal gene expression of genes involved 
in oxidative stress and inflammation between the three sample groups, 
using a commercial PCR array, to determine the effects of oxidative burden 
on genes within this population.
3. Investigate differences in gene expression between the three 
sample groups, focusing on genes whose expression were found to be 
altered in aim 2 in more detail, using RT-PCR analysis.
4. To culture mouse adipose cells (3T3-L1) to examine candidate gene 
expression in response to a 'biochemical stress'.
5. An additional aim was included to sequence the gene of interest found as a 
result of aims 2 and 3 for polymorphisms/mutations that may account for 
the change in gene expression observed.
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CHAPTER TWO
MATERIALS AND METHODS
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2.1 Human samples
2.1.1 Recruitment of subjects
The Welsh Institute of Metabolic and Obesity Surgery (WIMOS) provides bariatric 
services for all of Wales and is based at Morriston Hospital, Swansea. It was 
established in June 2011 and is a multi-disciplinary service offering weight loss 
surgery to approximately 70 patients a year. Prior to this, obesity surgery was 
carried out in an ad-hoc manner, with around 11 patients a year being funded for 
bariatric surgery on the National Health Service (NHS). The service comprises of two 
bariatric surgeons, physician, psychologist, dietician, physician and a specialist 
nurse. WIMOS is closely linked with Swansea University's College of Medicine where 
there is on-going research related to diabetes treatment, insulin resistance, exercise 
physiology and health care economics.
Participants were recruited from the bariatric-obesity clinic (Professor John Baxter/ 
M r Jonathan Barry/ M r Scott Caplin/ Professor Jeffrey Stephens) and general 
surgical clinics at Morriston Hospital, Swansea. Surgical procedures were carried out 
every Wednesday and private cases on occasional Sundays at the Princess of Wales 
Hospital, Bridgend. Liaison with the WIMOS Specialist Clinical Nurse Nia Eyre was 
maintained in regards to surgical lists and patient information to ensure patients 
met inclusion criteria for the study. Participants were included in the study if they 
were aged between 18 and 80 years of age, were undergoing an abdominal surgical 
procedure and were medically fit enough for surgery. Participants were excluded if
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they were unable to give informed consent or had a confirmed underlying
malignancy.
2.1.2 Collection of visceral adipose samples
Human visceral adipose tissue (hVAT) samples were collected from subjects that 
were categorised as being lean (L), where BMI<30; obese (O), where BMI>30 and 
obese with T2DM (ODM). Ethical approval (REC ref no.:08/W M W 0/68) was 
obtained for sample collection and informed consent was obtained prior to surgery. 
Sample collections were carried out by myself every Wednesday at Morriston 
Hospital, Swansea and the occasional Sunday for private surgery at the Princess of 
Wales Hospital, Bridgend, over a 32 month period between October 2009 and May 
2012. Collections began at 8.30am on the day of the surgery, when informed 
consent was obtained from subjects prior to any procedures. The order of subjects 
was defined by the surgical list, which was decided before the day of surgery.
During the procedures, theatre staff would allocate an area within the theatre for 
the collection apparatus to be set up. Samples were collected towards the end of 
the planned abdominal surgery and consisted of a 3x3cm cut of hVAT removed via 
laproscopic surgical scissors from the greater omentum. No additional incision was 
required and there was no risk associated with the collection. As the samples were 
removed they were cut into small pieces and placed in a 2ml centrifuge tube with 
1.5ml RNAIater® (Ambion Inc, UK) to preserve tissue. Tubes were then stored in a 
sample box until transportation to the Institute of Life Science, Swansea University
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where they were kept overnight at 4°C before storage at -20°C until required. At 
time of collection samples were anonymised with a sample number and no further 
contact was made with the participant. Problems during recruitment are described 
in detail in Chapter 7. Consent was given to collect additional clinical information. 
BMI was calculated by dividing the weight (in kilograms) of the patient by their 
height (in meters) squared and categorised as L, O and ODM. Blood pressure was 
measured during the patient's pre-operative check-up and individuals with a 
systolic BP >140 and/or a diastolic BP >90 mmHg or on antihypertensive 
medications were considered hypertensive.
2.2 Nucleic acid extractions
2.2.1 RNA
Total RNA was extracted from hVAT using RNeasy Lipid Tissue Mini Kit (Qiagen, UK) 
and was carried out following the manufacturer's protocol detailed below. All 
extractions were carried out within the Diabetes Research Laboratory in the 
Institute of Life Science, Swansea University under sterile conditions. Prior to every 
extraction all pipettes were cleaned with 70% ethanol, all micro-centrifuge tubes 
were sterilised by autoclaving and sterile RNase free filter tips were used to prevent 
RNA contamination. As RNA is known to be less stable than DNA at room 
temperature all work was carried out promptly and all samples were kept on ice 
when necessary. All buffers and spin columns were provided in the kit unless 
otherwise stated.
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Sample disruption and homogenisation
Human VAT samples weighing lOOmg were added to 1ml QIAzol lysis buffer in a 2ml 
ceramic matrix tube (MP Biomedicals, USA) on ice then homogenised for 20 
seconds in a FastPrep® Homogeniser (MP Biomedicals, USA). The samples were left 
on ice for 1 minute then homogenised for a further 20 seconds. Lysate was then 
transferred to a clean 1.5ml tube and left to incubate at room temperature (rtp) for 
5 minutes.
Separation of aqueous and organic phases
Chloroform (200|il) was added to the lysate, shaken for 15 seconds, left to incubate 
at rtp for 3 minutes then centrifuged for 15 minutes at 12,000rpm (13,400xg) at 
4°C. The upper aqueous phase was transferred to a clean 1.5ml tube, 500pl 70% 
ethanol added and mixed by vortex.
Total RNA purification
The sample was transferred to an RNeasy mini spin column and centrifuged for 15 
seconds at 13,000rpm (15,700xg), and the flow-through discarded. 700|il Buffer 
RW1 was added to the spin column and centrifuged for 15 seconds at 13,000rpm  
(15,700xg) and the flow-through discarded. 500pl Buffer RPE was added to the spin 
column and centrifuged for 15 seconds at 13,000rpm (15,700xg) and the flow­
through discarded. A further 500pl of Buffer RPE was added and centrifuged for 2 
minutes at 13,000rpm (15,700xg). The spin column was transferred to a clean 1.5ml 
tube and 30pl RNase free water added and centrifuged for 1 minute at 13,000rpm
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(15,700xg). This elution step was then repeated and the final volume of total RNA 
divided into 20pl aliquots and stored at -80°C.
RNA quantification
Total RNA concentration was quantified using a NanoDrop 8000 UV-Vis 
Spectrophotometer (Thermo Scientific, UK). Total RNA concentration was measured 
at an absorbance of 260nm. The purity of the RNA had to be such that absorbance 
levels between 260nm-230nm were between 1.8-2.2ng/pl to be free of protein 
contamination and 260nm-280nm between 1.8-2.0ng/pl to be free of DNA 
contamination as per manufacturer's instruction. All readings were blanked with 
RNase free water.
2.2.2 DNA
Total DNA was extracted from hVAT using QIAamp DNA Mini Kit (Qiagen, UK) and 
was carried out following the manufacturer's protocol detailed below. All 
extractions were carried out under sterile conditions. Prior to every extraction all 
pipettes were cleaned with 70% ethanol, all micro-centrifuge tubes were sterilised 
by autoclaving and sterile RNase free filter tips were used to prevent RNA 
contamination. All buffers and spin columns were provided in the mini kit unless 
otherwise stated.
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Sample disruption and homogenisation
In a 2ml centrifuge tube, hVAT samples weighing 25mg were broken up using a 
sterile scalpel and added to 180pl Buffer ATL and 20pl proteinase K and mixed by 
vortex. The samples were incubated at 56°C as per manufacturer's protocol until 
the tissue was completely lysed.
Total DNA purification
Tubes were briefly centrifuged before adding 4pl RNase A (lOOmg/ml), mixed by 
pulse vortexing for 15 seconds and incubated at rtp for 2 minutes. 200pl Buffer AL 
was added to the tubes and mixed by pulse vortexing for 15 seconds before 
incubation at 70°C for 10 minutes. Lysate was then transferred into a clean 1.5ml 
tube and left to incubate at rtp for 5 minutes. Tubes were briefly centrifuged before 
adding 200pl 100% ethanol and mixed by vortexing before being transferred to the 
QIAamp mini spin column, centrifuged at 8,000rpm (5,900xg) for 1 minute and the 
flow-through discarded. 500pl Buffer AW1 was added to the spin column and 
centrifuged at 8,000rpm (5,900xg) for 1 minute. The QIAamp spin column was then 
transferred to a clean collections tube, discarding the flow-through and 500pl 
Buffer AW2 added before centrifugation at 13,200rpm (16,100xg) for 3 minutes. 
This step was then repeated using a clean collection tube and then transferred to a 
clean 1.5ml centrifuge tube for elution.
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Elution of total DNA
Buffer AE (200pl) was added to the column and incubated at room temperature for 
5 minutes before centrifugation at 8,000rpm (5,900xg) for 1 minute. This was 
repeated with a further 200pl Buffer AE and resulting total DNA was aliquoted and 
stored at -20°C until needed.
DNA quantification
Total DNA concentration was quantified using a NanoDrop 8000 UV-Vis 
Spectrophotometer (Thermo Scientific, UK). Total DNA concentration was measured 
at an absorbance of 260nm. All readings were blanked with RNase free water.
2.3 Measures of oxidative damage
2.3.1 Relative change in ABTS* fluorescence
Plasma Total Antioxidant Status (TAOS), previously described by Sampson et al 
(2002) and Stephens et al (2009) is a method to measure the antioxidant capacity in 
a plasma sample. TAOS is a photometric microassay that determines a sample's 
capacity to inhibit the peroxidase-mediated formation of the 2, 2-azino-bis-3- 
ethylbensthiazoline-6-sulphonic acid (ABTS+) radical. The inhibition of ABTS+ 
formation is proportional to the sample's antioxidant capacity, therefore, if a 
sample has high levels of oxidative stress, the resultant TAOS will be low. The assay 
is split into two arms, a control and a test arm. In the control arm saline is incubated 
with hydrogen peroxide and ABTS. The hydrogen peroxide acts as a free radical 
donor causing the formation of the ABTS+ radical, producing a colourmetric change
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which can be measured at 405nm. As saline contains no antioxidant molecules the 
reaction goes to completion. In the test arm, the hydrogen peroxide and ABTS are 
instead incubated with the test plasma sample (which will contain antioxidant 
molecules) therefore preventing the reaction going to completion by varying 
degrees depending on the antioxidant content. It is then possible to calculate the 
percentage of inhibition of the reaction for the test sample relative to saline:
TAOS % = (Control absorbance - Test absorbance) /  Control absorbance X 100)
This method (followed as per Stephens et al, 2009) has not been used to measure 
TAOS in tissue homogenates. I conducted this protocol in 61 hVAT homogenates 
and the assay was not conclusive on four separate occasions. Therefore, in order to 
test oxidative capacity in hVAT homogenates this method was modified to measure 
the change in ABTS+ formation (AABTS+) within a sample relative to a saline control. 
The assay was carried out using the protocol method to determine AABTS+ as 
described below:
AABTS+= Sample absorbance/Control absorbance
The intra-assay coefficient of variation (CV) was 0.9 -  1.6%, while the inter-assay CV 
were 6.2 -  9.4% (raw data in appendix 1).
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Sample disruption and homogenisation
hVAT samples weighing 25mg were added to 250pl RIPA buffer and 1.3pl protease 
inhibitor cocktail (Sigma, UK) in a 2ml centrifuge tube. Samples were sonicated 
using a Sonics Vibra Cell VCX 130 ultrasonic processor (Sonics, USA) for 15 seconds, 
then centrifuged for 10 minutes at 4,200rpm (l,600xg) at 4°C. The supernatant was 
then transferred into a clean 2ml tube and stored at -80°C. Tissue homogenates 
were stable for 1 month.
Measurement of change in ABTS+
2.5pl phosphate buffered saline (PBS) for the control and 2.5pl hVAT homogenate 
samples were placed in a 96-well ELISA plate in triplicate. To each well was added 
20pl ABTS (20mmol/L), 20pl horse radish peroxidase (HRP) (30mU/ml) and 40pl PBS 
(pH7.4) (all Sigma, UK). To initiate the reaction 20pl H20 2 (O.lmmol/L) was added to 
each well and the plate was incubate at 37°C for 12 minutes.
Analysis o f data
After incubation, absorbance was read for each well using a Polarstar Omega plate 
reader (BMG Labtech, Germany) at a wavelength of 405nm. The increase in 
absorbance due to the accumulation of ABTS+ in each sample was read along with 
the absorbance of the PBS control. The relative change in ABTS+ was calculated as 
previously described.
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2.3.2 Thiobarbituric acid reactive substances assay
Lipid peroxidation as a measure of oxidative stress was investigated in hVAT 
homogenates using a thiobarbituric acid reactive substances (TBARS) assay (Cayman 
Chemical c/o Cambridge Bioscience, UK) (Armstrong et al, 1994; Yagi, 1998) and 
was carried out following the manufacturer's fluorometric protocol detailed below. 
All assays were carried out under sterile conditions. Prior to every assay all pipettes 
were cleaned with 70% ethanol, all micro-centrifuge tubes and tips were sterilised 
by autoclaving. hVAT samples were homogenised as described in section 2.3.1. The 
intra-assay CVs ranged from 5.2-7.1%, while the inter-assay CVs range from 16.2- 
19.6% (raw data in appendix 2).
Preparation of standards
25pl malondialdahyde (MDA) standard was diluted with 975pl double distilled 
water to obtain a stock standard solution of 12.5pM. Sterile 2ml centrifuge tubes 
were labelled A-H and the volume of MDA stock solution and water were added to 
each tube according to Table 2.1.
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Table 2.1: MDA fluorometric standards
Tube MDA (pi) W ater (pi) MDA concentration (pM)
A 0 1000 0
B 5 995 0.0625
C 10 990 0.125
D 20 980 0.25
E 40 960 0.5
F 80 920 1.0
G 200 800 2.5
H 400 600 5.0
TBARS assay
lOOpI of standard or sample were added to a labelled 15ml centrifuge tube 
containing lOOpI SDS solution and mixed by inversion. 4ml colour reagent was 
added to each tube and boiled for 1 hour. The tubes were cooled on ice for 10 
minutes and centrifuged for 10 minutes at 4,200rpm (l,600xg) at 4°C. As the 
reagent becomes unstable after 30 minutes immediate use is necessary. 150pl from 
each tube was plated in duplicate into a black 96 well plate and read 
fluorometrically using a Polarstar Omega plate reader (BMG Labtech, Germany) at 
an excitation wavelength of 530nm and an emission wavelength of 550nm.
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2.3.3 Measure of telomere length
As described in detail in section 1.7, telomeres are DNA repeat sequences found at 
the end of chromosomes that shorten during replication and are representative of 
the cell's biological age. Telomere length was measured according to the method 
described by Cawthon et al (2002), which comprises of a 2-step PCR protocol. A 
period of 5 days was spent at the Centre for Cardiovascular Genetics, University 
College London with Professor Steve Humphries's research group learning this 
method on human DNA. The technique compares the number of telomere DNA 
repeat sequences against a single copy gene (SCG) (acidic ribosomal 
phosphoprotein PO [36B4]) for each sample, producing a ratio value (T/S ratio) that 
can be compared between sample groups as a relative measure of telomere length. 
This technique has been previously used within DNA obtained from whole blood 
(Salpea et al, 2008), but has previously not been used with hVAT. The intra-assay 
CVs ranged from 0.3-3.2%, while the inter-assay CVs range from 2.1-3.7% (raw data 
in appendix 3).
Primer design and optimisation
Primers were previously designed and optimised for the human telomere sequence 
and for the SCG (acidic ribosomal phosphoprotein PO [36B4]) by members of the 
Centre for Cardiovascular Genetics, University College London. Primers were 
purchased from Eurofins MWG Operon (Germany) using the primer sequences 
shown in Table 2.2 and diluted using RNase free water as shown in Table 2.3.
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Performing telomere length assay
DNA extracted from hVAT (see section 2.2.2) was diluted with RNase free water to a 
5ng/pl concentration as described by Salpea et al (2008). Each sample and control 
was run in triplicate. For each sample 6pl diluted DNA (or water for control) was 
added to 12.5pl 2xSensimix SYBR No-ROX master mix (Bioline, UK), lp l telomere 
forward primer, lp l telomere reverse primer and 4.5pl PCR H20 . Using a Rotor- 
Gene 6000 Real-Time PCR Detection System (Corbett c/o Qiagen, UK) samples were 
run on the telomere program for an incubation of 10 minutes at 95°C followed by 
22 cycles of 15 seconds at 95°C and 120 seconds at 58°C. The method was repeated 
from the start using the SCG forward and reverse primers instead and run on the 
SCG program with an incubation of 10 minutes at 95°C followed by 30 cycles of 15 
seconds at 95°C and 60 seconds 58°C.
Telomere length data analysis
Raw data was analysed using the comparative quantification software (Rotor-Gene 
6000, Corbett Research Ltd, UK), which calculated the reaction 'take-off' point for 
each sample. The take-off point is 80% of the peak exponential amplification level. 
Using the take-off point and overall amplification for each reaction, the software 
calculated a relative number of repeats for telomere and SCG copies, termed the 
'rep cone7. These values allowed the T/S ratio to be calculated for each sample 
which is then used as a relative telomere length and can be compared between 
samples:
T/S ratio= Telomere rep conc/SCG rep cone
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Table 2.2: Telomere and SCG primer sequences
Name Sequence (5'-3') Length (bases)
Telo F' GG1 1 1 1 1GAGGG1GAGGG1GAGGG1GAGGG1GAGGG1 37
Telo R' T CCCG ACTAT CCCT ATCCCT AT CCCT AT CCCT AT CCCT A 39
SCG F' CAGCAAGTGGGAAGGTGTAATCC 23
SCG R' CCCATTCTATCATCAACGGGTACAA 25
Table 2.3: Telomere and SCG primer dilutions
Name Primer volume (pi) H20  volume (pi) Working Concentration (nM)
Telo F' 6.75 193.25 135
Telo R' 45.00 155.00 900
SCG F' 15.00 185.00 300
SCG R' 25.00 175.00 500
2.3.4 Comet assay
Comet is a single cell gel electrophoresis assay used for measuring DNA damage in 
individual cells. Damaged DNA containing fragments and strand breaks are 
separated using electrophoresis resulting in a characteristic "comet tail" shape and 
then visualised microscopically with Vista Green DNA dye.
46
An attempt was made at measuring DNA damage within hVAT homogenates using a 
methodology previously described by Cerda et al (1997). This method required 
strict laboratory conditions which were not feasible, and time restraints on 
optimising the method meant that an alternative commercial assay was required to 
gather reliable results. DNA damage was measured in hVAT homogenates using the 
commercially available Oxiselect™ 96-well Comet assay kit (Cell Biolabs Inc, UK) and 
carried out following the manufacturer's protocol detailed below. All assays were 
carried out under sterile conditions. Prior to every assay all pipettes were cleaned 
with 70% ethanol, all micro-centrifuge tubes and tips were sterilised by autoclaving. 
All samples were run in duplicate. The intra-assay CVs ranged from 5.5-7.6% while 
the inter-assay CVs range between 5.1-5.9%.
Sample preparation
hVAT samples were broken up using a sterile scalpel and added to 2ml ice cold cell 
dissociation buffer (PBS, 20m M EDTA without M g2+ and Ca2+) (Invitrogen, UK) in a 
2ml centrifuge tube. Samples were left to stand for 5 minutes on ice before the 
supernatant was then transferred to a clean 2ml tube avoiding any transfer of 
debris, centrifuged for 15 minutes at 13,000 rpm (15,700xg) and the resulting 
supernatant discarded. The remaining pellet of cells was re-suspended in 1ml ice 
cold PBS (without Mg2+ and Ca2+). Cell number was assessed using a Scepter™ 
handheld automated cell counter (Millipore, UK). Cells were diluted to give a cell 
count of 1X105. The cell suspensions were stored at 4°C until required.
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Preparation of reagents
Oxiselect™ Comet agarose was dissolved at 95°C for 20 minutes before being 
transferred to a 37°C waterbath until needed. Vista Green DNA dye was diluted 
1:10000 in TE Buffer (lOm M Tris, pH7.5, Im M  EDTA) and stored at 4°C protected 
from light. To prepare lxLysis buffer, 14.6g NaCI was added to 20ml EDTA solution 
and 10ml lOxLysis solution. The solution was adjusted to 90ml total volume using 
de-ionised water, mixed thoroughly until all NaCI had dissolved and adjusted to pH 
10 using 10M NaOH. The total solution was then made up to be 100ml using 
deionised water and stored at 4°C before use.
To prepare alkaline solution, 1.2g NaOH was added to 0.2ml EDTA solution and 
made up to a total volume of 100ml using deionised water. The solution was mixed 
thoroughly to dissolve NaOH and stored at 4°C before use. To prepare alkaline 
electrophoresis solution, 12g NaOH was added to 2ml EDTA solution and adjusted 
to 1L total volume using deionised water. The solution was mixed thoroughly to 
dissolve NaOH and stored at 4°C before use.
Comet assay
In a 96 well plate, maintained at 37°C using a heat block, 10pl cell suspension for 
each sample was added to 90|il pre-heated Oxiselect™ Comet agarose. All samples 
were pipetted to mix and 20pl immediately transferred onto the pre-heated (37°C) 
Oxiselect™ 96-well Comet slide using a multichannel pipette ensuring complete 
coverage of each well (Figure 2.1a). Maintaining a horizontal position the slide was
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incubated at 4°C for 15 minutes in the dark to allow the cell/agarose mixture to 
embed onto the slide. The slide was then immersed in 100ml lxLysis buffer for 1 
hour at 4°C in the dark to denature DNA. The lxLysis buffer was gently aspirated off 
and the slide immersed in 100ml pre-chilled alkaline solution for 30 minutes at 4°C 
in the dark.
Alkaline electrophoresis
Maintaining a horizontal position the slide was transferred from the alkaline 
solution to a horizontal electrophoresis chamber (Figure 2.1b). The chamber was 
filled with pre-chilled alkaline electrophoresis solution until the slide was covered. A 
current of 300mA at 24 volts was applied for 25 minutes as per manufacturer's 
protocol. This electric current results in migration of the damaged DNA fragments 
away from the intact DNA. Following electrophoresis the slide was transferred to a 
clean container and immersed in 100ml pre-chilled deionised water for 2 minutes. 
The water was then gently aspirated and the wash repeated a further two times, 
followed by a final wash with pre-chilled 70% ethanol for 5 minutes. The slide was 
carefully removed from the ethanol and allowed to air dry at rtp.
DNA staining and visualisation
50pl diluted Vista Green DNA dye was added to each well and incubated for 15 
minutes at room temperature. Using an Axio imager fluorescence microscope 
(Zeiss, Germany) the DNA migration could be visualised and photographed using a 
fitted Axiocam with FITC filter for measurement and further analysis (Figure 2.1c).
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Figure 2.1: Flowchart representation of Comet assay methodology
Healthy cells Damaged cells
a) lOpI sample suspension added to  90pl Oxiselect™ Comet agarose in a 96 well plate and 
transferred onto Oxiselect™ 96-well Comet slide, b) Comet slide transferred to  horizontal 
electrophoresis chamber w ith  24 volts applied fo r 25 minutes, c) DNA migration visualised and 
photographed fo r measurement and analysis.
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Analysis o f results
Analysis o f the Comet assay utilises 2 main parameters to measure cellular DNA 
damage, (i) Tail DNA% and (i) Tail Moment. Tail DNA% is the relative amount o f DNA 
in the tail compared to the total DNA of the cell (Figure 2.2) and is quantified by 
measuring DNA intensity using the following calculation:
Tail DNA% = (Tail DNA in ten s ity / Cell DNA intensity) x 100
Tail M om ent is a measure of the displacement between intact genetic material in 
the nucleus, known as the 'Comet Head' and the resulting 'Tail'. There are two 
commonly used methods o f calculating Tail Moment (Figure 2.2):
(i) Olive Tail M om ent = Tail DNA% x Tail M om ent Length
(ii) Extent Tail M om ent = Tail DNA% x Length of Tail
Figure 2.2: Structure of a resulting 'Comet'
H e a d
Tail Mom ent Length
(w ww.cellb io labs.com , accessed 10th September '12)
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For each sample, 50 cells were photographed using an Axio imager fluorescence 
microscope with Axiovision camera and a FITC filter. Cells were measured using the 
commercially available Comet assay specific software CometScore™ which allows 
automatic calculation of all parameters from the captured images, along with other 
measures to verify calculations manually. Measures calculated are defined in 
Appendix 4.
2.4 Gene expression analysis in hVAT using PCR arrays
Commercially available PCR arrays were utilised to analyse gene expression in RNA 
extracted from hVAT samples (section 2.2.1). All PCR arrays were carried out in a 
sterile, UV irradiated PCR hood. All pipettes were cleaned with 70% ethanol, all 
micro-centrifuge tubes were sterilised by autoclaving and sterile RNase free filter 
tips were used. Gene expression profiling was carried out using the RT2 Profiler PCR 
Oxidative Stress Arrays (Qiagen, UK) and was carried out following the 
manufacturer's protocol. These arrays allow the expression profile of 84 genes 
related to oxidative stress including peroxidises, peroxiredoxins, genes involved in 
ROS metabolism and superoxide metabolism, 5 housekeeping genes, controls for 
genomic DNA contamination, RNA quality and general PCR performance for quality 
control of the arrays as shown on the plate layout (Appendix 5).
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Genomic elimination
RNA concentration for each sample was calculated to determine the required 
volume. 2|il Genomic Elimination buffer was added to each finalised sample and 
RNase free water was added to give a total volume of lOpI, mixed via pipette and 
incubated for 5 minutes at 4°C then put on ice for 1 minute.
cDNA synthesis
mRNA contained within the total RNA was reverse transcribed in order to make 
cDNA. Reverse transcription master mix containing 4pl BC3 (5XRTbuffer3), lp l P2 
(primer + control mix), 2pl RE3 (RT enzyme mix 3) and 3pl RNase free water was 
added to lOpI of the RNA from the genomic elimination step. The mix was 
incubated for 15 minutes at 42°C, then 5 minutes at 95°C. The resulting cDNA 
reaction was diluted by adding 91pl RNase free water, vortexed and put on ice.
Real-Time PCR
A RT-PCR master mix sufficient for a 96-well plate was prepared containing 1275pl 
RT2 SYBR green qPCR mastermix, 102pl diluted cDNA reaction and 1173pl RNase 
free water. 25pl of master mix was pipetted into each well of the 96 well PCR array 
plate and sealed with a PCR plate film. The plate was centrifuged and transferred to 
a MylQ thermocycler (Biorad, Germany) and run for 1 cycle of 10 minutes at 95°C 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute (Figure 2.4).
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PCR array data analysis
Analysis of the RT-PCR array was performed using a specific validated online 
program (www.SABiosciences.com/pcrarraydataanalysis.php). The software shows 
comparisons between the groups, which allows the identification of significantly up 
or down regulated genes (p<0.05).
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Figure 2.3: Flowchart representation of the RT-PCR array methodology
Reverse transcribe RNA to cDNA
Add cDNA to RT2qPCR Master mix and aliquot into 96 well array plate
Run on Biorad MylQ thermocycler
Data analysis
Reverse transcription o f RNA to cDNA, which is then mixed w ith the RT qPCR Master mix, aliquoted 
in the 96 well plate and run on the RT thermocycler before data analysis.
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2.5 Real Time-Polvmerase Chain Reaction of genes of interest from PCR arrays
Genes that were found to be significantly up or down regulated in hVAT by the PCR 
array analysis were selected for further expression analysis using Real Time- 
Polymerase Chain Reaction (RT-PCR). RT-PCR is a sensitive technique for gene 
expression quantification of a target gene in a sample (Hruz et al, 2011) particularly 
in samples low in mRNA concentration such as fatty tissues (Pfaffl et al, 2002). 
Firstly, it requires the mRNA transcripts to be copied into complementary DNA 
(cDNA) via reverse transcription, which is then amplified and coupled to a PCR 
reaction. Fluorescence is used to follow the rate of amplification during the PCR 
reaction. During the exponential stage of the PCR reaction the fluorescence will 
meet a certain threshold when the number of PCR cycles to reach this threshold is 
measured (Ct value) and the concentration is directly proportional to the initial 
starting quantity of mRNA, therefore allowing the measurement of gene expression.
In a standard PCR, the reaction depends upon Taq polymerase, which is unable to 
use RNA as a template. Therefore, the initial step of RT-PCR is to convert mRNA into 
cDNA using an RNA-dependant DNA polymerase enzyme, reverse transcriptase, 
which uses the mRNA as a template to generate cDNA in the presence of oligo-dT or 
random decamer primers.
Internal standards are required during RT-PCR to ensure reverse transcription 
efficiency and to act as an internal control for sample to sample biases such as 
differences in RNA template quantities, stability of RNA and sample loading
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variation (Hruz et al, 2011). These standards are cellular RNA that undergo RT-PCR 
along with the target genes simultaneously, and is then used as a reference to 
normalise target genes expression (Karge et al, 1998). The standard or 
housekeeping gene is chosen as it is expressed at a constant level in all tissue types. 
A reliable housekeeping gene is (3-actin as it is a highly expressed gene and is 
frequently used as an internal standard for RT-PCR.
During RT-PCR, the detection of a fluorescent reporter which accumulates during 
the PCR reaction allows the quantification of an amplified product as the 
fluorescence is directly proportional to the amplified product. There are four main 
fluorophores used for RT-PCR (i) hybridisation probes, (ii) molecular beacons, (iii) 
Taqman probes (iv) SYBR Green 1. In this study the use of SYBR Green 1 dye is 
utilised to quantify gene expression as it requires a more simple approach and does 
not require the use of complex probes. SYBR Green 1 is an intercalating dye that 
binds directly to the minor grooves of DNA and on binding produces a fluorescent 
signal. The disadvantage of this method is that it is more susceptible to errors. 
There is a risk of non-specific binding to any double stranded DNA so the reaction 
requires full optimisation to minimise formation of primer dimers.
Primer design
RT-PCR primers were designed using gene sequence information from NCBI 
(http://www.ncbi.nlm .nih.gov/) or sequences that had been previously published 
(GPX1 primers, Boutet et al (2009); GSR primers, Corrales et al (2011)) and
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synthesised by Eurofins MWG Operon (Germany). For primer design, the final 
intron-exon boundary was located using the mRNA sequence and primers of 
approximately 20 nucleotides in length identified spanning this region, with an 
annealing temperature of approximately 60°C. Self-complementary sequences were 
avoided in order to prevent secondary structure formations. These primers were 
designed to amplify fragments of cDNA of 100-150 bp in size from GPxl, GSR, 
PPARy and IL-6 as target genes, and P-actin as a housekeeping gene. The resulting 
primer sequences are shown in Table 2.4. On arrival, all primers were re-hydrated 
using PCR H20  to a concentration of lOOpM. lOOpI of stock primer was transferred 
to a clean 1.5ml microcentrifuge tube and diluted with 567pl PCR H20 , aliquoted 
into 50pl measures and stored at -20°C.
Primer efficiency calculations
PCR efficiency calculations allow the determination of efficiency of each primer set. 
A dilution series of pooled cDNA from hVAT samples were run in triplicate for each 
primer set, allowing the best PCR efficiency estimation (Pfaffl et al, 2002). The 
percentage efficiency of the reactions was calculated using the following equation:
%Efficiency= (10(1/slope)) - l)  x 100
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cDNA synthesis
All reactions were carried out in a sterile, UV irradiated PCR hood with specially 
designated pipettes, sterile filter tips and micro-centrifuge tubes to reduce risk of 
contamination.
Table 2.4 RT-PCR Primer sequences for human samples
Name Sequence (5'-3') Length (bases)
GPxl F' GACTACACCCAGATGAACGAGC 22
GPxl R' CCC ACC AG G AACTT CT C A AAG 21
GSR F' ATCCCCGGTGCCAGCTTAGG 20
GSR R' AG CAATG TAACCTG CACCAACAA 21
PPARy F' AC AG CG ACTT G G C A AT ATTT ATT G 24
PPARy R' AGCTCCAGGGCTTGTAGCA 19
IL-6 F* CCT GAT CCAGTT CCT G CAG AA 21
IL-6 R' TCCTG CAG CC ACT G GTTCT 19
ACTB F' GATGGCCACGGCTGCTTC 18
ACTB R' TGCCTCAGGGCAGCGGAA 18
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mRNA contained within total RNA extracted from the hVAT (section 2.2.1) was 
reverse transcribed to make cDNA using a RETROscript kit (Ambion Inc, UK) 
according to the manufacturer's protocol. A master mix for the desired amount of 
reactions was prepared containing lp l oligo-dT primers, lp l random decamer 
primers, 2pl RT buffer, 4|il dNTP mix and lp l MMLV reverse transcriptase enzyme 
(100U) per reaction. The master mix was vortexed and centrifuged to ensure total 
mixing and 9pil aliquoted into 0.2ml micro-centrifuge tubes. lOOng of total RNA was 
added and brought to a total volume of 20pl with the addition of RNase free water. 
The tubes were vortexed and incubated at 44°C for 1 hour and 90°C for 10 minutes 
in order to denature the enzyme. The resultant cDNA was stored at -20°C until 
required.
RT- PCR
Each reaction contained 12.5pl iQ SYBR Green Supermix (Biorad, UK), 1|jlI forward 
primer (15pmol), lp l reverse primer (15pmol), 7.5|il PCR H20  and 3|il cDNA. A 
master mix for the desired amount of reactions was made containing all of the 
above reagents except the cDNA. The master mix was vortexed, centrifuged and 
aliquoted into micro-centrifuge tubes containing 3 reactions, as every sample was 
run in triplicate. 9^1 of sample cDNA (3pl per reaction) was added to each tube and 
mixed. 25pl of the final mix was aliquoted into the wells of a sterile 96-well PCR 
plate in triplicate. When samples were loaded the plate was sealed using an optical 
quality sealing tape sheet (Biorad, UK) and centrifuged.
Using a CFX Connect Real-Time PCR Detection System (Biorad, UK) samples were 
run for 1 cycle of 95°C for 3 minutes then 40 cycles of 94°C for 30 seconds, 60°C for 
30 seconds and 72°C for 30 seconds; 1 cycle of 55°C for 30 seconds; 1 cycle of 95°C 
for 30 seconds then 40 cycles of 55°C for 10 seconds.
Relative quantification
The 2'aact method was used to quantify the level of gene expression changes 
between groups in a relative fashion (Livak et al, 2001). The formula to calculate this 
was:
X=2-**ct
Where in this study:
X = Fold change in gene expression
A A C y  =  A C y  (sample group)" A C y  (control sample group)
A C y  =  C j(tes t sample)" (internal housekeeping gene)
2.6 Gene sequencing
After analysis of the PCR array and RT-PCR gene expression results in hVAT, one 
particular gene stood out as having differing levels of expression across the L, O and 
ODM sample groups. GSR codes an antioxidant enzyme involved in the maintenance 
of glutathione levels in environments of high oxidative burden. Alterations to the 
genetic code for the GSR gene may explain changes in expression. To investigate
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further, the GSR gene was selected for sequencing to identify any mutations or 
polymorphisms that may account for the expression difference observed in this 
cohort.
Primer design
GSR gene sequencing primers were designed using gene sequence information from 
NCBI (www.ncbi.nlm.nih.gov/) and synthesised by Eurofins MWG Operon 
(Germany). For primer design, the complete mRNA sequence for the GSR gene was 
used divided into 5 fragments of approximately 700bp each. Primers of 
approximately 20 nucleotides in length were identified spanning the different 
sections, with each primer set designed to overlap both the previous and following 
gene fragment to ensure none of the sequence was lost (Figure 2.4). Primers were 
designed with an approx annealing temperature of 60°C and self-complementary 
sequences were avoided in order to prevent secondary structure formations. The 
resulting primer sequences are shown in Table 2.5.
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Figure 2.4 Diagram of overlapping primers spanning mRNA sequence
3 '— ■ ■ ■ ■ ■
<  Primer set 1
<
Polymerase chain reaction
hVAT RNA for 61 samples was reverse transcribed to  cDNA (section 2.5). However, 
due to the position o f the various primer sets compared to the polyA tail differing 
amounts of oligo-dT and random decamer primers were used:
•  primer sets 1 and 2 - 2pl random decamer
• primer set 3 -  lp l  random decamer and lp l  oligo-dT
• primer sets 4 and 5 - 2pl oligo-dT
2pl cDNA for each sample was added to PCR reactions for each primer set, which 
consisted o f 10pl Buffer, 3pl MgCh, lp l  dNTP mix, lp l  forward primer, lp l  reverse 
primer, 0.5pl Taq polymerase enzyme and 31.5pl PCR H20. Samples were vortexed 
and centrifuged and transferred to MJ Research Thermal Cycler and run on the 
corresponding optimised program for each primer set (Table 2.6).
mRNA-3,162b
>
Primer set 2 >
<  Primer set 3 >
<  Primer set 4 >
<  Primer set 5
AAAAA 5'
>
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Table 2.5 GSR gene sequencing primer sequences
Name Sequence (5'-3') Length (bases)
GSR 1 F1 GCGCATGCTTAGTCACCGTG 20
GSR 1 R' GAT CCC AAG CCCACAATAG AG 21
GSR 2 F' CAATCTCACCAAGTCCCATATAG 23
GSR 2 R' GTGGCTGAAGACCACAGTTGG 21
GSR 3 F' G AA AAG CT CTT CTT ACTCCAG 21
GSR 3 R' GCTTTATATTTGGGATGAGGC 21
GSR 4 F' GTACATAATAGAACTTATTTATGG 24
GSR 4 R' CGGCTTCTCACATTACATGC 20
GSR 5 F' GCTGCTTCAAGGATGAGACC 20
GSR 5 R' TATAAGAAGAAAAGGCTGTAA1 1 1 1 25
64
Table 2.6 Programs for GSR sequencing primers
Primer set Program
GSR 1 94°C for 2mins
33 cycles of:
94°C for 30secs
56°C for 30secs
72°C for 25secs
15°C forever
GSR 2 94°C for 2mins
25 cycles of:
94°C for lOsecs
56°C for lOsecs
72°C for 15secs
15°C forever
GSR 3 94°Cfor 2mins
30 cycles of:
94°C for 30secs
62°C for 30secs
72°C for 25secs
15°C forever
GSR 4 94°Cfor 2mins
30 cycles of:
94°C for 30secs
56.7°C for 30secs
72°C for 25secs
15°C forever
GSR 5 94°C for 2mins
30 cycles of:
94°C for 30secs
57.8°C for 30secs
72°C for 25secs
15°C forever
PCR purification
PCR products were purified using QIAquick PCR purification kit (Qiagen, UK)
following the manufacturers protocol. 45pl PCR product for each sample was added
to 225|il Buffer PB and vortexed. Mixture was transferred to QIAquick spin column
and centrifuged at 13,000rpm (15,700xg) for 1 minute, the flow through was
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discarded and repeated for a further 1 minute. The QIAquick spin column was 
transferred into a clean 1.5ml tube, 50pl water added to the centre of the column 
membrane and centrifuged at 13,000rpm (15,700xg) for 1 minute. The resulting 
purified PCR products were labelled and stored at -20°C until sent for sequencing.
Sanger sequencing
Purified PCR products were sequenced by a commercial sequencing company 
(Source Bioscience, UK), which adopts the Sanger sequencing methodology. This 
method elongates complementary DNA sequences with a mix of dideoxynucleotides 
(ddNTPs) labelled with coloured fluorescent dye, each emitting light at different 
wavelengths. The resulting DNA sequence is fragmented and passed through a laser 
field and fluorescence detection device, which stimulate the fluorochromes and 
identifies bases in sequence order, displaying them in the form of a chromatograph.
Sequencing analysis
Resulting chromatographs were analysed and compared between samples by 
visualising the sequence using specific software (Chromas Lite Version 2.1.1) that 
allows the conversion of the chromatograph sequence into a format that can be 
exported into Mutation Surveyor® software. Mutation Surveyor® allows the 
comparison of each sample's sequence against a wildtype sequence, obtained from  
NCBI database, and hence the identification of any mutations between sample 
sequences. Any mutations observed are finally verified by re-sequencing.
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2.7 Mouse 3T3-L1 cell line
3T3 is a mouse (Mus musculus) fibroblast cell line. The LI generation is a continuous 
sub-strain of 3T3, which has been developed through clonal isolation. The cells have 
a complete cell cycle of 14 hours and require medium renewal every 2-3 days. The 
cell line contains insulin receptors, which in the presence of insulin and other 
factors, can induce differentiation from pre-adipocyte to adipocyte. This line has 
been widely used in in vitro association studies involving obesity and type 2 
diabetes (D'Esposito et ai, 2012).
2.7.1 Cell Culture
All cell culture and experiments were carried out within the sterile environment of a 
unidirectional laminar flow hood that was pre-cleaned with 70% ethanol and UV 
irradiated to reduce the risk of contamination. Prior to use, all media were pre­
warmed in a water bath at 37°C.
3T3-L1 cells were grown in 75cm2 flasks containing 30ml Dulbecco's Modified Eagle 
Medium media (DMEM) (either DMEM high glucose [4.5g/L] or DMEM low glucose 
[lg/L]), fetal bovine serum (FBS) (10%), penicillin-streptomycin (2%) and sodium 
bicarbonate (1%) and incubated in a 5% C02 environment at 37°C. When sub- 
culturing, cells were washed with PBS, trypsinised and re-suspended in 30ml of pre­
warmed medium. Cells were split 1 in 3 10ml of re-suspended cells and medium 
were transferred into 2 x clean 75cm2 flasks and 10ml remaining in the original
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flask. Each flask had an additional 20ml of pre-warmed media added and incubated 
in a 5% C02 environment at 37°C.
2.7.2 Pro-oxidant treatment of 3T3-L1 cells
Lipopolysaccharide (LPS) are found in the cell wall of Gram-negative bacteria, and 
act as an endotoxin, inducing strong responses in mammalian immune systems, so 
was used as a pro-oxidant biochemical stressor treatment. The LPS (Sigma, UK) used 
in the study was sourced from Escherichia coli and purified by phenol extraction. 
This LPS serotype has been used to stimulate B-cells and induce nitric oxide 
synthase (NOS) in human hepatocytes. A working concentration of lpg/m l for 
treatment was taken from previous studies conducted by Kizaki et al, (2002), with 
all experiments being conducted in triplicate. LPS was administered after 3 days of 
culturing to allow for healthy growth and confluency. Cells were left for a full 14 
hour cell cycle post treatment before being re-suspended in PBS for extraction of 
RNA.
2.7.3 RNA extraction from 3T3-L1 cells
Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen, UK) following the 
manufacturer's protocol. Prior to every extraction the hood and all pipettes were 
cleaned and UV irradiated, all micro-centrifuge tubes and RNA free water were 
sterilised by autoclaving and sterile RNase free filter tips were used.
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Before extraction, cells were suspended in 10ml PBS, centrifuged and supernatant 
discarded. Homogenisation was carried out by re-suspending the pellet in 600pl 
Buffer RLT mix (lOpI P-mecaptoethanol + 1ml Buffer RLT) and passing the lysate 
through a 20-gauge needle 5 times. Homogenised lysate was transferred to a 
RNeasy mini column and collection tube, centrifuged for 15 seconds at 10,000rpm  
(9,300xg) and flow through discarded. 700pl Buffer RW1 was added, centrifuged for 
15 seconds at 10,000rpm (9,300xg) and flow through discarded. 500pl Buffer RPE 
was added, centrifuged for 15 seconds at 10,000rpm (9,300xg) and flow through 
discarded, with the Buffer RPE step being repeated for a second time. The RNeasy 
column was placed in a clean centrifuge tube and the RNA was eluted by the 
addition of 50pl of RNase free water directly onto the column membrane and 
centrifuged for 1 minute at 10,000rpm (9,300xg). The elution step was repeated 
with a further 50pl of RNase free water and the final volume of total RNA was 
aliquoted into 20pl measures and stored at -80°C.
2.7.4 Mouse RT-PCR primer design
RT-PCR primers were designed using gene sequence information from the NCBI 
sequence database (www.ncbi.nlm.nih.gov/) and supplied by Eurofins MWG  
Operon (UK). For primer design, the final intron-exon boundary was located using 
the mRNA sequence and primers of approximately 20 nucleotides in length 
identified spanning this region, with an annealing temperature of approximately 
60°C. Self-complementary sequences were avoided in order to prevent secondary 
structure formations. These primers were designed to amplify fragments of cDNA of
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100-150 bp in size from mouse GPxl and GSR as target genes; and mouse (3-actin as 
a housekeeping gene. The resulting primer sequences are shown in Table 2.7. On 
arrival, all primers were re-hydrated using PCR H20  to a concentration of lOOpM. 
lOOpI of stock primer was transferred to a clean 1.5ml microcentrifuge tube and 
diluted with 567pl PCR H20 , aliquoted into 50pl measures and stored at -20°C.
Table 2.7 Mouse RT-PCR primer sequences
Name Sequence (S'-B1) Length (bases)
M GPxl F' C A AT GT A A A ATT G G G CTCG A A 21
M GPxl R' GTTTCCCGT G CAAT C AGTT C 20
M GSR F' AT CGTGCATG AATT CCG AGT 20
M GSR R' GGTGGTGGAGAGTCACAAGC 20
M ACTB F' ATGGAGGGGAATACAGCCC 19
M ACTB R' TT CTTT G CAG CT CCTT CGTT 20
All RT-PCR reactions were conducted as per the hVAT samples described earlier 
(section 2.5).
2.8 Statistical analysis
Statistical analysis was performed using SPSS (Version 19). Data are reported for 
those individuals within the L, O and ODM groups. Results are presented as mean
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and standard deviation. For data that was normally distributed after log 
transformation, the geometric mean and approximate standard deviation are 
shown. For data that could not be transformed to a normal distribution the median 
and interquartile range are given. Analysis of variance (ANOVA) was used to assess 
the association between group and baseline characteristics for data that was 
normally distributed after log transformation. For data that could not be 
transformed to a normal distribution analysis was carried out using the Kruskal- 
Wallis and Mann-Whitney tests. Chi-squared tests were used to compare 
differences in categorical variables by group. In all cases a P-value of < 0.05 was 
considered statistically significant. Two sided statistical testing was performed. Any 
further specific statistical analysis is detailed in each chapter.
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CHAPTER THREE
BIOMARKERS OF OXIDATIVE STRESS 
AND DNA DAMAGE IN VISCERAL ADIPOSE TISSUE
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3.1 Introduction
Oxidative stress is free radical-mediated damage caused by excess levels of ROS, as 
previously described (Section 1.1). In the case of increased levels of ROS, cells have 
defensive antioxidant systems that scavenge ROS and repair oxidative damage 
(Section 1.1.2). Increased oxidative stress is associated with obesity and T2DM  
(Codoner-Franch et al, 2011; Rehman et al, 1999), and can result in increased DNA 
damage within these populations (Apelt eta l, 2009; Tatsch eta l, 2012).
3.1.1 Measures of oxidative stress
During this chapter, experiments were undertaken to satisfy aim 1 as laid out in 
Chapter 1 (Section 1.10). In order to measure oxidative stress in hVAT in the three 
different subject groups (L, O and ODM) four methods were selected as markers to 
provide a "global" view of oxidative burden. Over recent years a number of 
measurements of oxidative stress have been developed, although few hold the 
reliability and specificity that is required for their use in a more clinical setting. To 
measure ROS directly is considered unfeasible due to their highly reactive state and 
short half-life (Brandes et al, 2005), therefore, common practice has adopted 
measures of ROS induced damage that result from high levels of oxidative stress. 
Meeting the objective of this study required the consideration of techniques that 
would gather the global oxidative status of the subjects and measure levels of 
resulting oxidative damage.
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3.1.2 Total antioxidant capacity
Antioxidant activity may be measured by the overall capacity of antioxidants, 
measurement of specific enzymes (SOD, catalase or GPx) or the resistance of a 
sample to an external oxidant. A marker of total antioxidant capacity was chosen, in 
the form of the TAOS assay. TAOS is a method, described by Sampson et al (2002), 
to measure global antioxidant levels in a sample relative to a saline control. It was 
chosen to allow the relative active antioxidant levels within the samples to be 
compared between subject groups; L, 0  and ODM. This method was the ideal 
choice as it was an established technique within the research group and was easily 
accessible and has been used widely within clinical studies (Dandana et al, 2011).
Although TAOS has become more widely used in studies examining oxidative stress 
it does have its limitations as do other measures of its kind. These methods work on 
the basis of a sample's ability to quench free radicals that are present such as 1,1- 
diphenyl-2-picrylhydrazl or, in the case of TAOS, ABTS+radicals. Drawbacks observed 
in measures of this type were inconsistencies in results between methods therefore 
showing no association or correlation. Also, variation within results have been 
observed during prolonged storage of samples proving concerns about the overall 
stability of the markers (Codoner-Franch et al, 2011). Measures of antioxidant 
capacity, such as those mentioned are predominantly measured within plasma 
samples. Therefore analysing this in hVAT samples was basic and experimental. Our 
review of the available literature has shown that the TAOS assay and other 
measures of total antioxidant capacity have not been used to measure antioxidant 
levels in AT homogenates. Therefore, this was novel basic work.
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3.1.3 Measures of lipid peroxidation
Increased levels of oxidative stress lead to the initiation of lipid peroxidation, which 
is the degradation of lipids (Section 1.1.3). TBARS was chosen as a method of 
measuring products of lipid peroxidation related to oxidative stress. The 
measurement of products of lipid peroxidation, such as aldehydes, have been 
widely used as a quantitative measure of oxidative stress in plasma samples in a 
number of studies. Increased levels of F2-isoprostanes have been observed in 
obesity and T2DM (Keaney et al, 2003; Helmersson et al, 2004). The measurement 
of plasma and urinary F2-isoprostanes have become the gold standard measures of 
lipid peroxidation In vivo, although, the techniques involves a complex protocol 
involving gas chromatography-mass spectrometry (GC-MS) analysis (Yin et al, 
2009).
Alternatively, TBARS assays quantify the concentration of MDA in samples as a 
marker of oxidative stress. MDA is the most widely studied peroxidation product, 
and as well as its use as a marker of oxidative stress it also has a mutagenic effect 
on DNA (Del-Rio et al, 2005). TBARS was chosen for this study due to its more basic 
methodology, without the requirement of mass spectrometry. It does however 
have its limitations as this spectrophotometric assay is not entirely specific to the 
measurement of MDA, as other aldehydes similar to MDA may also be detected. 
Previous studies using TBARS observed increased MDA concentration in plasma 
samples from obese subjects (Lima et al, 2004; Furukawa et al, 2013). This method, 
according to the literature, has not be used in hVAT samples.
3.1.4 Markers of oxidative DNA damage
Excessive ROS causes oxidative damage to DNA that may cause premature cell 
senescence, often a result of telomere shortening (Section 1.7) or damage in the 
form of strand breaks. Two markers of DNA damage were chosen to compare the 
extent of oxidative damage in subjects with obesity and T2DM. These were (i) a 
PCR-based method to measure telomere length and (ii) a Comet assay to quantify 
DNA damage, such as double strand breaks, associated with oxidative stress.
A method for the measurement of telomere length was chosen with the rationale 
that telomeres have been observed to shorten at a faster rate in environments of 
oxidative stress, such as in obesity and T2DM (Zglinicki, 2002). Telomere length is an 
established measure that we and collaborators at UCL have used (Salpea et al, 
2009). This made it accessible for me to visit the research group at UCL to learn the 
technique and adapt it for the laboratory in Swansea. Previous studies have 
examined telomere lengths in a number of different tissues (but not AT) and found 
that overall there was little difference in telomere length between tissue types 
(Friedrich et al, 2000), but did show that leukocytes may serve as a surrogate for an 
individual's telomere length; as a result since then most studies have focused on 
using leukocytes for this technique. This does not mean that the method is not 
successful in other tissues, although no literature has been described examining 
telomere lengths with AT.
As another method of measuring oxidative DNA damage a commercial Comet assay 
was chosen. Initially an in-house assay protocol was attempted following a method
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described by Cerda et al (1997) although optimisation was unsuccessful due to very 
strict conditions that were unable to be met. For this reason a commercially 
available alternative was utilised. The Comet assay was chosen as it is widely used 
as a quick and reliable way to analyse DNA damage in individual cells. In the past it 
has been used to investigate oxidative damage in relation to various conditions, 
including diabetes (Ibarra-costill et al, 2010) and to study the effects of prescription 
drugs on cells (Sliwinska et al, 2008). Previous studies using the Comet assay to 
investigate DNA damage in obesity found a positive association between DNA 
damage, BMI, antioxidant status and MDA concentration (Bukhari et al, 2010). No 
literature was found using the Comet assay to examine DNA damage in AT samples, 
as the majority of studies used blood plasma for analysis.
3.2 Aims
The purpose of the work described in this chapter was firstly to attempt to measure 
two different biomarkers of oxidative stress (AABTS+ and TBARS) and two markers 
of DNA damage (telomere length and Comet) in hVAT. The second aim was to 
examine these biomarkers in samples obtained from lean, obese and obese patients 
with T2DM in order to get an overview of the difference in oxidative burden 
between the groups in this population that may be associated with obesity and/or 
diabetes.
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3.3 Methods
Biomarkers of oxidative stress (AABTS+ and TBARS) and DNA damage (telomere 
length and Comet) were measured in 61 hVAT samples. Samples were categorised 
as L, which have a BMI <30; O, which have a BMI>30 and ODM with a BMI>30 and 
have T2DM.
3.3.1 Biomarkers of oxidative stress in visceral adipose tissue
3.3.1.1 AABTS+ within hVAT homogenate samples relative to saline control
Relative change in ABTS+ (AABTS+), as described in detail in Chapter 2 (Section 2.3.1) 
is a protocol modified from a previously described method that measured total 
antioxidant status (TAOS) in plasma (Sampson et al, 2002; Stephens et al, 2009). 
This protocol was developed to allow use of tissue homogenates instead of blood 
plasma samples. AABTS+ was successfully measured in hVAT homogenates of 61 
subjects. Higher levels of ABTS+ formation is indicative of increased levels of 
oxidative stress in the hVAT samples.
3.3.1.2 Thiobarbituric acid reactive substances
Thiobarbituric acid reactive substances (TBARS) is a marker of lipid peroxidation 
(Section 1.1.3), a mechanism of cellular injury and an indicator of oxidative stress. 
The assay measures malondialdehyde (MDA) concentration, as a natural product of 
lipid peroxidation, which readily reacts with 2-thiobarbituric acid (TBA) to form a 
red fluorescent adduct that is measured fluorometrically. TBARS can be used to 
assay lipid peroxidation in plasma, serum, urine, tissue homogenates and cell 
lysates. Tissue homogenates from hVAT (Section 2.3.1) were successfully assayed in
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61 subjects (Section 2.3.2). Using an MDA standard curve the concentration of MDA 
in the homogenates was calculated. Higher concentration of MDA is indicative of a 
higher level of lipid peroxidation, and therefore, higher oxidative stress within the 
hVAT.
3.3.2 Biomarkers of DNA damage in visceral adipose tissue
3.3.2.1 Telomere length
As described in Chapter 1 (Section 1.7), telomeres are DNA repeat sequences found 
at the end of chromosomes that shorten during replication and are therefore 
representative of the cell's biological age. As discussed, environments of high 
oxidative stress potentially lead to accelerated telomere shortening and have been 
implicated in the pathogenesis of T2DM. Telomere length was successfully 
measured in DNA extracted from 61 hVAT samples (Sections 2.2.2 and 2.3.3). 
Relative telomere length was calculated as the ratio of telomere repeats to single­
copy gene copies, termed the T/S ratio, using a validated quantitative PCR-based 
method.
3.3.2.2 Comet assay
The Comet assay was utilised as a marker of DNA damage. It is a method to visualise 
DNA damage within a cell by the use of electrophoresis resulting in 'comet-like' tails 
that can be measured microscopically. The longer the comet tail the higher degree 
of damage. Comet assay was successfully carried out on hVAT homogenates from 
61 samples in duplicate (Section 2.3.4).
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3.3.3 Statistical analysis
I chose to analyse the differences between all groups (L v 0  v ODM), as well as 
subcategorising by L v O+ODM, which groups lean v all obese subjects together; and 
L+O v ODM, grouping subjects with no diabetes against those with diabetes.
Data was analysed as described in Chapter 2 (Section 2.8). For samples run in 
triplicate, average values were used for analysis. TBARS and TAOS data were 
normally distributed after log transformation, so geometric mean and approximate 
standard deviation are shown. T/S ratio data could not be transformed to a normal 
distribution so the median and interquartile ranges are given. All data from the 
Comet assay were normally distributed and presented as mean and standard 
deviation for all measures, with exception of 'Tail mean intensity' which could not 
be transformed to a normal distribution and is displayed as median and 
interquartile range. Data were analysed using the Kruskal-Wallis test for non- 
parametric data.
3.4 Results
3.4.1 Baseline characteristics
3.4.1.1 Lv Ov  ODM
hVAT samples were collected from 61 subjects, grouped as L, 0  and ODM 
(L/O/ODM: 20/20/21), to investigate the association between oxidative stress and 
baseline characteristics. As shown in Table 3.1, age was significantly different across 
groups (P=0.028). The L group was approximately 5 years older than the O group 
and approximately 11 years older than ODM group, with a significant linear
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relationship across groups from L, 0  to ODM (P=0.006). As expected a significant 
difference was seen in the weight and BMI (P=<0.001 for both), being greatest in 
the ODM group. There was no significant difference in blood pressure (SBP or DBP) 
between groups, however as expected blood glucose levels were significantly higher 
in the ODM group (P=0.015). Plasma levels of creatinine (P=0.016) and albumin 
(P=0.046) were significantly lower in the ODM group.
DNA and RNA concentration was quantified to ensure required concentration and 
purity for examination. DNA concentration showed no different between groups 
but of interest the RNA concentration was 20% lower in the ODM group compared 
to L and 0 , however this did not reach significance (P=0.422). Although not 
significantly different there was a higher proportion of males in the L group and 
there was no difference in smoking status between groups. Significant co­
morbidities seen in the ODM group were hypertension (P=0.009) and obstructive 
sleep apnoea (OSA) (P=0.001). A significantly higher proportion of subjects in the 
ODM group were on statin (P=0.020) and ACE inhibitor (P=0.043) therapies.
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Table 3.1 Baseline characteristics compared between groups
Lean
(n=20)
Obese
(n=20)
O b ese /T2D M
(n=21)
P
Age (years) 55.3 (17.4) 49.7(10.8) 44.3 (8.6) 0.028
Weight (kg) 73.5(13.1) 119.6(36.1) 136.9 (26.5) <0.001
BMI (kg/m2) 25(2.8) 41 (10.8) 50(10.7) <0.001
SBP (mmHg) 139 (23.4) 130 (17.0) 144 (19.7) 0.130
DBP (mmHg) 80(13.2) 79 (11.9) 76 (14.3) 0.604
Glucose (mmol/L)* 5.7 (0.6) 5.6 (0.3) 8.1 (1.6) 0.015
Cholesterol (mmol/L) 5.3 (1.4) 5.5 (1.7) 4.8 (1.2) 0.501
HDL-C (mmol/L) 1.5 (0.3) 1.2 (0.3) 1.1 (0.3) 0.053
LDL-C (mmol/L) 3.3 (1.1) 3.5 (1.6) 2.6 (0.9) 0.229
Triglycerides (mmol/L) 1.2 (0.2) 1.6 (0.8) 2.7 (1.4) 0.057
Creatinine (pmol/L) 78.2 (17.5) 78.7 (12.6) 66.3 (14.4) 0.016
Albumin (mmol/L) 46.7 (8.1) 43.4(2.4) 42.2 (4.5) 0.042
DNA (ng/pl) 15.6 (6.3) 15.1 (6.7) 15.2 (12.1) 0.980
RNA (ng/pl) 98.0 (61.4) 96.7 (51.7) 77.0(55.1) 0.422
Males % (n) 55.0(11) 40.0(8) 35.0(7) 0.359
Current smoker % (n) 25.0(5) 25 0(5) 14.3(3) 0.648
Hypertension % (n) 20.0 (4) 25.0(5) 61.9 (13) 0.009
OSA % (n) 0(0) 15.0(3) 47.6(10) 0.001
Statins % (n) 5.0(1) 30.0(6) 42.9 (9) 0.020
ACE inhibitor % (n) 20.0 (4) 10.0(2) 42.9(9) 0.043
Baseline characteristics o f hVAT samples in L, O and ODM groups. Log transform ed data. Mean and 
standard deviation shown or geometric mean and approximate standard deviation fo r log 
transform ed data. Analysis perform ed by ANOVA after appropriate transform ation. x 2~test was usec* 
to compare groups. P-value shows significance where P<0.05
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3.4.1.2 L v O+ODM
Prior to analysis, I chose to examine baseline characteristics between L v O+ODM to 
look at the effects of obesity between groups. The results are detailed in Table 3.2. 
Age (P=0.020), weight (P<0.001) and BMI (P<0.001) were significantly different 
between groups. Blood pressure and cholesterol levels were not significantly 
different between the two groups and although not significant, glucose levels were 
higher in the O+ODM subjects. HDL-C (P=0.031) and albumin (P=0.014) were 
significantly lower in the O+ODM group, and there was no significant difference in 
gender. There were more than four times the number of subjects with hypertension 
in the O+ODM group but this was not statistically significant. All subjects with OSA 
fell into the O+ODM group, therefore making it significant (P=0.005); and there was 
a significantly higher proportion of subjects on statin treatment in the obese 
subjects (P=0.008).
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Table 3.2 Baseline characteristics betw een lean and obese groups (O +O D M )
Lean
(n=20)
Obese+Obese T2D M  
(n=41)
P
Age (years) 55.3 (17.4) 46.9(10.0) 0.020
Weight (kg) 73.5 (13.1) 128.7 (32.2) <0.001
BMI (kg/m2) 25 (2.8) 46(11.6) <0.001
SBP (mmHg) 139 (23.4) 137 (19.5) 0.799
DBP (mmHg) 80(13.2) 77 (13.0) 0.441
Glucose (mmol/L)* 5.7 (0.6) 7.1 (0.7) 0.162
Cholesterol (mmol/L) 5.3 (1.4) 5.0(1.3) 0.659
HDL-C (mmol/L) 1.5 (0.3) 1.1 (0.3) 0.021
LDL-C (mmol/L) 3.3 (1.1) 2.8 (1.2) 0.448
Triglycerides (mmol/L) 1.2 (0.2) 2.4 (1.4) 0.094
Creatinine (pmol/L) 78.2 (17.5) 72.2 (14.8) 0.173
Albumin (mmol/L) 46.7 (8.1) 42.7 (3.7) 0.014
DNA (ng/pl) 15.6(6.3) 15.1 (9.6) 0.841
RNA (ng/pl) 98.0(61.4) 86.9(53.6) 0.472
Males % (n) 55.0(11) 36.6(15) 0.172
Current smoker % (n) 25.0(5) 19.5(8) 0.331
Hypertension % (n) 20.0 (4) 43.9(18) 0.068
OSA % (n) 0(0) 31.7 (13) 0.005
Statins % (n) 5.0(1) 36.6(15) 0.008
ACE inhibitor % (n) 20.0 (4) 26.8(11) 0.561
Baseline characteristics between lean and obese (O+ODM) groups to look at effects o f obesity 
between groups. Log transform ed data. Mean and standard deviation shown or geom etric mean 
and approxim ate standard deviation for log transform ed data. Analysis performed by ANOVA after 
appropriate transform ation. x 2_test was used to compare groups. P-value shows significance where 
P<0.05
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3.4.1.3 L+0 v ODM
I chose to examine baseline characteristics between L+O v ODM to look at the 
effects of non-diabetes (n=40) and diabetes (n=21). The results are shown in Table 
3.3. Age (P=0.022), weight (P<0.001) and BMI (P<0.001) were significantly different 
between groups. There was no significant difference in blood pressure, cholesterol, 
lipoprotein and albumin levels. Levels of plasma glucose (P=0.004) and triglycerides 
(P=0.019) were significantly higher in the group with diabetes. There was a higher 
proportion of males in the non-diabetes group although this was not significant. 
RNA concentration was lower in the diabetes group compared to non-diabetes 
although this difference was not significant. The co-morbidity hypertension 
(P=0.002) and OSA (P<0.001) were significantly more prevalent in the subjects with 
diabetes and more subjects in the diabetes group were on statin (P=0.032) and ACE 
inhibitor treatments (P= 0.016).
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Table 3.3 Baseline characteristics between no-diabetes (L+O) and diabetes
groups
No Diabetes  
(n=40)
Diabetes
(n=21)
P
Age (years) 52.5 (14.5) 44.3 (8.6) 0.022
Weight (kg) 96.0(35.3) 136.9 (26.5) <0.001
BMI (kg/m2) 33(10.9) 50(10.7) <0.001
SBP (mmHg) 135 (20.9) 144 (19.7) 0.116
DBP (mmHg) 79(12.5) 76(14.3) 0.339
Glucose (mmol/L)* 5.6 (0.4) 8.1 (1.6) 0.004
Cholesterol (mmol/L) 5.4 (1.5) 4.8 (1.2) 0.244
HDL-C (mmol/L) 1.3 (0.3) 1.1 (0.3) 0.060
LDL-C (mmol/L) 3.4 (1.3) 2.6 (0.9) 0.084
Triglycerides (mmol/L) 1.4 (0.6) 2.7 (1.4) 0.019
Creatinine (pmol/L) 78.4 (15.1) 66.3 (14.4) 0.004
Albumin (mmol/L) 45.2 (6.4) 42.2 (4.5) 0.065
DNA (ng/|il) 15.4 (6.4) 15.2 (12.1) 0.927
RNA (ng/|il) 97.4(56.0) 77.0(55.1) 0.188
Males % (n) 47.5 (19) 35.0(7) 0.288
Current smoker % (n) 25.0(10) 14.3(3) 0.606
Hypertension % (n) 22.5 (9) 61.9 (13) 0.002
OSA % (n) 7.5(3) 47.6(10) <0.001
Statins % (n) 17.5(7) 42.9(9) 0.032
ACE inhibitor % (n) 15.0(6) 42.9(9) 0.016
Baseline characteristics between non-diabetes (L+O) and diabetes groups to look at the effect o f 
diabetes between groups Log transform ed data. Mean and standard deviation shown or geometric 
mean and approxim ate standard deviation fo r log transform ed data. Analysis perform ed by ANOVA 
after appropriate transform ation. x 2-test was used to compare groups. P-value shows significance 
where P<0.05
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3.4.2 Biomarkers of oxidative stress in visceral adipose tissue
3.4.2.1 AABTS+ within hVAT homogenate samples relative to saline control
AABTS+ data analysis was carried out using a modified calculation from  previously 
described TAOS assay (Sampson et al, 2002; Stephens et al, 2009); in order to  give a 
change in ABTS+ form ation  per sample relative to  saline control results. There was 
no overall d ifference in AABTS+ between groups (Figure 3.1) (L v O v ODM: 2.0 (0.1) 
v 2.0 (0.3) v 1.9 (0.01), P=0.813). Additionally, no difference was observed when L 
group was compared to  combined O+ODM group (L v O+ODM: 2.0 (0.1) v 2.0 (0.2), 
P=0.752) (Figure 3.2); or when combined L+O group was compared to  ODM group 
(L+O v ODM: 2.0 (0.2) v 1.9 (0.1), P=0.518) (Figure 3.3).
Figure 3.1 AABTS+ between groups relative to saline
2.5 -| P=0.813
L O ODM
Group
Relative AABTS+ between groups. Geometric mean and approximate standard deviation shown
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Figure 3.2 AABTS+ betw een lean and obese groups (O+ODM ) relative to  saline
P= 0.752
O+ODM
Group
Relative AABTS' between lean and obese (O+ODM) groups to look at effects o f obesity. Geometric 
mean and approximate standard deviation shown
Figure 3.3: AABTS+ between no-diabetes (L+O) and diabetes groups relative to 
saline
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Relative AABTS* between no-diabetes (L+O) and diabetes groups to look at effects of diabetes. 
Geometric mean and approximate standard deviation shown
P= 0.518
No Diabetes Diabetes
Group
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3.4.2.2 Thiobarbituric acid reactive substances (TBARS)
TBARS were measured as an ind icator o f oxidative stress in 61 hVAT homogenates 
using an MDA standard curve to  calculate the concentration o f MDA w ith in  each 
sample. As shown in Figure 3.4, there was no significant change in MDA 
concentration between groups (L v 0  v ODM (pM): 19.6 (8.4) v 18.4 (11.4) v 9.8 
(3.8), P=0.110). A higher MDA concentration was observed in the L group when 
compared to  combined O+ODM group although not significant (L v O+ODM (pM ): 
19.6 (8.4) v 13.5 (7.1), P=0.238) (Figure 3.5). A significantly lower MDA 
concentration was observed in the ODM group when compared to  the combined 
L+O (L+O v ODM (pM): 19.0 (10.0) v 9.8 (3.8), P=0.036) (Figure 3.6).
Figure 3.4 MDA concentration between groups
P= 0.115
30
5  25
L O ODM
Group
MDA concentration between groups. Geometric mean and approximate standard deviation shown
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Figure 3.5 MDA concentration between lean and obese groups (O +O DM )
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P= 0.238
O+ODM
Group
MDA concentration between lean and obese (O+ODM) groups to  look at effects of obesity. 
Geometric mean and approximate standard deviation shown
Figure 3.6 MDA concentration between no-diabetes (L+O) and diabetes 
groups
35
P= 0.036
Q 10
No Diabetes Diabetes
Group
MDA concentration between no-diabetes (L+O) and diabetes groups to look at effects of diabetes. 
Geometric mean and approximate standard deviation shown
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3.4.3 Biomarkers of DNA damage in visceral adipose tissue
3.4.3.1 Telomere length
Relative te lom ere length was calculated as the ratio o f telom ere repeats to  single­
copy gene copies (T/S ratio) in 60 DNA samples. As shown in the box p lo t (Figure 
3.7), T/S ratio was fou r tim es higher in ODM subjects when compared to  L and 0  
groups (L v 0  v ODM: 1.0 [0.8 - 4.3] v 1.0 [0.9 - 4.2] v 4.4 [2.1 - 4.8], P=0.064) w ith  a 
significant d ifference between O and ODM groups (P=0.048). There was no 
significant d ifference observed in the T/S ratio between the L group and combined 
O+ODM group (L v O+ODM: 1.0 [0 8 - 4.3] v 3.8 [0.9 - 4.8], P=0.221) (Figure 3.8); 
however this was significantly higher fo r diabetes group compared to  no-diabetes 
group (L+O v ODM: 1.0 [0.9 - 4.2] v 4.4 [2.1 -  4.8], P=0.019) (Figure 3.9).
Figure 3.7 Median telomere length (T/S ratio) between groups
P= 0.064
7 (--------------------------------------1--------------------------------------1
P= 0.048
0   t----------------------------------------------------------i—
L O ODM
Group
T/S ratios between groups. Median and in terquartile  range shown. Coloured marker shows median, 
'box' shows quartile  range and outer markers show m inim um  and maximum values
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Figure 3.8: Median telomere length (T/S ratio) between lean and obese (O+ODM) 
groups
P= 0.221
5 -
4o
+3
E 
§  3
2
O+ODM
Group
T/S ratio between lean and obese (O+ODM) groups to look at effects of obesity. Median and 
interquartile range shown. Coloured marker shows median, 'box' shows quartile range and outer 
markers show minimum and maximum values
Figure 3.9: Median telomere length (T/S ratio) between no-diabetes (L+O) and 
diabetes groups
P= 0.019
5 -
No Diabetes Diabetes
Group
T/S ratio between no-diabetes (L+O) and diabetes groups to look at effect of diabetes between 
groups. Median and interquartile range shown. Coloured marker shows median, 'box' shows quartile 
range and outer markers show minimum and maximum values
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3.4.3.2 Comet assay
The Comet assay was utilized to calculate several previously described comet 
parameters (Section 2.3.4, Appendix 4) as a measure of DNA damage in 61 hVAT 
samples. Examples of comets analysed for each group are shown in Figure 3.10. As 
shown in Table 3.4, there was no significant difference between the groups for any 
comet measures. No significant difference in parameters was seen between L and 0  
groups. When comparing O and ODM groups there was a significant difference 
found in Comet intensity (1.1 x 105 [33403.4] v 1.4 x 105 [38356.4], P=0.023), Head 
intensity (3.3 x 104 [8276.1] v 3.9 x 104 [11731.0], P=0.048) and Tail intensity (7.9 x 
104 [28272.3] v 9.9 x 104 [28799.1], P=0.030).
There was no significant difference observed in comet parameters between the L 
group and combined O+ODM group so results have not been tabulated. When 
comparing the non-diabetes subjects to the diabetes groups (L+O v ODM) the Head 
intensity for ODM group was significantly higher (3.3 x 104 [8856.4] v 3.9 x 104 
[11731.0], P=0.033) (Table 3.5).
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Figure 3: Examples of comets from  each group
ODM
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Table 3.4 Comet measures compared between groups
Lean Obese Obese/T2DM
D
(n=20) (n=20) (n=21)
r
Comet length (pm) 77.45 (12.0) 76.99 (8.1) 79.00 (6.9) 0.764
Comet height (pm) 59.88 (5.4) 60.00 (9.5) 62.28 (5.9) 0.476
Comet area (pm2) 3.7 x 103 (906.6) 3.7 x 103 (805.3) 4.0 x 103 (674.0) 0.418
Comet intensity 
(cd x 1000)
1.2 x 105 (44980.1) 1.1 x 10s (33403.4) 1.4 x 10s (38356.4) 0.102
Comet mean intensity 
(cd x 1000)
27.35 (10.1) 26.65 (5.7) 30.39 (7.9) 0.293
Head diameter (pm) 36.81 (4.0) 36.90 (4.8) 38.75 (3.7) 0.245
Head area (pm2) 2.1 x 103 (639.7) 2.2 x 103 (463.9) 2.3 x 103 (554.7) 0.307
Head intensity 
(cd x 1000)
3.4 x 104 (9567.3) 3.3 x 104 (8276.1) 3.9 x lO 4 (11731.0) 0.096
Head mean intensity 
(cd x 1000)
17.98 (6.2) 15.88 (4.6) 17.18 (4.9) 0.448
Head DNA (%) 30.04 (7.5) 31.25 (8.3) 29.30 (3.8) 0.652
Tail length (pm) 40.65 (10.1) 40.09 (5.7) 40.25 (4.6) 0.969
Tail area (pm2) 1.6 x 103 (468.3) 1.5 x 103 (445.5) 1.6 x 103 (347.8) 0.746
Tail intensity 
(cd x 1000)
8.9 x 104 (37579.9) 7.9 x 104 (28272.3) 9.9 x 104 (28799.1) 0.139
Tail mean intensity* 
(cd x 1000)
82.43
[57.5-313.3]
64.43
[53.9-632.7]
77.97
[55.3-150.11
0.897
Tail DNA (%) 69.96 (7.5) 68.75 (8.3) 70.70 (3.8) 0.652
Tail moment 29.40 (8.6) 28.67 (6.4) 29.20 (3.9) 0.936
Olive moment 16.24(3.3) 16.09 (2.9) 16.53(1.9) 0.870
Comet parameters between groups. Mean and standard deviation shown. # Data not normalised 
after log transformation shown as median and interquartile range
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Table 3.5 Comet measures betw een no-diabetes (L+O) and diabetes groups
Lean+Obese
(n=40)
Obese/T2DM
(n=21)
P
Comet length (pm) 77.22 (10.1) 79.00(6.9) 0.472
Comet height (pm) 59.92 (7.6) 62.28(5.9) 0.221
Comet area (pm 2) 3.7 x 103 (846.46) 4.0 x 103 (674.0) 0.186
Comet intensity 
(cd x 1000)
1.2 x lO 5 (39564.7) 1.4 x 105 (38 3 5 6.4) 0.055
Comet mean intensity 
(cd x 1000)
27.00 (8.1) 30.39 (7.9) 0.121
Head diameter (pm) 36.85 (4.3) 38.75 (3.7) 0.093
Head area (pm 2) 2.1 x lO 3 (553.4) 2.3 x 103 (554.7) 0.145
Head intensity 
(cd x 1000)
3.3 x 104 (8856.4) 3.9 x 104 (11731.0) 0.033
Head mean intensity 
(cd x 1000)
16.93 (5.5) 17.18 (4.9) 0.863
Head DNA (%) 30.64 (7.8) 29.30(3.8) 0.461
Tail length (pm) 40.37 (8.1) 40.25 (4.6) 0.951
Tail area (pm 2) 1.6 x 103 (452.5) 1.6 x 103 (347.8) 0.565
Tail intensity 
(cd x 1000)
8.4 x 104 (33252.7) 9.9 x 104 (28 7 99.1) 0.089
Tail mean intensity* 
(cd x 1000)
69.15 [57.4-319.2] 77.97 [55.3-150.1] 0.773
Tail DNA (%) 69.36 (7.8) 70.70(3.8) 0.461
Tail moment 29.04 (7.5) 29.20(3.9) 0.927
Olive moment 16.16 (3.1) 16.53 (1.9) 0.616
Comet parameters between non-diabetes (L+O) and diabetes groups to look at the effect o f 
diabetes. Mean and standard deviation sh o w n .* Data not normalised after log transform ation shown 
as median and interquartile  range
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3.5 Discussion
The aim of the work in this chapter was to examine two markers of oxidative stress 
and two markers of DNA damage in hVAT and examine the differences in samples 
from L, O and ODM patients. Four different markers were chosen to get an overall 
understanding of the extent of oxidative burden within this sample set. TAOS was 
chosen to measure global oxidative stress within the samples and examine any 
differences in overall antioxidant levels between the three groups. As a measure of 
oxidative stress-induced lipid peroxidation the TBARS assay was used. DNA damage 
was measured using two different markers of oxidative damage. Firstly, a measure 
of telomere length, to observe any damage present at chromosomal level, and a 
commercial Comet assay to assess DNA fragmentation due to damage such as 
strand breaks which has been shown to be more common in oxidative stress.
Overall, no differences were observed between groups for both AABTS+ and MDA 
concentration in the hVAT samples. Sampson et al (2002) measured plasma TAOS 
and F2-isoprostanes in a sample of patients with T2DM and without T2DM. They 
observed no significant difference in TAOS between subjects with and without 
T2DM, but did observe differences in plasma F2-isoprostanes. This may have been 
related to the fact that plasma TAOS assay is a less sensitive assay than the F2- 
isoprostanes measure. However, more recent studies using the TAOS assay to 
measure oxidative capacity found that the plasma TAOS assay has good correlations 
with plasma F2-isoprostanes and associated with prospective CHD risk (Stephens et 
al, 2006). Previous studies have not examined the measurement of TAOS in tissue 
homogenates. I chose to examine the use of TAOS in tissue homogenates but as the
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assay did not work (see Chapter 2) it was modified to measure AABTS+ formation. 
As the use of tissue homogenates was experimental in the case of the AABTS+ assay 
it was to be expected that the results obtained may have been limited. These 
results were not different between groups. Further work is required to examine the 
use of total antioxidant measures in tissue homogenates. Although adipose would 
be suspected to be a site of high oxidative stress it may not necessarily be a site of 
high antioxidant production.
With respect to TBARS there was no significant change in MDA concentration 
between groups. A higher MDA concentration was observed in the L group when 
compared to combined O+ODM group but this was not significant, although a 
significantly lower MDA concentration was observed in the ODM group compared 
to the L+O group. This result was not expected, as I would expect to see an 
increased oxidative state within the ODM group due to the double burden of 
diabetes and obesity, therefore resulting in increased levels of lipid peroxidation. 
The paradoxical lower MDA level observed in patients with T2DM compared to the 
other groups may be a result of acute oxidative cellular damage leading to the 
initiation of apoptotic and antioxidant pathways. Sturgeon et al (2010) found a 
significantly lower MDA concentration in subjects of a lower aged group when 
compared to a group of middle-aged to older subjects and an increased 
concentration in overweight middle-aged to older participants compared to those 
of a normal weight. This suggests that age, as well as weight, was associated with 
increased lipid peroxidation in that study. TBARS have not been measured in hVAT 
previously as they are routinely measured using blood plasma. Another possible
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explanation for the results observed for AABTS+ and TBARS may be due to the 
assays being carried out on hVAT homogenates, which may be low in 
oxidants/antioxidants compared to other tissue types.
With respect to markers of DNA damage, telomere length (T/S ratio) was four times 
higher in ODM subjects when compared to L and 0  groups. A significant difference 
was seen between 0  and ODM groups, with the T/S ratio being higher in the ODM 
group. There was no significant difference when comparing groups by obesity (L v 
O+ODM), but was four times greater in the diabetes group, when comparing by 
diabetes status (L+O v ODM). It would have been expected that telomeres would 
shorten at a quicker rate in conditions of increased oxidative burden, such as 
diabetes and obesity. The surprisingly higher T/S ratio seen in the group with T2DM  
suggests that telomere shortening was not a fundamental factor within this 
population. The paradoxically higher T/S ratio in obese patients with diabetes has 
not been seen in past studies, for example, Salpea et al (2010) found telomere 
length to be significantly shorter in patients with T2DM compared to controls, but 
this study was not conducted in patients who were morbidly obese. The lower T/S 
ratios observed in the L+O group may be due to the significantly higher mean age of 
this group. Previous studies have shown that telomere length shortens with age 
(Houben et al, 2008; Astrup et al, 2010). The difficulty in comparing these studies is 
that historically telomere length is measured in leukocyte DNA, whereas the 
experimental use of hVAT DNA may not show the same relationship between 
telomere senescence and diabetes, primarily due to cell turnaround time and 
antioxidant capacity. The novel part of this study was the use of hVAT in this
otherwise commonly used method. A study by Friedrich and colleagues (2000) 
looked at telomere length in different tissue types including leukocytes, skin and 
synovial tissue. The results determined that overall telomere length differs between 
tissue types dependent on the proliferation rates of the tissue, although, when 
comparing two types of tissue from one donor there is linear correlation between 
the two. This suggests that the rate at which a telomere shortens is tissue 
independent as far as genetically determined regulation was considered. So the 
measurement of telomere length in one tissue may be used as a determinant of 
relative telomere length in other tissues from the same individual. The results in this 
chapter may also be due to sample size as numbers in this sample set are far lower 
compared to past studies, which may account for the difference in results (Salpea et 
al, 2010).
There was a significant difference found in Comet intensity, head intensity and tail 
intensity in the ODM group. This suggests a greater overall DNA content detected 
within the cells although not necessarily high percentage of reported DNA damage 
as a high amount of DNA remained within the nucleus of the cells. There was no 
significant difference observed between the L and O+ODM groups. The head 
intensity for diabetes group was significantly higher than the group with no 
diabetes. This suggests a lower amount of damaged DNA fragments migrating from 
the nucleus, which is what would be expected in the samples with diabetes and 
therefore, expected to have increased oxidative stress. In previous studies, comet 
assay results are described using the parameters 'Tail moment' and 'Olive moment', 
which are calculated as described in Chapter 2 (Section 2.3.4). Neither of these
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measures proved significant showing no overall difference in DNA damage between
the groups.
Previous studies looking at DNA damage in lymphocytes of patients with T2DM  
found that levels of basal endogenous and oxidative DNA damage using a measure 
of mean tail DNA were significantly higher compared to patients without T2DM  
(Blasiak et al, 2004). Their results agree with other studies showing an increased 
extent of DNA damage in peripheral blood lymphocytes in patients with diabetes 
(Collins et al, 1998; Dincer et al, 2002a; Rehman et al, 2004). However, similar to my 
results, some studies show no association between diabetes and increased DNA 
damage (Anderson eta l, 1998).
Thakkar and Jain (2010) describe the use of the Comet assay to visualise the extent 
of active cell death or apoptosis within the cells. They found that cells undergoing 
apoptosis show particularly high levels of fragmented DNA in each cell due to the 
increased formation of double strand breaks. This results in a very small percentage 
of DNA remaining within the 'head' of the comet. With respect to my results taking 
this into account, it may show that the cells from the ODM samples are undergoing 
a higher rate of apoptosis. My results showed, though not significant, a lower 
percentage of DNA in the head and a higher percentage DNA in the tail of cells from 
the ODM samples compared to samples in the L and O groups. This may suggest 
that the cells have reached a threshold of oxidative stress that can no longer be 
recovered and have therefore initiated programmed cell death or apoptosis.
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It has been considered that age of onset of T2DM may play a role in the subject's 
susceptibility to DNA damage and impairment of repair mechanisms (Blasiak, 2004), 
with subjects over the age of 50 often having co-existing pathophysiological 
conditions that may contribute to further impairment of DNA repair pathways. 
Previous studies have also highlighted the importance of glycaemic control and its 
role in DNA damage and repair (Collins et al, 1998; Dincer et al, 2002; Blasiak et al, 
2004). Within this sample set there were significantly higher blood glucose levels in 
the ODM group, which suggests that due to poor glycaemic control these subjects 
should, in fact, show a higher level of DNA damage. This, however, was not 
observed. There may be other confounding factors such as an individual's 
medication, as statins (particularly Simvastatin) for example, have been found to 
have protective properties against oxidative stress induced DNA damage in patients 
with T2DM (Manfredini et al, 2010; Shin et al, 2005). A significantly higher 
percentage of the subjects in the ODM group were receiving statin treatment, 
which may explain the protective effect against oxidative stress observed in this 
chapter.
Overall, previous studies showed a higher level of oxidative DNA damage in patients 
with T2DM compared to those without (Lodovici et al, 2008; Collins et al, 1998). 
There is an association between increased levels of oxidative damage products and 
the development of further complications in patients with diabetes (Collins et al, 
1998; Dincer et al, 2002). As with telomere senescence, the level of DNA damage is 
expected to be increased in older patients. Kushwaha et al (2011) found that there 
was an increased background level of DNA damage in rats over time, which is
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supported by other studies by Hamilton et al (2001) and Fraga et al (1990). In these 
studies the products of DNA damage showed increased levels in rodent tissue and 
were found to be strongly correlated to the age of the specimens. This age related 
DNA damage was considered to be accumulated due to a combination of increased 
oxidative stress and a lower level of DNA repair over time.
Previous studies in this area were carried out using plasma leukocytes and not AT. It 
may be that the defining reason for the lack of conclusive results is due to the use of 
hVAT instead of leukocytes.
There were limitations and problems encountered with the experiments within this 
chapter. Firstly, my studies were conducted in hVAT as no blood was collected for 
parallel studies in plasma, as the original focus was on fat. This would have been 
useful to determine if the results gathered in this work are a reliable representation 
of the samples' oxidative burden or, in fact, restricted by the use of hVAT instead of 
leukocytes. Secondly, the in-house Comet assay could not be successfully optimised 
so a commercial kit was used in its place. Finally, from the outset, the work in hVAT 
homogenates was novel, with a lack of reports in the scientific literature on the 
methods employed. This makes the outcome of this work important as careful 
consideration is required for future work in this area.
When the results from these four assays are combined it is possible to get an overall 
view of the level of oxidative damage in the hVAT of this population. To analyse 
oxidative stress at a global level AABTS+ and TBARS were used as markers resulting
in no significant difference between the groups suggesting that T2DM was not 
associated with an environment of high oxidative stress within these samples. To 
follow on from this, the samples were analysed at a chromosomal/DNA level using 
telomere length and Comet as measures of DNA damage, again showing no 
significant differences to suggest that DNA damage was the trigger factor for T2DM  
in these subjects.
According to previous literature I expected to see a progressive increase in oxidative 
stress in the O and ODM subjects examined here. This, however, was not seen. 
Instead a protective effect was seen in the ODM subjects with lower levels of lipid 
peroxidation and less DNA damage observed. There may be changes in gene 
expression levels in antioxidant genes within the AT that may result in a protective 
effect against oxidative stress. In order to examine this, gene expression studies 
were carried out focusing on genes involved in oxidative stress and inflammation to 
determine any changes may explain the results seen in the chapter.
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CHAPTER 4
GENE EXPRESSION DIFFERENCES 
IN OBESITY AND DIABETES
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4.1 Introduction
Changes in DNA, such as base alterations, can affect an individual's risk of disease or 
response to medication. DNA alterations not only are observed within the actual 
DNA sequence in the form of mutations or polymorphisms, but also can occur as an 
alteration in levels of gene expression. A study by Apelt and colleagues (2009) 
showed that differences in gene expression may have wider reaching knock-on 
effects on the expression and activity of other biochemical molecules and influence 
the overall function of a physiological process. Their investigations focused on the 
expression of erythrocyte acid phosphatase {ACPI), a cell cycle regulation factor, 
and the resulting biological effects on glutathione reductase (GSR) activity, finding 
that increased expression of ACPI had a significant negative effect on GSR activity. 
This decreased GSR activity was found to be associated with hypertension, 
especially in patients with T2DM (Apelt etal, 2009).
In this chapter the focus is on gene expression levels in hVAT samples in obesity and 
T2DM. The previous chapter showed a surprisingly low level of oxidative stress in 
subjects with T2DM. It may be hypothesised that a difference in gene expression of 
antioxidant genes in defence against the high level of oxidation was observed in 
these samples, therefore, reducing the overall oxidative burden. In order to 
examine this, a gene expression study was carried out focusing particularly on genes 
involved in oxidative stress pathways in AT, in an attempt to determine any 
differences that may occur between obesity and T2DM. A similar study was carried 
out in mice by Nadler and colleagues (2000) looking at a high number of gene 
transcripts in adipose tissue from lean, obese and obese mice with diabetes. They
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identified differences in expression of genes involved in adipocyte differentiation in 
obese mice and genes involved in signal transduction and energy transduction in 
mice with varying degrees of hyperglycaemia. The study utilised DNA microarrays, 
which analyse high numbers of gene transcripts simultaneously. An alternative 
method of gene expression analysis is RT-PCR, which allows the examination of 
selected candidate genes of interest using specific primers. To satisfy the 
requirement in this part of the study the use of DNA microarrays is too large scale 
and too high in cost. Therefore the use of RT-PCR arrays was chosen as the most 
suitable method of analysis, both in terms of scale and price.
RT-PCR arrays allow the gene expression profiles of 84 genes to be analysed in a 
sample simultaneously, including built in quality control measures. Arrays may be 
designed to look at particular individual genes of interest, although to get a general 
overview of any changes that may be occurring in particular pathways, for example 
those involved in oxidative stress, commercially available arrays are designed with a 
focused panel of genes from each area of scientific interest. As mentioned, in this 
chapter the focus was on oxidative stress so a PCR array containing a panel of genes 
involved in oxidative stress and antioxidant defence was used. This panel includes 
genes involved in ROS metabolism, such as superoxide dismutase (SOD) and NADPH 
oxidase (A/OX); oxidative response genes, such as glutathione peroxidase (GPX) and 
apolipoprotein E (APOE); and antioxidant genes, including GPX genes and catalase 
(CAT).
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Previous studies have found oxidative stress-induced gene expression changes in 
obesity and T2DM. Peroxiredoxin (PRDX), an antioxidant which is highly expressed 
in AT, was found to have significantly reduced expression within obese mice and in 
human subjects with a BMI>25 (Huh et al, 2012). According to Sadi and colleagues 
(2009), rats with induced diabetes displayed decreased expression in SOD and CAT 
but showed no difference in GPX expression (Sadi eta l, 2009).
4.2 Aim
The purpose of the work described in this chapter was to examine the expression 
profiles of 84 genes involved in pathways of oxidative stress in 30 hVAT samples 
using commercially available PCR arrays and examine any gene expression 
differences seen between samples classified as L, O and ODM. It was hypothesised 
that genes involved in defence against oxidative stress would show increased 
expression in the samples with increased oxidative stress. In the previous chapter, 
results from the complete sample population showed that oxidative stress markers 
were increased in the O group and then significantly decreased in the ODM group. 
For this reason, genes involved in antioxidant pathways are expected to show 
differing expression accordingly, although a smaller sample set is studied in this 
chapter.
4.3 Methods
4.3.1 PCR array
PCR array data were collected for 30 samples chosen from consecutive patients 
undergoing surgery, with blinding as to the nature of the samples (L/O/ODM:
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11/9 /10). RNA was extracted from the hVAT as previously described (Section 2.2.1) 
and reverse transcribed to cDNA (Section 2.4). Using the SABiosciences Human 
Oxidative Stress and Antioxidant Defense RT2 Profiler PCR Array (Section 2.4), the 
expression profile of 84 genes (detailed in Figure 2.3) related to oxidative stress 
including peroxidises, peroxiredoxins, genes involved in ROS metabolism and 
superoxide metabolism were analysed. The 96 well plates included 5 housekeeping 
genes, plus integrated controls for genomic DNA contamination, RNA quality and 
PCR performance for quality control of the arrays. cDNA samples were combined 
with the provided RT-PCR master mix, aliquoted into the PCR arrays and run on a 
Biorad MylQ thermocycler.
4.3.2 Data analysis
Analysis of the array data was carried out using the specific online program 
(www.SABiosciences.com/pcrarraydataanalysis.php). The program utilises the 2'AACT 
quantification method to calculate the level of gene expression change in the 
samples. The formula to calculate this was:
X=2-aact
Where in this study:
X = Fold change in gene expression
A A C y  =  A C y  (sample group)" A C y  (Control sample group)
A C y  =  Cy(test sample)" C y (Internal housekeeping gene)
109
When comparing groups of samples mean CT values were used. The software shows 
differences in fold change between the groups in different visual formats allowing 
identification of up or down regulated genes. Any genes with a fold-change of more 
than 2-fold, as described by manufacturer, were flagged to be further investigated 
and any genes that differed between groups P<0.05 were considered significant.
4.4 Results
4.4.1 Baseline characteristics
4.4.1.1 L v O v  ODM
hVAT samples from 30 subjects, which were grouped as L, 0  and ODM, were 
selected while blinded to their classification (L/O/ODM: 11/9/10). Baseline 
characteristics of subjects were analysed for differences between groups as this 
sample set differed from the previous chapter. As shown in Table 4.1, the only 
significant differences between the groups were understandably weight and BMI, 
with both being significantly higher in the ODM group (P<0.001 for both weight and 
BMI); and hypertension, which was significantly higher in the ODM group compared 
to others (P=0.033).
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Table 4.1 Baseline characteristics compared betw een groups
Lean
( n = l l )
Obese
(n=9)
O b ese/T2D M
(n=10)
P
Age (years) 54.8 (17.9) 52.3 (9.0) 42.6 (11.4) 0.120
Weight (kg) 71.0(13.6) 108.7 (30.8) 144.2 (28.2) <0.001
BMI (kg/m2) 25 (2.2) 37(9.0) 51 (12.3) <0.001
SBP (mmHg) 138 (26.1) 130(17.9) 142 (18.0) 0.455
DBP (mmHg) 81 (14.4) 81 (11.0) 76(9.7) 0.558
Glucose (mmol/L)* 5.2 (0.3) 6.1 (0.4) 8.7 (1.8) 0.058
Cholesterol (mmol/L) 5.9 (1.8) 5.7 (2.4) 5.2 (1.2) 0.761
HDL-C (mmol/L) 1.5 (0.4) 1.0 (0.2) 1.1 (0.2) 0.082
LDL-C (mmol/L) 3.9 (1.5) 3.8 (2.1) 2.9 (0.8) 0.419
Triglycerides (mmol/L) 1.3 (0.2) 2.1 (0.5) 2.6 (1.5) 0.437
Creatinine (pmol/L) 76.8 (20.6) 79.5 (9.4) 68.9 (18.2) 0.401
Albumin (mmol/L) 47.9 (10.8 42.8(2.9) 41.4 (5.6) 0.166
RNA (ng/pl) 93.8 (60.3) 73.0 (38.5) 59.2 (46.2) 0.294
Males % (n) 45.5 (5) 44.4 (4) 40.0 (4) 0,966
Current smoker % (n) 36.4 (4) 33.3 (3) 20.0(2) 0.682
Hypertension % (n) 9.1 (1) 22.2 (2) 60.0(6) 0.033
OS A % (n) 0(0) 11.1 (1) 30.0(3) 0.127
Statins % (n) 9.1 (1) 11.1 (1) 50.0(5) 0.050
ACE inhibitor % (n) 27.3 (3) 11.1 (1) 50.0(5) 0.176
Baseline characteristics o f hVAT samples in L; 0  and ODM groups. Log transform ed data. Mean and 
standard deviation shown or geometric mean and approximate standard deviation fo r log 
transform ed data. Analysis performed by ANOVA after appropriate transform ation. x 2~test was usec* 
to compare groups. P-value shows significance where P<0.05
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4.4.1.2 L v O+ODM
Prior to analysis, I chose to examine baseline characteristics between L v O+ODM to 
look at the effects of obesity between groups. Results are detailed in Table 4.2. 
Weight and BMI were significantly different between groups (P=<0.001 for both). 
Although not significant, glucose levels were higher in the O+ODM subjects, whilst 
HDL-C levels were significantly higher in L group compared to O+ODM (P=0.040). 
There were higher percentages of subjects with hypertension and OSA in the 
O+ODM group, although the prevalence for both was not significant. Although 
there were more patients in the O+ODM group on statin and ACE inhibitor 
treatment, the percentage difference was not significant.
4.4.1.3 L+O v ODM
I chose to examine baseline characteristics between L+O v ODM to look at the 
effects of non-diabetes (n=20) and diabetes (n=10), results are shown in Table 4.3. 
Age, weight and BMI were significantly different between groups (P=0.042, P<0.001 
and P<0.001 respectively). Blood glucose was significantly higher in subjects with 
diabetes (P=0.020). There were a higher proportion of males in the non-diabetes 
group, though not significant. The co-morbidities hypertension and OSA were more 
prevalent in the subjects with diabetes, with hypertension being significant 
(P=0.011); and more subjects in the diabetes group were on statin and ACE inhibitor 
treatment, with statin use being significant (P=0.015).
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Table 4.2 Baseline characteristics betw een lean and obese groups (O +O D M )
Lean
(n = H )
Obese + Obese T2D M  
(n=19)
P
Age (years) 54.8 (17.9) 47.2 (11.2) 0.161
Weight (kg) 71.0(13.6) 127.4 (33.9) <0.001
BMI (kg/m2) 25(2.2) 45(12.8) <0.001
SBP (mmHg) 138 (26.1) 136(18.5) 0.836
DBP (mmHg) 81 (14.4) 78 (10.4) 0.611
Glucose (mmol/L)* 5.2 (0.3) 7.7 (1.4) 0.066
Cholesterol (mmol/L) 5.9 (1.8) 5.3 (1.5) 0.614
HDL-C (mmol/L) 1.5 (0.4) 1.1 (0.2) 0.040
LDL-C (mmol/L) 3.9 (1.5) 3.1 (1.3) 0.472
Triglycerides (mmol/L) 1.3 (0.2) 2.5 (1.3) 0.226
Creatinine (pmol/L) 76.8 (20.6) 73.6 (15.5) 0.637
Albumin (mmol/L) 47.9 (10.8) 41.9 (4.7) 0.060
RNA (ng/pl) 93.8 (60.3) 65.7(42.2) 0.145
Males % (n) 45.5 (5) 42.1 (8) 0.858
Current smoker % (n) 36.4 (4) 26.3 (5) 0.789
Hypertension % (n) 9.1 (1) 42.1 (8) 0.057
OSA % (n) 0(0) 21.1 (4) 0.102
Statins % (n) 9.1 (1) 31.6(6) 0.161
ACE inhibitor % (n) 27.3(3) 31.6(6) 0.804
Baseline characteristics between lean and obese (O+ODM) groups to look at effects of obesity 
between groups. Log transform ed data. Mean and standard deviation shown or geometric mean 
and approximate standard deviation fo r log transform ed data. Analysis performed by ANOVA after 
appropriate transform ation. x 2 test was used to compare groups. P-value shows significance where 
P<0.05
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Table 4.3 Baseline characteristics betw een non-diabetes (L+O) and diabetes
groups
No Diabetes  
(n=20)
Diabetes
(n=10)
P
Age (years) 53.7(14.3) 42.6 (11.4) 0.042
Weight (kg) 88.0(29.5) 144.2 (28.2) <0.001
BMI (kg/m2) 30(8.9) 51 (12.3) <0.001
SBP (mmHg) 135 (22.6) 142 (18.0) 0.350
DBP (mmHg) 81 (12.6) 76(9.7) 0.277
Glucose (mmol/L)* 5.6 (0.4) 8.7 (1.8) 0.020
Cholesterol (mmol/L) 5.8 (1.9) 5.2 (1.2) 0.456
HDL-C (mmol/L) 1.2 (0.3) 1.1 (0.2) 0.737
LDL-C (mmol/L) 3.8 (1.7) 2.9 (0.8) 0.176
Triglycerides (mmol/L) 1.8 (0.6) 2.6 (1.5) 0.283
Creatinine (pmol/L) 77.9 (16.5) 68.9 (18.2) 0.186
Albumin (mmol/L) 46.1 (9.0) 41.4 (5.6) 0.150
RNA (ng/|il) 84.4(51.5) 59.2 (46.2) 0.201
Males % (n) 45.0 (9) 40.0(4) 0.794
Current smoker % (n) 35.0(7) 20.0(2) 0.682
Hypertension % (n) 15.0(3) 60.0(6) 0.011
OSA % (n) 5.0(1) 30.0(3) 0.058
Statins % (n) 10.0(2) 50.0(5) 0.015
ACE inhibitor % (n) 20.0(4) 50.0(5) 0.091
Baseline characteristics between non-diabetes (L+O) and diabetes groups to look at the effect o f 
diabetes between groups Log transform ed data. Mean and standard deviation shown or geometric 
mean and approximate standard deviation fo r log transform ed data. Analysis performed by ANOVA 
after appropriate transform ation. x 2'tes t was usec* to  compare groups. P-value shows significance 
where P<0.05
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4.4.2 PCR arrays
hVAT samples were assayed using the SABiosciences Human Oxidative Stress and 
Antioxidant Defense RT2 Profiler PCR Array. Gene expression fold changes for 84 
genes between groups, compared to control (L) were assessed (Appendix 4).
4.4.2.1L v O
The scatter graph in Figure 4.1 shows the fold change in gene expression between 
controls (L) and 0  subjects. Each marker symbolises a gene from the array and the 
genes that lay outside of the 2-fold change boundary are labelled red for increased 
and green for decreased expression levels. There were two genes that had an 
increased expression by more than 2-fold; glutathione peroxidase 1 (GPxl) and 
glutathione reductase {GSR). Only GSR was found to be have a significant difference 
in expression between L and 0  subjects of +2.15 (P=0.026). Fold change values for 
genes found to show increased/decreased expression (according to the adopted 2- 
fold cut-off) are shown in Table 4.4.
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4.4.2.2 Lv ODM
The scatter graph in Figure 4.2 shows the fold change gene expression between 
controls (L) and ODM subjects. There were 15 genes with increased expression in 
ODM compared to L, including 2 genes from the glutathione peroxidase family, GSR 
and keratin 1 (KRT1). Genes with decreased expression were albumin (ALB), APOE 
and cytochrome A alpha polypeptide (CYBA). GSR showed significantly increased 
expression in the ODM subjects, with a fold-change o f +2.56 (P=0.021). Fold change 
values for genes found to show increased/decreased expression (according to the 
adopted 2-fold cut-off) are shown in Table 4.5.
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4.4.2.3 O v ODM
The scatter graph in Figure 4.3 shows the fold change gene expression between 
controls (O) and ODM subjects. Four genes showed increased expression; DUOX2, 
GPX6, KRT1 and proteoglycan 3 (PRG3), whilst decreased expression was seen in 
ALB, CYBA and GPX1, although none of the changes were significant. Fold change 
values for genes found to show increased/decreased expression (according to the 
adopted 2-fold cut-off) are shown in Table 4.6.
121
Fi
gu
re
 
4.3
 
Di
ffe
re
nc
e 
in 
ge
ne
 
ex
pr
es
si
on
 
be
tw
ee
n 
ob
es
e 
an
d 
ob
es
e 
T2
DM
 
gr
ou
ps
<  CQ O  Q  U4 ll- 0
O o
OO
<’lD«l»a-vZ I  dnojb) orGoi
Sc
at
te
r 
gr
ap
h 
sh
ow
in
g 
ge
ne
 
ex
pr
es
si
on
, 
wh
er
e 
gr
ou
p 
1 
is 
O 
an
d 
gr
ou
p 
2 
is 
O
D
M
. 
Ea
ch
 
m
ar
ke
r 
de
no
te
s 
a 
ge
ne
 
an
d 
ba
nd
 
lin
es
 
de
fin
e 
2 
bo
un
da
ry
. 
He
at
 
ma
p 
re
pr
es
en
ts
 
96 
w
el
l 
ar
ra
y 
pl
at
e,
 w
he
re
 
red
 
pix
els
 
sh
ow
 
in
cr
ea
se
d 
an
d 
gr
ee
n 
sh
ow
 
de
cr
ea
se
d 
ex
pr
es
sio
n 
of 
ge
ne
s
Ta
bl
e 
4.6
 
Fo
ld 
ch
an
ge
 
di
ffe
re
nc
e 
in 
ob
es
e 
T2
DM
 
co
m
pa
re
d 
to 
ob
es
e 
gr
ou
p
u
soOS
in
2 .
0)W5C
OJXU
-a
o-Q
E
LO
oCl
H  IN  r l  ^  r l  rO O
rsj lo cn rsj ro
o  o  o  o  o  o  o
LD
o
o
o
o
rsi
ro
o
oo
d lo  oo 
ro
oo' 
o
<j) r*
o
o
o
o
r-s rs00 cncn rH r-.
o LO LD LO
rH r—1 rH rH
O
o
o
o
o
o
o
O
o
o
o
o
o
o
o
CD d
ro LO
°9
rH rH
ro 00
o rsi rsi rsj
cuT3
’-t-i
CL
CU
CL>
0
Cl
ro
JC
_ Q .
co
LO
rsi
1
X !
CU
E
o
>-
1—
o
4 - '
u
co
rH  LD
CU CU
L 0  L 0
ro ro -a -a
rsi
cu
ro
T3
cu cu 
c l  a. 
cu cu c c
c u
^ o 
£  S. 3<  U Q
CO
o
X  X4-J -M
ro ro
+-> 4->J3 _D
ro
c
ro
<_>
O rH ^
E «- 00 E .E o cu
QJX
CO
r s l  
<  XCO o
6 i
rH LD rH ro
X X 1—
CL CL QC OC
<2? X CL
H N Ifl N in rt N
O rH o  rH o  rH o<  <  CO 00 U  U  Ll_
T3
q j
QJ
"D
(UC
OJ
DO
LO
§OX
LO
c
QJ
QJ
"D
CTO
C
o
a.x
QJ
T3
QJ
QJ
C
QJ
CUD
LO
§OX
LO
■a
QJoc
oO
TJ
QJ
QJ
X
13
LO
O
LO
o
ov
a .
lo  a j  
QJ S.
i -  qj 
CL X
QJ
C
QJ00
QJ
CUD
C
12
3
4.4.2.4 L v O+ODM
The scatter graph in Figure 4.4 shows the fold change gene expression between 
controls (L) and O+ODM subjects to look at the effects of obesity. Six genes showed 
increased expression including KRT1, thyroid peroxidase (TPO) and SOD3, while 
CYBA and APOE had decreased expression. The GSR gene in particular showed a 
significant increase in expression of +2.36 (P=0.02). Fold change values for genes 
found to show increased/decreased expression (according to the adopted 2-fold 
cut-off) are shown in Table 4.7.
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4.4.2.5 L+O v ODM
The scatter graph in Figure 4.5 shows the fold change gene expression between 
controls (L+O) and ODM subjects to look at the effects of diabetes. Five genes 
showed increased expression including GPx6, KRT1 and lactoperoxidase (LPO), 
whilst ALB, CYBA and GPxl showed decreased expression, although none were 
significant. Fold change values for genes found to show increased/decreased 
expression (according to the adopted 2-fold cut-off) are shown in Table 4.8.
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4.4.3 Overview of GSR expression between groups
Throughout analysis the expression levels of GSR showed a significant increase in 
the O group and a further increase in expression in ODM subjects (both compared 
to L). Due to these significant changes in expression, an overview of GSR expression 
profile between groups observed throughout this chapter is shown in Figure 4.6. A 
significant difference was observed between subjects in the L and 0  groups (L v O:
1.00 v 2.15, P= 0.026) and between L and ODM groups (L v ODM: 1.00 v 2.56, P= 
0.021). The difference between O and ODM in GSR expression increased, although 
this was not significant (P= 0.565). Difference across all groups was not significant 
(P= 0.194).
Figure 4.6 Fold change of GSR between groups
P= 0.021
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GSR fold change between groups. P-value shows significance where P<0.05
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4.5 Discussion
The aim of the work in this chapter was to examine the expression profiles of genes 
involved in pathways related to inflammation and oxidative stress in hVAT samples 
and examine any gene expression differences between samples classified as L, 0  
and ODM. 30 samples were obtained consecutively from surgical patients across 
the 3 categories (L, O, ODM: 11/9 /10) and assayed using a commercially available 
PCR array kit. The resulting data was uploaded into the online analysis program for 
examination and results were classed as noteworthy if there was a 2-fold change 
compared to that of the control group and considered significant if P<0.05. Of the 
84 genes associated with oxidative stress and inflammation examined there was a 
total of 19 genes that showed a difference in expression of more than 2 fold during 
group comparisons. However, only one gene, GSR, showing significant differences 
in expression between groups for O, ODM and O+ODM when all compared to 
controls (L).
GSR is a gene encoding the antioxidant enzyme glutathione reductase, which plays a 
pivotal role in the maintenance of cellular glutathione by reducing the oxidised form 
(GSSG) to the antioxidant scavenging reduced form (GSH). Levels of GSR expression 
were observed to increase significantly in obese patients and then continue to 
increase in obese patients with diabetes. This increased GSR expression is not what 
has been reported in recent literature. Apelt and colleagues (2009) surmised that as 
the glutathione antioxidant system acts as a ROS scavenger it should be expected 
that levels of GSR increase with BMI regardless of co-morbidities, although
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increased oxidative stress and increased BMI in fact leads to antioxidant systems 
having an alternative effect and favouring oxidative damage (Apelt et al, 2009). In 
an environment of high oxidative stress, active GSR levels are ultimately decreased 
due to flavin adenine dinucleotide (FAD) demand by GSR being greater than the 
availability as dietary riboflavin is insufficient. Calabrese and colleagues (2012) 
observed significantly decreased levels of systemic reduced GSH and increased 
oxidised GSSG in patients with T2DM, resulting in a 68% decrease in GSH/GSSG ratio 
overall (Calabrese et al, 2012). It can be assumed that the decreased reduction of 
GSSG to GSH is due to a decreased level of active GSR or even NADPH+, which this 
redox reaction in dependent on. If NAPDH+ levels had been diminished during the 
polyol pathway; a pathway involved in glucose metabolism, then there may not be 
adequate levels to assist in GSSG reduction.
Although there are contradictory studies in this area, there are possible 
explanations for the occurrence of increased GSR in the O and ODM subjects. 
Studies have shown that patients with diabetes, metabolic syndrome and those at 
high risk of developing T2DM, such as in obesity, have lower plasma concentrations 
of reduced GSH (Yoshida et al, 1995; Sharma et al, 2000). It may be assumed that 
the increased gene expression of GSR observed in this study is to counteract this 
imbalance. There appear to be two main mechanisms that cause the diminished 
levels of GSH, which in turn may cause the up regulation of GSR in order to  
rebalance levels by oxidising cellular GSSG. Firstly, glucose and insulin have direct 
effects on the synthesis of GSH. Low levels of GSH have been observed in 
hyperglycaemia due to changes in the rate limiting enzyme of GSH production,
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glutamate cysteine ligase (GCL). In environments of chronic high glucose exposure, 
there are decreased mRNA levels for regulatory subunits of GCL resulting in an 
overall decrease in cellular GSH (Urata et al, 1996; Catherwood et al, 2002). This 
may lead to increased expression of GSR to maintain the GSH/GSSG ratio balance. In 
contrast, high cellular insulin levels have been seen to increase GSH in patients with 
diabetes by increasing the activity of GCL in QSH synthesis pathway (Bravi et al, 
2006). These findings may explain why, in this study, an increase in GSR was seen in 
O subjects, but also ODM subjects. In the subjects with diabetes there is an 
environment of high glucose and diminished insulin activity. Increased glucose 
levels have been shown to decrease systemic GSH and combined with the lack of 
insulin to increase GSH synthesis there will be a low GSH production overall. It is 
presumed that this low GSH stimulates the increased expression of GSR to 
counteract this imbalance of the GSH/GSSG ratio. If this ratio is not regained and 
maintained then the high glucose/ low insulin levels increase ROS and combined 
with the low GSH production ultimately result in weakened defences against 
oxidative stress and increased oxidative damage (Ballatori et al, 2009).
Secondly, the lack of required NADPH necessary for GSH regeneration from its 
oxidised GSSG form via GSR has been observed to cause reduced GSH. NADPH levels 
may be diminished due to its over consumption within the polyol pathway, 
responsible for the conversion of glucose to sorbitol via aldose reductase activity. In 
nomoglyceamic conditions, little glucose enters the polyol pathway but during 
hyperglycaemia glucose that is not utilised for energy enters for reduction to
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sorbitol. During this pathway NADPH levels are diminished resulting in reduced 
levels available for the glutathione redox reaction.
Additionally, GSR has been identified as having protective effects in diseases 
associated with oxidative stress such as atherosclerosis (Qiao et al, 2007). It may be 
assumed that the increased expression of GSR seen in the obese patients within this 
study is in fact due to the cells protective mechanism against such conditions.
With respect to albumin, Insenser and colleagues (2012) studied the expression 
change of circulating proteins, such as albumin, and explained observed differences 
by the fact that whole adipose samples were used instead of separate adipocytes 
and stromal vascular fraction as seen in other literature (Insenser et al, 2012; 
Kheterpal et al, 2011; Peinado et al, 2010). During this study, whole adipose 
samples were used, which may determine the expression levels of particular 
circulating proteins that have been seen here.
The genes of particular interest found in this chapter were GSR and GPX1 due to the 
differences in expression observed across the three subject groups. In order to 
verify these results and to look at these genes in more detail they were investigated 
further using a basic RT-PCR method.
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CHAPTER 5
GENE EXPRESSION ANALYSIS USING RT-PCR IN HUMAN 
AND MOUSE SAMPLES
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5.1 Introduction
As results from Chapter 4 show, there was a difference in gene expression seen 
between the three sample groups (L, O and ODM) in 19 genes associated with 
oxidative stress. In particular, differences were seen in the expression of the GSR 
gene, which was significantly increased in O and ODM subjects when compared to L 
control samples; and although no significant difference in GPX1 expression was 
seen, there was an increase in 0  subjects and a decrease in ODM subjects. To take 
these findings further, this chapter aims to further investigate the expression of GSR 
and GPX1 genes between the three groups and verify the results seen in Chapter 4 
via real-time PCR analysis. Alongside these two target genes the expression of 
PPARy and IL-6 will also be analysed as two other target genes and ACTB as a 
control housekeeping gene.
5.1.1 GSR
GSR is an antioxidant enzyme that plays a vital role in the glutathione redox cycle, a 
system for reduced glutathione (GSH) regeneration. This mechanism involves the 
catalytic conversion of oxidised glutathione (GSSG) to its reduced form, GSH, by 
NAPDH-dependant GSR (Ahmadpoor et al, 2009) (Figure 5.1). It is responsible for 
the maintenance of circulating GSH levels, making up the primary defence against 
oxidative stress by scavenging ROS and repairing damage (Pastore et al, 2003). The 
regeneration of GSH through GSR requires NADPH, generated via glucose-6- 
phosphate dehydrogenase (G6PDH) during the conversion of glucose-6-phosphate 
into ribulose 5-phosphate in the pentose phosphate pathway. In conditions of 
increased oxidative stress the GSR gene is expected to have increased expression in
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order to  reduce oxidised g lutathione (GSSG) to  its GSH form  to  protect against 
oxidative stress. This gene was chosen fo r fu rthe r investigation due to  the 
significant differences in gene expression observed in the previous chapter.
Figure 5.1. GSH redox cycle
Pentose phosphate Glutathione redox
pathway cycle
Glucose-6-P
I  ^n a d p - ^ ^  gsh
I ^G 6 P D H  J ^ S R  V g P x
I  V n a d p h ^  ^  G S S G ^  ^
ROOH
Ribu lose-5-phosphate
G6PDH; glucose-6-phosphate dehydrogenase, GSR; G lutathione reductase, GPx; G lutathione 
peroxidise
5.1.2 GPX1
GPX1 is the most common GPX isoform, which is responsible fo r the detoxification 
o f H20 2 in order to  prevent oxidative stress (Halliwell et al, 1992). Its role in the 
prevention o f oxidative stress has also been determ ined in mouse models (Brigelis- 
Flohe and Kipp, 2009). This antioxidant enzyme is involved in the same pathways as 
GSR and its efficiency in neutralisation o f peroxides is re liant on the intact GSH 
pathway (H irrlinger and Drignen, 2010). This gene was chosen for fu rthe r
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investigation due to the differences in gene expression, although not statistically 
significant, observed in the previous chapter as well as its association with GSR 
within the GSH pathway.
5.1.3 PPARy
Peroxisome proliferator-activated receptor gamma (PPARyj is a gene that encodes 
the gamma subtype of PPAR. The PPAR subfamily of nuclear receptors are 
responsible for transcription regulation of various genes. In particular, PPARy is an 
adipocyte specific transcription factor, which plays a role in the regulation of 
adipocyte function and has been associated with the pathology of obesity (Wagener 
et al, 2010). The main function of PPARy is to regulate adipocyte differentiation and 
glucose homeostasis (Vidal-Puig et al, 1997). It influences glucose homeostasis, 
insulin sensitivity and blood pressure in obese patients via its role in adipocyte 
differentiation, fat deposition and its effect on plasma leptin levels. PPARy has also 
been found to regulate macrophage activation, which is important for the synthesis 
of inflammatory cytokines. The PPARy gene was chosen for investigation due to its 
regulatory role on AT and its previous association with diabetes, making it an 
interesting target within this population.
5.1.4 IL-6
IL-6 is a pro-inflammatory cytokine involved in the induction of the acute phase 
inflammatory response. IL-6 has been associated with (3-cell differentiation, fat 
degradation and inflammatory disorders, such as diabetes (Kritiansen et al, 2005), 
where increased circulating levels are present years prior to diagnosis. IL-6 was
chosen as a target gene in this study due to its association with chronic 
inflammatory states such as diabetes and obesity.
Due to surprisingly low levels of oxidative stress observed in the study samples, 
especially ODM subjects, it was decided that these genes would be examined in 
parallel in an induced pro-oxidative state mouse cell line.. This will allow the 
comparison of gene expression of the target genes in human and mouse samples.
GSR and GPX1 gene expression was investigated in the treated 3T3-L1 cells as these 
genes showed increased expression in 0  hVAT samples in Chapter 4. The 3T3-L1 
murine cell line is commonly used in gene expression studies and was readily 
available to examine the target gene expression during induced oxidative stress. LPS 
was chosen as a pro-oxidant agent to induce a state of high oxidative stress within 
the cell line as it has been widely used in previous literature as a 'stressor' (Kizaki et 
al, 2002). LPS is a component of the outer cell wall of gram-negative bacteria and 
plays a crucial role in protecting the bacteria against damaging agents. LPS acts as a 
toxin, actively inducing the host's immune response. In this study, the pro- 
inflammatory characteristic of LPS was used to induce a high oxidative environment 
in which the 3T3-L1 cells were grown prior to gene expression analysis.
5.2 Aim
The purpose of the work described in this chapter was firstly to analyse candidate 
gene expression in hVAT samples. Two genes showing significant expression 
differences in Chapter 4, GSR and GPX1, are examined further by RT-PCR analysis,
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along with IL-6 and PPARy, to examine differences between samples from lean, 
obese and obese patients with T2DM. Secondly, the aim was to culture 3T3-L1 
mouse cell line to examine candidate gene expression in response to a 'biochemical 
stress'. Gene expression of Gsr and Gpxl was examined further in the mouse 3T3-L1 
cell line in a basal state and in a state of 'biochemical stress', induced by LPS 
treatment. This allows in vitro interrogation of the expression and function of the 
identified genes.
5.3 Methods
5.3.1 RT-PCR gene expression analysis in human samples
RT-PCR analysis was carried out on 48 hVAT samples, including those examined in 
Chapter 4. RNA was extracted from the hVAT as previously described (Section 2.2.1) 
and reverse transcribed to cDNA (Section 2.5). Specific primers were designed using 
gene sequence information from NCBI (www.ncbi.nlm.nih.gov/) or sequences that 
had been previously published (GPX1 primers, Boutet et ol, (2009); GSR primers, 
Corrales e ta l, (2011)) and synthesised by Eurofins MWG Operon.
5.3.2 RT-PCR gene expression analysis in mouse samples
RT-PCR analysis was carried out on 3T3-L1 cells that had undergone pro-oxidant 
treatment in vitro with LPS, as previously described (Section 2.7). The concentration 
of LPS used was taken from previous literature (Kizaki et ol, 2002). Experiments 
were conducted in triplicate. LPS was administered after 3 days of culturing and left 
for a complete 14 hour cell cycle post treatment. RNA was extracted from cells 
(Section 2.7.3), reverse transcribed to cDNA (Section 2.5) and resulting cDNA
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pooled. Specific primers were designed using gene sequence information from NCBI 
(www.ncbi.nlm.nih.gov/) and synthesised by Eurofins MWG Operon.
5.3.3 Analysis of results
Results were analysed using the 2'AACT quantification method, previously described 
in Chapter 2 (section 2.5) to calculate the level of gene expression change between 
groups in a relative fashion (Livak et al, 2001). Hence, for each group the mean CT 
values obtained for each gene were determined. The ACT values for each test gene 
were subsequently calculated normalising gene expression to p-actin, and the 
factors X G s r ,  X G p x i ,  X|L_6 and XppARV were established for each group in order for 
comparisons to take place. Subsequent N-fold differences <0.5 were considered as 
decreased gene expression, while over expression was defined as >2.0 fold increase 
in line with the PCR arrays used in the previous chapter. Due to limited comparisons 
made, P-values were unable to be calculated, so results are expressed as relative 
fold-change compared to a control group.
5.4 Results
5.4.1 Baseline characteristics 
5.4.1.1L v O v ODM
hVAT samples from 48 subjects, categorised as L, O and ODM (L/O/ODM: 
17/15/16), were selected including the same samples that were analysed in Chapter 
4. Baseline characteristics of subjects were analysed for differences between groups 
as this sample set differed from previous chapters, results are shown in Table 5.1. A 
significant difference was seen in weight (P<0.001) and BMI (P<0.001) between
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groups, both being highest in the ODM group. HDL-C levels in the L subjects were 
significantly higher than O and ODM groups (P=0.019), whilst both creatinine and 
albumin were seen to be significantly different across groups (P=0.035 and P=0.037 
respectively). A significantly higher percentage of the ODM group had hypertension 
(P=0.027) and OSA (P=0.001) compared to the other groups, as well as a 
significantly higher percentage of subjects on statin treatment (P=0.040).
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Table 5.1 Baseline characteristics compared between groups
Lean
(n=17)
Obese
(n=15)
O b ese/T2D M
(n=16)
P
Age (years) 53.8 (16.7) 51.8(11.5) 44.4 (9.5) 0.109
Weight (kg) 74.4 (13.3) 116.7 (33.9) 141.9 (25.8) <0.001
BMI (kg/m2) 26 (2.6) 40 (11.2) 52(10.7) <0.001
SBP (mmHg) 137 (22.2) 130(18.6) 142 (18.4) 0.284
DBP (mmHg) 81 (12.5) 79(12.7) 76 (13.3) 0.478
Glucose (mmol/L)* 5.7 (0.6) 5.8 (0.4) 8.1 (1.5) 0.062
Cholesterol (mmol/L) 5.7 (1.3) 5.8 (1.7) 4.8 (1.2) 0.270
HDL-C (mmol/L) 1.6 (0.3) 1.1 (0.3) 1.1 (0.2) 0.019
LDL-C (mmol/L) 3.6 (1.1) 3.7 (1.7) 2.6 (0.7) 0.138
Triglycerides (mmol/L) 1.2 (0.2) 1.9 (0.5) 2.3 (1.3) 0.253
Creatinine (pmol/L) 79.3 (18.2) 81.6 (11.2) 67.6(15.6) 0.035
Albumin (mmol/L) 47.3 (8.7) 43.0(2.8) 41.7 (4.6) 0.037
RNA (ng/pl) 88.1 (52.6) 89.0 (47.2) 61.5 (42.0) 0.205
Males % (n) 52.9 (9) 40.0(6) 37.5 (6) 0.630
Current smoker % (n) 29.4 (5) 26.7 (4) 18.8 (3) 0.924
Hypertension % (n) 17.6(3) 33.3 (5) 62.5 (10) 0.027
OSA % (n) 0(0) 13.3(2) 50.0(8) 0.001
Statins % (n) 5.9(1) 33.3 (5) 43.8(7) 0.040
ACE inhibitor % (n) 23.5 (4) 13.3(2) 50.0(8) 0.066
Baseline characteristics of 48 hVAT samples in L, 0  and ODM groups. Log transform ed data. Mean 
and standard deviation shown or geometric mean and approximate standard deviation for log 
transform ed data. Analysis performed by ANOVA after appropriate transform ation. x2Test was us^d 
to  compare groups. P-value shows significance where P<0.05
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5.4.1.2 L v O+ODM
Prior to analysis, I chose to examine baseline characteristics between L v O+ODM to 
look at the effects of obesity between groups. Results are detailed in Table 5.2. As 
expected, weight (P<0.001) and BMI (P<0.001) were significantly different between 
groups. HDL-C levels were significantly higher in L group compared to O+ODM 
(P=0.005), as were albumin levels (P=0.011). There were almost three times the 
number of subjects with hypertension in the O+ODM group (P=0.035) and all 
subjects with OSA fell into the O+ODM group (P=0.008). A higher proportion of 
subjects in the O+ODM group were also found to be on statin treatment (P=0.014).
5.4.1.3 L+O v ODM
I chose to examine baseline characteristics between L+O v ODM to look at the 
effects of non-diabetes (n=32) and diabetes (n=16), results are shown in Table 5.3. 
Age (P=0.042), weight (P<0.001) and BMI (P<0.001) were all significantly different 
between groups. Unsurprisingly, blood glucose levels were found to be significantly 
higher in the subjects with diabetes (P=0.020), whilst LDL-C (P=0.043) and creatinine 
(P=0.010) were both higher in patients in the non-diabetes group. The co­
morbidities hypertension (P=0.011) and OSA (P<0.001) were significantly more 
prevalent in the subjects with diabetes and more subjects in this group were also on 
statin and ACE inhibitor treatments, with ACE inhibitor showing a significant 
difference (P=0.025).
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Table 5.2 Baseline characteristics between lean v obese (O +O DM ) groups
Lean
(n=17)
Obese + Obese T2D M  
(n=31)
P
Age (years) 53.8 (16.7) 48.0(11.0) 0.152
Weight (kg) 74.4 (13.3) 129.7 (32.2) <0.001
BMI (kg/m2) 26(2.6) 46(12.3) <0.001
SBP (mmHg) 137 (22.2) 136(19.2) 0.863
DBP (mmHg) 81 (12.5) 77 (12.8) 0.304
Glucose (mmol/L)* 5.7 (0.6) 7.3 (1.2) 0.166
Cholesterol (mmol/L) 5.7 (1.3) 5.1 (1.4) 0.448
HDL-C (mmol/L) 1.6 (0.3) 1.1 (0.2) 0.005
LDL-C (mmol/L) 3.6 (1.1) 2.9 (1.1) 0.343
Triglycerides (mmol/L) 1.2 (0.2) 2.2 (1.2) 0.144
Creatinine (pmol/L) 79.3 (18.2) 74.1 (15.2) 0.304
Albumin (mmol/L) 47.3 (8.7) 42.2 (4.0) 0.011
RNA (ng/pl) 88.1 (52.6) 75.3 (46.1) 0.388
Males % (n) 52.9 (9) 38.7 (12) 0.342
Current smoker % (n) 29.4 (5) 22.6 (7) 0.815
Hypertension % (n) 17.6(3) 48.4(15) 0.035
OSA % (n) 0(0) 32.3 (10) 0.008
Statins % (n) 5.9(1) 38.7 (12) 0.014
ACE inhibitor % (n) 23.5 (4) 32.3 (10) 0.525
Baseline characteristics between lean and obese (O+ODM) groups to look at effects o f obesity 
between groups. Log transform ed data. Mean and standard deviation shown or geometric mean 
and approximate standard deviation fo r log transform ed data. Analysis performed by ANOVA after 
appropriate transform ation. x 24est was used to  compare groups. P-value shows significance where 
P<0.05
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Table 5.3 Baseline characteristics between non-diabetic and diabetic groups
No Diabetes  
(n=32)
Diabetes
(n=16)
P
Age (years) 52.9 (14.3) 44.4 (9.5) 0.038
Weight (kg) 94.2 (32.8) 141.9 (25.8) <0.001
BMI (kg/m2) 32 (10.6) 52 (10.7) <0.001
SBP (mmHg) 134 (20.7) 142 (18.4) 0.214
DBP (mmHg) 80(12.4) 76 (13.3) 0.270
Glucose (mmol/L)* 5.8 (0.5) 8.1 (1.5) 0.017
Cholesterol (mmol/L) 5.8 (1.5) 4.8 (1.2) 0.101
HDL-C (mmol/L) 1.3 (0.4) 1.1 (0.2) 0.084
LDL-C (mmol/L) 3.7 (1.4) 2.6 (0.7) 0.043
Triglycerides (mmol/L) 1.6 (0.6) 2.3 (1.3) 0.148
Creatinine (pmol/L) 80.3 (15.2) 67.6 (15.6) 0.010
Albumin (mmol/L) 45.6 (7.2) 41.7 (4.6) 0.057
RNA (ng/pl) 88.5 (49.3) 61.5(42.0) 0.074
Males % (n) 46.9 (15) 37.5 (6) 0.537
Current smoker % (n) 28.1 (9) 18.8 (3) 0.857
Hypertension % (n) 25.0(8) 62.5(10) 0.011
OSA % (n) 6.2 (2) 50.0(8) <0.001
Statins % (n) 18.8(6) 43.8(7) 0.066
ACE inhibitor % (n) 18.8(6) 50.0(8) 0.025
Baseline characteristics between non-diabetes (L+O) and diabetes groups to look at the effect o f 
diabetes between groups Log transform ed data. Mean and standard deviation shown or geometric 
mean and approximate standard deviation fo r log transform ed data. Analysis performed by ANOVA 
after appropriate transform ation. / 2-test was used to  compare groups. P-value shows significance 
where P<0.05
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5.4.2 RT-PCR gene expression analysis in human samples
HumanVAT samples from 48 subjects, categorised as L, 0  and ODM (L/O/ODM: 
17/15/16), were selected, including the same samples that were analysed in 
Chapter 4, to investigate gene expression of 4 genes, GSR, GPX1, IL-6 and PPARy, 
normalised against ACTB as a housekeeping gene. Results are shown in Table 5.4.
GSR showed no difference in gene expression in the 0  group, however did show a 
increased fold change of 2.28 in ODM, relative to L. In the ODM group, GSR showed 
a 2.36 fold-change when compared to 0  subjects. GPX1 gene expression showed no 
difference between groups. IL-6 had increased gene expression of 3.01 and 2.03 in 
the O and ODM groups respectively, relative to L, however, no difference was 
observed in ODM compared to O subjects. PPARy gene expression showed no 
difference between groups
When the samples were grouped by obesity (L v O+ODM), GSR, GPX1 and PPARy 
showed no difference in gene expression in the obese subjects (O+ODM) relative to 
L, whilst IL-6 showed increased gene expression of 2.46 in the obese group 
(O+ODM). Results were analysed with subjects grouped as having no diabetes and 
diabetes (L+O v ODM). GSR showed increased gene expression of 2.33 in the group 
with diabetes relative to the no diabetes group. No difference was seen in 
expression of GPX1, IL-6 and PPARy between the groups.
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Table 5.4 Fold change gene expression in hVAT samples
Compared groups Gene Fold change Expression change
LvO GSR 0.97 <r*
GPX1 1.12
IL-6 3.01 *
PPARy 0.65
L v ODM GSR 2.28 t
GPX1 1.97 <-»
IL-6 2.03 *
PPARy 0.66 <r±
O v ODM GSR 2.36 *
GPX1 1.77
IL-6 0.67 <r*
PPARy 1.03
Lv (O + ODM) GSR 1.51 <->
GPX1 1.48 O
IL-6 2.46 *
PPARy 0.66
(L + O) v ODM GSR 2.33
GPX1 1.88
IL-6 1.21
PPARy 0.82 <-»
Table 5.3 Summary of hVAT gene expression values showing their status
< 0.5 decreased gene expression (denoted by 40
> 2.0 increased gene expression (denoted by 10
0.5 -  2.0 no difference in gene expression (denoted by <-»)
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5.4.3 RT-PCR gene expression analysis in mouse samples
Mouse 3T3-L1 cells were cultured in conditions of high and low glucose and treated  
with LPS in order to induce a pro-oxidative environment. Treated cells were 
analysed to investigate gene expression of 2 genes, Gsr and Gpxl, normalised 
against Actb as a housekeeping gene, results are shown in table 5.5. In 3T3-L1 cells 
cultured in medium with high glucose content, Gsr and Gpxl gene expression 
showed no difference after LPS treatment relative to untreated cells. In cells grown 
in medium with low glucose content, Gsr showed no difference in gene expression 
with LPS treatment, whilst Gpxl showed decreased expression of 0.33 fold with LPS 
treatment relative to untreated cells.
Table 5.5 Fold change gene expression in treated 3T3-L1 samples
Treatment Gene Fold change Expression change
High glucose 
(LPS v No LPS)
Gsr 0.91 <r>
Gpxl 1.27
Low glucose 
(LPS v No LPS)
Gsr 0.62
Gpxl 0.33
Table 5.4 Summary of mouse treated 3T3-L1 gene expression values showing their status 
< 0.5 decreased gene expression (denoted by 40  
> 2.0 increased gene expression (denoted by T')
0.5 -  2.0 no difference in gene expression (denoted by <->)
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5.5 Discussion
The aim of the work in this chapter was firstly, to analyse gene expression of the 
antioxidant genes GSR, GPX1, PPARy and IL-6 in hVAT samples. Forty eight samples 
from across the three groups (L/O/ODM: 17/15/16) were analysed by RT-PCR to 
investigate gene expression. No difference in GSR expression was observed in the 0  
group compared to the L, although a significant increase in expression was seen in 
the ODM group when compared to both L and O groups. This does not completely 
agree with the previous gene expression results in Chapter 4 gathered using a 
commercial PCR array kit, in which GSR expression was observed to increase 
significantly in O subjects and a further increase was seen in ODM. The only 
explanation for this difference lies within the methodology. Firstly, more samples 
were analysed via RT-PCR than using the commercial arrays, which may shift the 
overall outcome. Also there are fundamental differences between PCR array kits, 
such as those used in Chapter 4 which are highly optimised and use different 
primers and mastermix solutions, and a lab based PCR protocol that may account 
for these discrepancies.
When looking at GPX1 gene expression, no difference was observed in expression 
levels between the three groups. These results do not agree with what was 
previously seen when examining GPX1 gene expression via PCR array analysis, 
which showed an increased GPX1 expression in obese patients and then decrease in 
obese patients with T2DM. An increased GPX1 expression would have been 
expected due to increased cellular oxidative burden within these samples, which
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would be counteracted by the up regulation of antioxidants, such as GPX1, in 
defence against excess ROS. This was not seen in this part of the study.
In the case of IL-6, increased gene expression was observed in the O and ODM 
groups compared to L, although no significant difference was observed between the 
0  and ODM subjects. In the past, levels of IL-6 mRNA expression, as well as systemic 
levels of IL-6 have been observed to increase with adiposity, with approximately a 
third originating from adipose (Mohamed-Ali et al, 1997), predominantly from VAT 
rather that subcutaneous tissue (Fried et al, 1997). Previous observations have 
recorded different levels of IL-6 gene expression within different tissues and within 
different adipose depots (Wozniak et al, 2009). This may explain the results 
observed here. Also differences in expression between different parts of AT has 
been described (Fried et al, 1997, Yudkin et al, 2000), but as total adipose was used 
in this study this will not be a defining factor.
Similarly, PPARy showed no change in gene expression between groups. Previous 
studies have described an increased adipose expression of PPARy mRNA in obesity 
although a decrease in expression was acknowledged in the case of low calorie 
dieting in adipose tissue from obese patients (Vidal-Puig et al, 1997). This is 
interesting because all subjects in the ODM category were undergoing bariatric 
surgery at the time of sample collection. For this type of surgery to  be undertaken 
the patient must undertake a strict, low calorie pre-operative diet, in order to 
reduce liver size ready for surgery. It would be assumed that a reduced PPARy 
expression should have been observed here due to this low calorie diet that is
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maintained weeks prior to surgery and sample collection, although no decrease in 
expression was found. There are two mRNA splice variants of PPARy, which are 
highly expressed in hVAT, both of which are found in equal proportions within the 
tissue in obese and diabetic patients (Vidal-Puig et al, 1997). The limited difference 
in expression seen in this study may not be attributed to these splice variants as it 
can be assumed that they are expressed at similar levels in the sample set used 
here.
When analysing the subjects group by obesity (L v O+ODM) there was no difference 
in gene expression found for GSR, GPX1 and PPARy, however, an increased 
expression of IL-6 was observed in the obese subjects. Again, this is attributed to 
increased IL-6 levels with increased adiposity. Interestingly, GSR showed an 
increased expression in patients with diabetes when compared to subjects without 
diabetes (L+O v ODM), while no change was observed in the other genes. This 
increased GSR expression does not correspond to results from Chapter 4, where no 
difference in expression was seen in the GSR gene when analysing diabetes against 
non-diabetes groups.
Analysis of gene expression in a mouse cell line focused on Gsr and Gpxl only. Due 
to surprisingly low levels of oxidative stress observed in the human population, 
especially ODM subjects, Gsr and Gpxl were examined in parallel in an induced pro- 
oxidative state. The 3T3-L1 mouse cell line was used to examine candidate gene 
expression of Gsr and Gpxl in a basal state and under the influence of a 
'biochemical stressor7, in this case LPS. After one whole cell cycle post treatm ent
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with LPS, no differences in gene expression of Gsr were observed in cells grown in 
high glucose or low glucose conditions. In the human samples, an increased 
expression was seen, particularly in the ODM subjects, so it would therefore be 
expected that the LPS induced state of oxidative stress would induce increased 
expression of Gsr in the mouse cell line. This may not have been seen as mouse cells 
are more resistant to LPS exposure compared to human cells, which are more 
sensitive as they contain lower levels of circulating antibodies than mice (Warren et 
al, 2010).
Gpxl gene expression showed no difference in mouse cells grown in high glucose 
medium, which agrees with the results seen in the human samples via RT-PCR. 
When grown in low glucose conditions Gpxl did show decreased gene expression 
when treated with LPS.
Results from the RT-PCR array analysis and the lab based RT-PCR gene expression 
analysis clearly show an increased expression of GSR in ODM subjects. Although 
unexplained, conflicting results have been shown for the 0  group. It may be that 
the increased expression of GSR is having an overall protective effect against 
oxidative stress in the ODM subjects, where surprisingly lower levels of oxidative 
markers were measured. To gain an insight into possible reasons for the increased 
expression of GSR in this group, it would be important to look at the gene at the 
DNA level to examine the sequence for possible mutations that may explain this 
observation.
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CHAPTER 6
SEQUENCING FOR GSR GENE VARIANTS
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6.1 Introduction
Throughout the previous chapters increased GSR gene expression has been 
observed in ODM subjects. This suggests a protective effect against oxidative stress, 
since the results in Chapter 3 show markers of oxidative stress being notably lower 
in this group. This observation may be simply due to an increased level of oxidative 
stress in ODM subjects prior to this study, which initiated a high expression of GSR 
in defence against excess ROS resulting in an overall decrease in oxidative stress at 
the time samples were collected.
Several methods were considered to investigate GSR expression, including the 
measurement of GSR activity by monitoring NADPH consumption within a sample. 
Commercial kits are available to assay the oxidation of NADPH to NADP+, which is 
monitored by the decrease in absorbance at 340 nm. The rate of decrease in 
absorbance is directly proportional to the GSR activity in the sample. The 
measurement of overall GSR activity in AT samples via this method was not carried 
out due to time restraints and expense.
Another explanation for the increased GSR expression in ODM subjects may be an 
alteration within the sequence of the GSR gene, which may cause this increased 
expression within this sample group. In order to investigate this in more detail, the 
GSR gene was selected for gene variant sequencing to identify any possible 
mutations/polymorphisms that may account for the increased expression observed 
in previous chapters. Several studies have looked at gene variants of other 
antioxidant genes and have observed differences in enzyme expression and activity
155
as a result of polymorphisms. An example of which is the Alal6Val polymorphism 
within the SOD gene, where the TT genotype results in lower activity (Flekac et al, 
2008). Recent studies focusing on IL-6 polymorphisms have observed an association 
between gene variants and an individual's susceptibility to T2DM and its 
complications (Saxena et al, 2013). In particular a significant association has been 
found between the IL-6 gene -572 C/G polymorphism and T2DM risk (Yin et al, 
2013).
6.1.1 Glutathione antioxidant system
GSR is an antioxidant enzyme, which plays a pivotal role in the glutathione 
antioxidant system. GSH, along with its related enzymes, makes up the primary 
defence against oxidative damage by neutralising excess ROS and repairing any 
damage caused (Pastore et al, 2003). As previously described, the glutathione 
antioxidant system is responsible for maintaining cellular defence against H2C>2. This 
occurs due to glutathione peroxidases restoring GSH levels by reducing GSSG, which 
has been found to be up-regulated by p53 (Hussain et al, 2004). GSH homeostasis is 
dependent on its synthesis, uptake of exogenous GSH and redox recycling.
GSH synthesis consists of two sequential ATP-dependent steps catalysed by GCL and 
GSH synthetase (GS), which occurs entirely in the cytosol (Meister and Tate, 1976) 
(Figure 6.1). The cellular concentration of GSH is regulated by the GCL catalysed 
formation of y-glutamyl-cysteine, which is feedback-inhibited by GSH (Griffith and 
Meister, 1979). This reaction is dependent on cellular adenosine triphosphate (ATP)
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which is hydrolysed to  adenosine diphosphate (ADP) supplying the energy required 
fo r the reaction.
Figure 6.1 GSH synthesis
ATP ADP ATP ADP
Glutamate + Cysteine v *  y — glu — cys + Glycine
GCL GS
GSH synthesis consisting of tw o ATP-dependent steps catalysed by glutamate cysteine ligase (GCL) 
and GSH synthetase (GS)
GSH is principally found in its biologically active reduced th io l form , GSH (Circu and 
Yee Aw, 2008). In an oxidizing environm ent there is an increased oxidation o f GSH 
to  its disulphide form , GSSG, resulting in a decreased GSH:GSSG ratio. The 
GSH:GSSG ratio is normally m aintained at approxim ately 100:1, but when affected 
by oxidative burden can fall as low as 4:1 (Circu and Yee Aw, 2008). This oxidant 
induced GSH:GSSG imbalance has been found to  play a role in the in itia tion  o f the 
apoptotic cascade and can play a vital role in deciding cell fate (Merad-Boudia et al, 
1998).
A mechanism fo r cellular GSH regeneration is com m only known as the GSH redox 
cycle (Figure 6.2), which involves the catalytic conversion o f oxidised GSSG to  its 
reduced form , GSH, by NAPDH-dependant GSR (Ahmadpoor et al, 2009). GSR is a 
ubiquitous FAD-containing flavoenzyme (Pai and Schulz, 1983) tha t is d istributed in 
both the cytoplasm and m itochondria (Circu and Yee Aw, 2008).
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Figure 6.2 GSH redox cycle
NADP* <S . GSH ^  ^  ROOH
Pentose phosphate 
pathway
Glucose----------------- > NADPH GSSG ^  ^  R-OH
GSR; Glutathione reductase, GPx; G lutathione peroxidase
The reduction o f GSSG to  GSH via GSR is dependent on the presence o f NADPH/H+ 
as a proton donator, producing NADP+. The required am ount fo r the GSR system is 
high, w ith  up to  10% o f glucose uptake being used to  produce sufficient levels o f 
NADPH. However, high amounts o f NADPH/H+ are also required fo r cholesterol 
synthesis, so in the case o f high oxidative stress there  may be lim ited or no free 
NADPH as it w ill be used up to  a higher degree w ith in  the activated GSR system. The 
result is a decreased to ta l cholesterol level in any environm ent o f oxidative stress 
and an increase in GSR activity. Therefore, cholesterol levels fo r production o f LDL-C 
w ill be reduced. The activity o f GSR in environm ents o f oxidative stress is dependent 
on FAD and ACPI (Apelt et al, 2009). In the event o f the GSR system failing due to 
the lack o f FAD during oxidative stress then NADPH/H+ w ill become available and 
increased cholesterol production w ill occur.
The human GSR gene is located on chromosome 8 at position p21.1. It is over 4.9kb 
in size and contains 13 exons (Kelner et al, 2000). The complete gene encodes a 522
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amino acid long polypeptide. Sequencing of the mRNA sequence of the gene was 
utilised in order to identify gene variants.
6.2 Aim
The purpose of the work described in this chapter was to analyse the GSR gene 
sequence for variants that may account for the increased gene expression observed 
in previous chapters. Any variants identified would then be compared between the 
three sample groups.
6.3 Methods
6.3.1 Sequencing of the GSR gene
The sequencing of the GSR gene for variants was carried out using specific primers 
designed to complement the mRNA template in five overlapping segments as 
described in Chapter 2 (Section 2.6). The method used reverse transcribed mRNA as 
a template, with resulting PCR products being purified and sent to Source 
Bioscience (Nottingham, UK) for sequencing. mRNA sequence was successfully 
gathered for 26 samples. The resulting sequence scores were analysed using 
Mutation Surveyor to determine potential variants. Samples containing potential 
variants were sent for re-sequencing for verification.
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6.4 Results
6.4.1 Baseline characteristics 
6.4.1.1L v O v ODM
hVAT samples from 26 subjects, categorised as L, O and ODM, were successfully 
sequenced (L/O/ODM: 9 /9 /8 ). Baseline characteristics of subjects were analysed for 
differences between groups as this sample set differed from the previous chapter, 
results are shown in Table 6.1. There was no significant difference in age across 
groups although the L and 0  subjects were approximately 12 years older than the 
ODM group. Weight and BMI were significantly higher in the ODM group (P<0.001 
for both), as was blood glucose (P=0.044). HDL-C levels in the L subjects were 
significantly higher (P=0.019), whilst a significantly higher percentage of subjects in 
the ODM group were on statin (P=0.025) and ACE inhibitor (p=0.024) treatments.
6.4.1.2 L v O+ODM
Prior to analysis, I chose to examine baseline characteristics between L v O+ODM to 
look at the effects of obesity between groups. Results are detailed in Table 6.2. 
Weight and BMI were significantly higher in the O+ODM group (P<0.001 for both), 
whilst HDL-C levels were significantly higher in L group (P=0.010). There was a 
higher proportion of subjects with hypertension and OSA in the O+ODM group, 
although this was not statistically significant. A higher percentage of subjects in the 
O+ODM group were on statin treatment and ACE inhibitors, although again this was 
not significant.
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Table 6.1 Baseline characteristics compared betw een groups
Lean
(n=9)
Obese
(n=9)
O b ese /T2D M
(n=8)
P
Age (years) 53.3 (18.4) 52.3 (9.0) 39.9 (11.1) 0.100
Weight (kg) 72.8(14.3) 108.7 (30.8) 143.8 (31.7) <0.001
BMI (kg/m2) 25(1.7) 37 (9.0) 52 (13.6) <0.001
SBP (mmHg) 130(21.3) 130(17.9) 144 (19.9) 0.274
DBP (mmHg) 77 (12.7) 81 (11.0) 77 (10.5) 0.695
Glucose (mmol/L)* 5.1 (0.3) 6.1 (0.4) 9.3 (1.9) 0.044
Cholesterol (mmol/L) 7.2 (-) 5.7 (2.4) 5.4 (1.3) 0.613
HDL-C (mmol/L) 1.7 (-) 1.0 (0.2) 1.1 (0.2) 0.019
LDL-C (mmol/L) 4.9 (-) 3.8 (2.1) 3.1 (0.7) 0.435
Triglycerides (mmol/L) 1.1 (-) 2.1 (0.5) 2.6 (1.6) 0.604
Creatinine (pmol/L) 74.7 (21.0) 79.5 (9.4) 65.4 (18.8) 0.274
Albumin (mmol/L) 45.2 (4.4) 42.8 (2.9) 40.4 (5.8) 0.128
RNA (ng/pl) 96.8 (61.9) 73.0(38.5) 64.5 (50.7) 0.412
Males % (n) 44.4 (4) 44.4 (4) 37.5 (3) 0.947
Current smoker % (n) 22.2 (2) 33.3 (3) 25.0(2) 0.774
Hypertension % (n) 11.1 (1) 22.2 (2) 62.5(5) 0.057
OSA % (n) 0(0) 11.1 (1) 25.0(2) 0.273
Statins % (n) 0(0) 11.1 (1) 50.0(4) 0.025
ACE inhibitor % (n) 11.1 (1) 11.1 (1) 62.5(5) 0.024
Baseline characteristics of 28 hVAT samples in L, O and ODM groups. Log transform ed data. Mean 
and standard deviation shown or geometric mean and approximate standard deviation for log 
transform ed data. Analysis performed by ANOVA after appropriate transform ation. x 2-test was used 
to compare groups. P-value shows significance where P<0.05
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Table 6.2 Baseline characteristics betw een lean and obese (O +O DM ) groups
Lean
(n=9)
Obese + Obese T2D M  
(n=17)
P
Age (years) 53.3 (18.4) 46.5(11.6) 0.255
Weight (kg) 72.8 (14.3) 125.2 (35.5) <0.001
BMI (kg/m2) 25(1.7) 44 (13.4) <0.001
SBP (mmHg) 130(21.3) 137 (19.6) 0.452
DBP (mmHg) 77 (12.7) 79 (10.6) 0.638
Glucose (mmol/L)* 5.1 (0.3) 8.0 (1.5) 0.069
Cholesterol (mmol/L) 7.2 (-) 5.5 (1.5) 0.326
HDL-C (mmol/L) 1.7 (-) 1.1 (0.2) 0.010
LDL-C (mmol/L) 4.9 (-) 3.4 (1.3) 0.281
Triglycerides (mmol/L) 1.1 (-) 2.5 (1.3) 0.359
Creatinine (pmol/L) 74.7 (21.0) 72.4 (16.1) 0.768
Albumin (mmol/L) 45.2 (4.4) 41.4 (4.8) 0.071
RNA (ng/pl) 96.8(61.9) 69.0 (43.4) 0.193
Males % (n) 44.4 (4) 41.2(7) 0.873
Current smoker % (n) 22.2 (2) 29.4(5) 0.823
Hypertension % (n) 11.1 (1) 41.2 (7) 0.114
OSA % (n) 0(0) 17.6(3) 0.180
Statins % (n) 0(0) 29.4(5) 0.070
ACE inhibitor % (n) 11.1 (1) 35.3 (6) 0.186
Baseline characteristics between lean and obese (O+ODM) groups to  look at effects o f obesity 
between groups. Log transform ed data. Mean and standard deviation shown or geometric mean 
and approximate standard deviation fo r log transform ed data. Analysis perform ed by ANOVA after 
appropriate transform ation. x 2Test was usecl t0  compare groups. P-value shows significance where 
P<0.05
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Table 6.3 Baseline characteristics betw een no-diabetes and diabetes groups
No Diabetes  
(n=18)
D iabetes
(n=8)
P
Age (years) 52.8 (14.1) 39.9 (11.1) 0.031
Weight (kg) 90.8 (29.7) 143.8 (31.7) <0.001
BMI (kg/m2) 31 (8.9) 52 (13.6) <0.001
SBP (mmHg) 130(19.1) 144 (19.9) 0.104
DBP (mmHg) 79 (11.7) 77 (10.5) 0.690
Glucose (mmol/L)* 5.6 (0.4) 9.3 (1.9) 0.015
Cholesterol (mmol/L) 6.1 (2.1) 5.4 (1.3) 0.518
HDL-C (mmol/L) 1.2 (0.4) 1.1 (0.2) 0.901
LDL-C (mmol/L) 4.1 (1.8) 3.1 (0.7) 0.261
Triglycerides (mmol/L) 1.9 (0.7) 2.6 (1.6) 0.422
Creatinine (pmol/L) 76.9 (16.3) 65.4 (18.8) 0.128
Albumin (mmol/L) 44.3 (4.0) 40.4 (5.8) 0.070
RNA (ng/pl) 84.9 (51.5) 64.5 (50.7) 0.359
Males % (n) 44.4 (8) 37.5(3) 0.741
Current smoker % (n) 27.8 (5) 25.0(2) 0.847
Hypertension % (n) 16.7(3) 62.5(5) 0.019
OSA % (n) 5.6(1) 25.0(2) 0.152
Statins % (n) 5.6(1) 50.0(4) 0.008
ACE inhibitor % (n) 11.1(2) 62.5(5) 0.006
Baseline characteristics between non-diabetes (L+O) and diabetes groups to look at the effect o f 
diabetes between groups Log transform ed data. Mean and standard deviation shown or geometric 
mean and approximate standard deviation fo r log transform ed data. Analysis performed by ANOVA 
after appropriate transform ation. x 2~test was usecl t0  compare groups. P-value shows significance 
where P<0.05
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6.4.1.3 L+0 v ODM
I chose to examine baseline characteristics between L+O v ODM to look at the 
effects of non-diabetes (n=18) and diabetes (n=8), results are shown in Table 6.3. 
Age, weight and BMI were significantly different between groups (P=0.031, P<0.001 
and P<0.001 respectively). Blood glucose was significantly higher in subjects with 
diabetes (P=0.015). There was a higher prevalence of hypertension and OSA in 
subjects with diabetes, although only hypertension was significant (P=0.019), and a 
significantly higher percentage of subjects were on statin and ACE inhibitor 
treatments (P=0.008 and P=Q.006 respectively).
6.4.2 Sequencing of GSR gene variants
The sequencing of the GSR mRNA was successful in 26 hVAT samples. The 
sequencing was carried out using primers designed to complement the mRNA 
template in five overlapping segments. The PCR products for the separate 
fragments were verified using polyacrylamide gel electrophoresis to account for any 
samples that proved unsuccessful during sequencing. Examples of the gel images 
are shown in Figure 6.3. They show that products from primer set 1, which were 
designed to amplify the sequence at the 5' end, were unsuccessful. The sequence 
amplified using primer set 2 were successful but at a low efficiency, which could still 
be sequenced, whilst primer set 3 had a high affinity and produced PCR products 
ideal for sequencing. Intact sequence scores were collected for primer sets 2 and 3. 
Primer set 4 and 5 were not analysed as they lay outside of the gene coding 
sequence.
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Figure 6.3 Polyacrylamide gel images of PCR products.
Polyacrylamide gel images showing PCR products for primer set 1 (1), prim er set 2 (2) and prim er set 
3 (3)
Initial analysis showed 1 sample from  the O group w ith  a possible variant. This was 
shown on the resulting chrom atograph as a heterozygous base change at position 
419 from  C->A, which would result in an amino acid change from  proline (P) -> 
threonine (T). This P419T variant is shown in Figure 6.4.
Figure 6.4 Chromatograph showing position of P419T variant
<0 50 60 70 80 90 100 110 120 130 140 150
A G GAAGAT TC a *  A T T A G AT T A T i  A CA A CA T C CCA AC 7G T G GT C T  TCA GC CAC C CC C C T A T TGG G ACAGI GG G AC TCA CG G A AG AT G A i  GC C A T T C A T A A AT A T GG AA T AG A A
P419T
Sequence trace where black peaks denote G, green peaks denote A, red peaks denote T and blue 
peaks denote C. At position 419 tw o peaks, one blue and one green, can be seen as a possible 
heterozygote variant
The sample containing the potentia l P419T variant was sent fo r re-sequencing fo r 
verification. To be re-sequenced the sample underwent both forw ard and reverse 
sequencing to  ensure the resulting sequence was correct. The resulting
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chromatograph is shown in Figure 6.5. The P419T variant was not observed after re­
sequencing.
Figure 6.5 Chromatograph showing position of P419T variant post verification
0 50 00 70 80 80 100 110 120 130 140 ISO
J G i K l T T C C  K A T T i  G A T T A T A i C A i C i T C C C i i C T G  T GGT C7 TCAG C a C C C C C C  TAT T GGG1 CA GT GGG i C T C i C G G  A 1 G i T G A i C C C A I T C A T i i i T i T  G G A i T i G  11A
P419T no longer present
Sequence trace where black peaks denote G, green peaks denote A, red peaks denote T and blue 
peaks denote C. At position 419 only one blue peak can be seen
6.5 Discussion
The aim o f the work in this chapter was to  sequence the GSR gene fo r variants. In 
the previous chapters GSR showed an increased expression w ith in  the ODM group. 
It was hypothesised tha t possible gene variants could be responsible fo r this 
increased expression. In order to  analyse this in more detail, mRNA fo r the GSR 
gene was sequenced using specific primers tha t spanned the gene in 5 overlapping 
fragments. hVAT from  26 subjects were successfully sequenced fo r variants, 
although the 5' end o f the mRNA was unable to  be sequenced due to  primers being 
unable to  bind. This lim ited a ffin ity  seen w ith in  the firs t prim er set was due to  the 5' 
sequence being the furthest point from  the polyA tail making the binding o f 
primers, although specific, unstable. Primer set 4 and 5 were spanning sequence 
outside o f the coding area so this was le ft unanalysed.
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Initial analysis showed one subject from the 0  group as having a possible P419T 
variant, which after searching NCBI was potentially a novel gene variant. This 
variant was shown as a heterozygous C->A base change, which would result in an 
amino acid change from proline (P) -> threonine (T). The presence of this base 
change may ultimately cause an alteration in the overall structure and function of 
the resulting enzyme. However, after verification via re-sequencing this variant was 
lost. This suggests that the initial variant observed was in fact an anomaly that may 
have occurred during the PCR reaction.
Gene mutations can be formed at different scales, from small point mutations, 
through to small deletions of the entire genes or larger deletions that span one or 
more genes. The latter would not be detectable because the affected cells would 
not survive (Zhang et al, 2007).
Overall, no gene variants within the GSR gene were observed in the mRNA of hVAT 
samples. This suggests that a gene variation is not the explanation for the increased 
expression observed in previous chapters. Although no variants were observed 
within this gene, this still does not rule out DNA alteration as the cause of the 
increased expression of GSR in the ODM group. Alternatively, analysis of splice 
variants of GSR may hold the key to the gene's increased expression. Splicing of 
primary transcripts have been shown to play a vital role in the expression of genes, 
where gene splicing can ultimately result in protein variation and altered expression 
levels of single genes (Mironov et al, 1999).
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CHAPTER SEVEN
DISCUSSION
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The overall aim of this thesis was to investigate the role of AT in obesity and T2DM  
focusing on markers of oxidative stress and gene expression in hVAT from subjects 
categorised as L, O and ODM. This cross-sectional study was carried out to 
determine any changes in levels of oxidative stress between these groups, as well 
as identifying particular genes that may contribute to these conditions.
7.1 Biomarkers of oxidative stress
When investigating two biomarkers of oxidative stress (AABTS+ and TBARS) and two 
markers of DNA damage (telomere length and Comet assay) in hVAT it was 
expected that oxidative stress levels would increase across groups due to the higher 
levels of oxidative burden associated with obesity and T2DM. When analysing 
overall antioxidant capacity in the hVAT, no difference in ABTS+ radical formation 
was observed across the groups suggesting an overall lower level of total 
antioxidants than was expected to be seen in the 0  and ODM groups. When 
measuring levels of lipid peroxidation, there was a significant difference in MDA  
concentration between the three groups with the ODM group being significantly 
lower. Telomere length, as a measure of oxidative DNA damage, was significantly 
longer in subjects with diabetes, which is the opposite to what was expected as 
telomere shortening is generally associated with T2DM. When measuring DNA 
damage using the Comet assay no difference was observed between the three 
groups, although when stratifying by diabetes status there was a significant amount 
of undamaged DNA remaining in the nucleus of the cells after electrophoresis. This 
result again is surprising as an increase in DNA damage was expected in the ODM 
subjects. Overall, there appeared to be a protective mechanism in the subjects with
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diabetes as they displayed a decreased level of oxidative stress compared to the 
other groups, which showed no significant difference in any of the markers. A 
significant proportion of the subjects in the ODM category were on ACE inhibitor 
and statin therapy, which may be confounding the results in these experiments as 
these therapies may be minimising the effects of oxidative stress.
7.2 Gene expression in hVAT
While looking at gene expression differences in obesity and diabetes, via the use of 
commercial PCR array kits, 19 genes were found to show either increased or 
decreased expression. In particular, an increase in GSR across the groups was 
observed with a particular significance in both O and ODM when compared to L 
control. Also a significant difference was seen in the grouped O+ODM subjects 
when compared to the L controls. It was assumed that this difference in gene 
expression was due to reduced levels of GSH, within the glutathione redox system, 
due to hyperglycaemia. As a result of this, there is increased expression of the 
reducing enzyme, GSR, to maintain a healthy GSH: GSSG ratio and rebalance the 
redox system. From this it was concluded that in an environment of excessive 
oxidative burden, depletion of GSH due to increased plasma glucose levels causes 
increased expression of GSR. Although not significant, an increased in gene 
expression of GPX1 was observed in 0  subjects and decrease in ODM subjects. An 
increased GPX1 expression would have been expected in the ODM group due to 
increased cellular oxidative burden within these samples, which would be 
counteracted by the increased expression of antioxidants, such as GPX1, in defence 
against excess ROS. This was not seen here.
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When investigating gene expression via RT-PCR analysis no difference in GSR 
expression was observed in the 0  group compared to the L, although a significant 
increase in expression was seen in the ODM group when compared to both L and 0  
groups. However, GSR expression was increased in patients with diabetes when 
compared to subjects without diabetes (L+O v ODM). There was no difference in 
expression of GPX1 observed between the groups. These results differ from the 
gene expression results seen via a commercial PCR array kit. The difference was put 
down to the altered sample set as a greater number of samples were analysed by 
RT-PCR, which may account for the change in overall results. Also there may be 
some variance between the two methods of analysis. When utilising a commercial 
array kit, which is highly optimised and uses different primers and mastermix 
solutions, results should be expected to differ to a degree when compared to a 
conventional, lab based PCR protocol. Other than the differences explained here 
there is no overall conclusion as to why the results for GPX1 and GSR expression 
may differ between the techniques.
An increased gene expression of IL-6 was observed in the 0  and ODM groups 
compared to L, which was expected due to the association between IL-6 and 
increased adiposity. No significant difference was observed between the O and 
ODM subjects, which suggests the IL-6 expression difference is associated with 
obesity rather than diabetes. When looking at PPARy there was no difference of any 
significance seen between the three groups.
7.3 Stimulation studies
The aim of this stimulation study was to examine candidate gene expression in 
response to a 'biochemical stress7 in the 3T3-L1 mouse cell line. Gene expression of 
Gsr and Gpxl was examined at basal state and in a state of 'biochemical stress7, 
induced by LPS treatment. Cells grown in low glucose conditions showed a 
decreased expression of Gpxl after treatment with LPS. This was in fact the 
opposite to what should be expected. In an environment of high oxidative stress, 
induced by LPS treatment, Gpxl is expected to increase expression in order to 
reduce oxidative burden. This unexpected result may be due to the difference in 
species or because the mouse cells were not an obese model, whereas the human 
samples were obese with diabetes. The combination of obesity and diabetes may 
affect the overall gene expression.
7.4 Glutathione reductase sequencing
The previous results had shown a significant difference in the gene expression of 
the GSR gene in ODM subjects. It was suspected that possible gene variants were 
responsible for this increased expression. In order to analyse this in more detail, 
mRNA for the GSR gene was sequenced in order to identify any causative gene 
variants. Overall there were no gene variants identified within the coding region of 
the gene suggesting that an alteration to the DNA sequence of the gene was not 
the causative factor of the increased expression observed. It may be important in 
future work to consider the influence of splice variants within the GSR gene that 
may be effecting the overall expression in this population.
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7.5 Conclusion
The subjects that make up the ODM group are a unique subset of subjects, both 
physiologically and biochemically. These patients were under extreme oxidative 
burden due to not only their excess weight but also elevated blood glucose levels as 
a result of T2DM and the added burden of existing comorbidities that these 
inflammatory conditions induce, for example endothelial dysfunction. This study 
has demonstrated that there are indeed increased levels of oxidative stress within 
the O group, but may not be to an extent that the current antioxidant systems are 
overwhelmed and, therefore, need to increase efficiency and production. It has 
been observed that the ODM subjects had increased levels of oxidative stress to the 
extreme that the antioxidant systems were required to "kick it up a gear" and 
increase cellular antioxidant levels. Additionally, the intense drug therapies that 
these patients are undergoing due to their condition, may be contributing to the 
overall positive effect on the individuals defence against oxidative stress.
It is difficult to conclude whether the lower levels of oxidative stress measured in 
the ODM subjects was a result of the increased GSR expression observed in the 
hVAT or if there remains an unseen factor influencing the dramatic expression 
change seen in this group of subjects.
From these conclusions, it may be hypothesised that within this sample set, the 
situation of oxidative stress is in fact reversible as the antioxidant capacity in these 
subjects is evident, and in combination with correct drug therapy it may be possible 
to combat oxidative burden and reduce the subsequent damage inflicted upon the
cells. Particularly within the ODM subjects in this study, bariatric surgery may play a 
positive role in the correction of this oxidative state and it would be of interest to 
be able to follow up this study by repeating this analysis one year post-operative to 
see if oxidative burden has improved in these subjects. This, however, would not be 
feasible unless the same patients were undergoing further abdominal surgery for 
the collection of hVAT.
7.6 Limitations
Although every effort was made to address any problems met within the study, it 
was unavoidable that some would arise. These are detailed below.
7.6.1 Recruitment of samples
The hVAT samples analysed in this study were collected from the bariatric-obesity 
clinic and general surgical clinics, Morriston Hospital. As with all surgery there may 
be reasons for them not being carried out on the scheduled day. For this reason 
there were many occasions where no samples were successfully collected. Also, the 
majority of the O samples and all of the ODM samples were collected from bariatric 
surgery, which in the initial stages of the sample collection were very few making 
collection very slow. Once WIMOS was established in 2011 there were far more 
suitable candidates to collect from, although for this reason the completion of 
sample collections took longer than anticipated.
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7.6.2 Baseline characteristics
During sample collections no additional clinical data was gathered directly from the 
subject at the time of surgery, so all baseline characteristics were gathered from 
medical notes at a later date. For this reason there are some measures unavailable 
for particular individuals. There were limited measures of waist circumference for 
the subjects so this could not be analysed. There was a significant difference in age 
across the three groups with an older population in the L category and then 
progressively lower in the O and ODM groups. This may be a confounding factor as 
age may have an independent impact on the markers measured in this study. This 
was not taken into consideration during statistical analysis where regression 
analysis could have been carried out to account for this. It is also important to 
address the mixture of therapies the subjects were taking. There were a number of 
subjects on a mixture of oral hyperglycaemic agents, antihypertensive agents and 
anti-depressive agents, which may have confounding effects on the markers 
measured in this thesis. Therefore, results must be interpreted with this in mind.
7.6.3 Markers of oxidative stress
When measuring TAOS, the use of hVAT homogenate was experimental. The overall 
outcome of the use of homogenates was inconclusive, therefore the calculation 
was altered to calculate relative change in ABTS+ radical formation. This is explained 
in detail in chapter 2 (section 2.3.1).
Initially an in house protocol for the Comet assay was experimented with although 
due to very strict conditions the optimisation proved difficult in the timescale
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allowed. For this reason the protocol was replaced with a commercially available kit 
to provide reliable results. In the future, I would like to return to the in house 
protocol and complete its optimisation.
All of the markers adopted for this study are normally measured in blood plasma 
samples or urine. The use of these techniques with hVAT homogenates was 
completely experimental. For this reason it would have been advantageous to have 
corresponding blood plasma samples available to validate these techniques for the 
use of hVAT.
7.6.4 Gene sequencing
Primer set 1 was not successfully optimised due to the sequence being too far from 
the poly A tail to bind effectively. Therefore, much of the coding sequence for the 
GSR gene was not sequenced successfully due to primer set 4 and 5 spanning 
completely non-coding sequence and the ATG stop codon was positioned within 
the sequence spanned by primer set 3.
7.7 Further work
In the future it would be beneficial to be able to validate these techniques for the 
use of hVAT by comparison with blood plasma samples. At the time of sample 
collection, tissue was also collected from the subcutaneous depot in each of the 
subjects, although these samples were not used in this study. It may be of use to 
analyse these samples in the same way to compare any differences between depots 
in this population. A new proposal is being written to follow on from the results of
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this study. This work will look at visceral fat, liver and muscle as three important 
organs that play a crucial role in taking up glucose from the blood in obesity and 
type 2 diabetes. These organs become "resistant" to insulin resulting in elevated 
blood glucose levels and ultimately diabetes. The study will examine differences in 
the behaviour of genes involved in insulin signalling, inflammation and free radical 
damage within samples of visceral fat, liver and muscle from subjects who are lean, 
obese and obese with type 2 diabetes. These tissues will be examined using the 
same techniques as described here. The work could potentially identify proteins 
and molecules which might lead to new treatments to prevent and treat these 
common conditions.
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APPENDIX 1
Raw data for AABTS+ validation
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Intra-assay variability
Replicate A B C D E F
1 0.203 0.197 0.201 0.201 0.200 0.200
2 0.198 0.196 0.205 0.197 0.201 0.200
3 0.198 0.201 0.201 0.199 0.203 0.202
Inter-assay variability
Replicate A B C
1 0.215 0.230 0.219
2 0.199 0.203 0.226
3 0.185 0.186 0.191
4 0.204 0.194 0.206
These tables contain the intra- and inter-assay variation for AABTS+ as described in Chapter 
3
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APPENDIX 2
Raw data for TBARS validation
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APPENDIX 3
Raw data for telom ere length validation
182
Intra-assay variability
Replicate A B C D E F
1
10.3 10.1 10.4 10.3 10.3 10.3
9.9 10.1 10.0 10.0 10.0 10.2
11.1 10.0 9.9 10.5 11.3 10.2
10.1 10.6 10.9 10.1 10.1 9.8
10.0 10.7 10.5 10.6 10.4 10.5
9.7 9.8 9.6 9.9 10.0 9.9
2
19.0 18.9 19.0 18.8 18.8 19.2
18.9 19.0 19.1 18.9 18.8 19.2
20.1 19.3 19.3 19.6 20.1 19.4
19.2 19.6 19.9 18.8 18.8 18.8
20.4 19.2 18.7 19.5 19.2 19.3
19.3 19.4 19.0 19.0 19.0 19.2
Inter-assay variability
Replicate A B C D E F G H
1
9.9 10.1 10.0 10.0 10.0 10.2 10.3 10.1
10.4 10.3 10.3 10.3 11.1 10.0 9.9 10.5
11.3 10.2 10.1 10.6 10.9 10.1 10.1 9.8
10.0 10.7 10.5 10.6 10.4 10.5 9.7 9.8
9.6 9.9 10.0 9.9 9.8 10.2 10.0 10.0
10.2 10.0 10.8 10.1 10.7 11.0 10.2 10.8
2
19.0 18.9 19.0 18.8 18.8 19.2 18.9 19.0
19.1 18.9 18.8 19.2 20.1 19.3 19.3 19.6
20.1 19.4 19.2 19.6 19.9 18.8 18.8 18.8
20.4 19.2 18.7 19.5 NA NA 19.2 19.3
19.3 19.4 19.0 19.0 19.0 19.2 19.1 19.1
19.0 19.1 19.6 19.0 19.3 19.5 18.8 19.3
These tables contain the intra- and inter-assay variation for telomere length as described in 
Chapter 3
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APPENDIX 4
Measures of DNA in the Comet assay
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Name of measure Description
Comet length
Comet height 
Comet area
Comet intensity
Comet mean intensity
Head diameter
Head area 
Head intensity
Head mean intensity
Head DNA (%)
Tail length
Tail area
Tail intensity
Tail mean intensity
Tail DNA (%)
Tail moment 
Olive moment
Total comet length measured at the widest point from the comet 
head to tail
Total comet height measured form the lowest point to highest 
Total comet area including the comet head, tail and any 
displacement of DNA in the cell
Total comet fluorescence intensity representative of total DNA 
content of the cell
Mean total comet fluorescence intensity across the total comet 
area
Diameter of the comet head representative of the diameter of the 
cell's nucleus
Total area of comet head representative of nucleus area of the cell 
Total comet head fluorescence intensity representative of total 
undamaged DNA content of the cell's nucleus
Mean comet head fluorescence intensity across the total comet 
head area
Percentage of DNA in the comet head representative of the total 
undamaged DNA in the nucleus
Length of the comet tail representative of the migration of 
damaged DNA in the cell
Total comet tail area representative of the total amount of 
damaged DNA migrated away from the cell's nucleus
Total comet tail fluorescence intensity representative of total 
damaged DNA content of the cell
Mean comet tail fluorescence intensity across the total comet tail 
area
Percentage of DNA in the comet tail representative of the total 
damaged DNA migrated away from the cell's nucleus
An overall measure of displacement of damaged DNA from the 
nucleus of the cell (Tail DNA% X Length o f Tail)
An alternative measure of 'Tail moment' (Tail DNA% X Tail Moment 
Length)
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APPENDIX 5
Array plate layout and list of genes included
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Well Symbol Description
A01 ALB Albumin
A02 ALOX12 Arachidonate 12-lipoxygenase
A03 ANGPTL7 Angiopoietin-like 7
A04 AOX1 Aldehyde oxidase 1
A05 APOE Apolipoprotein E
A06 ATOX1 ATX1 antioxidant protein 1 homolog (yeast)
A07 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3
A08 CAT Catalase
A09 CCL5 Chemokine (C-C motif) ligand 5
A10 CCS Copper chaperone for superoxide dismutase
A l l CSDE1 Cold shock domain containing E l, RNA-binding
A12 CYBA Cytochrome b-245, alpha polypeptide
BOl CYGB Cytoglobin
B02 DGKK Diacylglycerol kinase, kappa
B03 DHCR24 24-dehydrocholesterol reductase
B04 DUOX1 Dual oxidase 1
B05 DUOX2 Dual oxidase 2
B06 DUSP1 Dual specificity phosphatase 1
B07 EPHX2 Epoxide hydrolase 2, cytoplasmic
B08 EPX Eosinophil peroxidase
B09 FOXM1 Forkhead box M l
BIO GLRX2 Glutaredoxin 2
B l l GPR156 G prote n-coupled receptor 156
B12 GPX1 Glutath one peroxidase 1
COl GPX2 Glutath one peroxidase 2 (gastrointestinal)
C02 GPX3 Glutath one peroxidase 3 (plasma)
C03 GPX4 Glutath one peroxidase 4 (phospholipid hydroperoxidase)
C04 GPX5 Glutath one peroxidase 5 (epididymal androgen-related protein)
C05 GPX6 Glutath one peroxidase 6 (olfactory)
C06 GPX7 Glutath one peroxidase 7
C07 GSR Glutath one reductase
C08 GSS Glutath one synthetase
C09 GSTZ1 Glutath one transferase zeta 1
CIO GTF2I General transcription factor Ili
C l l KRT1 Keratin 1
C12 LPO Lactoperoxidase
DOl MBL2 Mannose-binding lectin (protein C) 2, soluble
D02 MGST3 Microsomal glutathione S-transferase 3
D03 MPO Myeloperoxidase
D04 MPV17 MpV17 mitochondrial inner membrane protein
D05 MSRA Methionine sulfoxide reductase A
D06 MT3 Metallothionein 3
D07 MTL5 Metallothionein-like 5, testis-specific (tesmin)
D08 NCF1 Neutrophil cytosolic factor 1
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D09 NCF2 Neutrophil cytosolic factor 2
DIO NME5 Non-metastatic cells 5, protein expressed in (nucleoside- 
diphosphate kinase)
D l l NOS2 Nitric oxide synthase 2, inducible
D12 NOX5 NADPH oxidase, EF-hand calcium binding domain 5
EOl NUDT1 Nudix (nucleoside diphosphate linked moiety X)-type motif 1
E02 OXR1 Oxidation resistance 1
E03 OXSR1 Oxidative-stress responsive 1
E04 PDLIM1 PDZ and LIM domain 1
E05 IPCEF1 Interaction protein for cytohesin exchange factors 1
E06 PNKP Polynucleotide kinase 3'-phosphatase
E07 PRDX1 Peroxiredoxin 1
E08 PRDX2 Peroxiredoxin 2
E09 PRDX3 Peroxiredoxin 3
ElO PRDX4 Peroxiredoxin 4
E l l PRDX5 Peroxiredoxin 5
E12 PRDX6 Peroxiredoxin 6
FOl PREX1 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac 
exchange factor 1
F02 PRG3 Proteoglycan 3
F03 PRNP Prion protein
F04 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase)
F05 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)
F06 PXDN Peroxidasin homolog (Drosophila)
F07 PXDNL Peroxidasin homolog (Drosophila)-like
F08 RNF7 Ring finger protein 7
F09 SCARA3 Scavenger receptor class A, member 3
FIO SELS Selenoprotein S
F l l SEPP1 Selenoprotein P, plasma, 1
F12 SFTPD Surfactant protein D
GOl SGK2 Serum/glucocorticoid regulated kinase 2
G02 SIRT2 Sirtuin 2
G03 SOD1 Superoxide dismutase 1, soluble
G04 SOD2 Superoxide dismutase 2, mitochondrial
G05 SOD3 Superoxide dismutase 3, extracellular
G06 SRXN1 Sulfiredoxin 1
G07 STK25 Serine/threonine kinase 25
G08 TPO Thyroid peroxidase
G09 TTN Titin
GIO TXNDC2 Thioredoxin domain containing 2 (spermatozoa)
G i l TXNRD1 Thioredoxin reductase 1
G12 TXNRD2 Thioredoxin reductase 2
HOI B2M Beta-2-microglobulin
H02 HPRT1 Hypoxanthine phosphoribosyltransferase 1
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H03 RPL13A Ribosomal protein L13a
H04 GAPDH Glyceraldehyde-3-phosphate dehydrogenase
H05 ACTB Actin, beta
H06 HGDC Human Genomic DNA Contamination
H07 RTC Reverse Transcription Control
H08 RTC Reverse Transcription Control
H09 RTC Reverse Transcription Control
H10 PPC Positive PCR Control
H l l PPC Positive PCR Control
H12 PPC Positive PCR Control
190
APPENDIX 6
Raw data for PCR arrays
191
Appendix 4 PCR array data: Fold change between groups compared to control 
(L)
0 O D M
Position Symbol Fold Change (95%CI) P Fold Change (95%CI) P
A01 ALB 1.1179 (0.39, 1.85) 0.40 0.3617 ( 0.04, 0.68 ) 0.40
A02 ALOX12 0.9958 (0.52, 1.4 ) 0.93 1.6753 ( 0.72, 2.63 ) 0.16
A03 ANGPTL7 1.0344 (0.15, 1.92) 0.88 1.2265(0.24,2.21) 0.61
A04 AOX1 1.284 (0.41, 2.16) 0.33 1.4503 ( 0.53, 2.37 ) 0.26
A05 APOE 0.4976 (0.09, 0.90) 0.23 0.4933 ( 0.15, 0.83 ) 0.13
A06 ATOX1 1.254 (0.64, 1.87) 0.29 1.0913 ( 0.57, 1.61 ) 0.42
A07 BNIP3 1.1702 (0.49, 1.85) 0.35 1.0433 ( 0.46, 1.62 ) 0.51
A08 CAT 1.2298 (0.49, 1.97) 0.32 1.2927 ( 0.50, 2.09 ) 0.24
A09 CCL5 1.5625 (0.61, 2.52) 0.23 1.6758 ( 0.81, 2.54 ) 0.18
A10 CCS 1.0727 (0.61, 1.53) 0.54 1.2317 ( 0.63, 1.83 ) 0.33
A l l CSDE1 1.5133 (0.67, 2.35) 0.18 1.8196(0.64,3.00) 0.15
A12 CYBA 0.9105 (0.00001, 3.49) 0.52 0.1724 ( 0.00001, 0.69 ) 0.99
B01 CYGB 1.2195 (0.39, 2.05) 0.41 1.8125(0.35,3.28) 0.17
B02 DGKK 1.7295 (0.14, 3.32) 0.23 2.1521 ( 0.60, 3.70 ) 0.25
B03 DHCR24 1.7819 (0.73, 2.84) 0.13 1.6145 ( 0.60, 2.63 ) 0.21
B04 DUOX1 1.2612 (0.37, 2.15) 0.35 1.8658 ( 0.59, 3.15 ) 0.08
B05 DUOX2 0.9715 (0.19, 1.75) 0.46 2.1072 ( 0.19,4.03 ) 0.27
B06 DUSP1 1.4253 (0.00001, 3.00) 0.34 1.9288 ( 0.00001, 4.29 ) 0.25
B07 EPHX2 1.372 (0.52, 2.22) 0.32 1.5073 ( 0.63, 2.39 ) 0.17
B08 EPX 1.1322 (0.67, 1.60) 0.61 1.2433 ( 0.64, 1.85 ) 0.31
B09 FOXM1 1.2019 (0.55, 1.85) 0.39 1.1309 ( 0.63, 1.63 ) 0.57
BIO GLRX2 1.2404 (0.53, 1.95) 0.27 1.2843 ( 0.62, 1.95 ) 0.24
B l l GPR156 1.2281 (0.05, 2.40) 0.81 1.8693 ( 0.12, 3.62 ) 0.34
B12 GPX1 2.0383 (0.69, 3.38) 0.16 0.6747 ( 0.00001, 1.96 ) 0.29
C01 GPX2 0.8685 (0.40, 1.34) 0.75 1.1468(0.60, 1.69) 0.55
C02 GPX3 1.1353 (0.42, 1.85) 0.44 1.5708 ( 0.46, 2.68 ) 0.20
C03 GPX4 1.2254 (0.47, 1.99) 0.32 1.1092 ( 0.39, 1.82 ) 0.40
C04 GPX5 1.7268 (0.19, 3.27) 0.35 2.4415 ( 0.37, 4.51 ) 0.25
C05 GPX6 0.8715 (0.00001, 1.75) 0.89 2.4817 ( 0.32, 4.64 ) 0.19
C06 GPX7 1.1942 (0.63, 1.76) 0.33 1.0485 ( 0.56, 1.54 ) 0.46
C07 GSR 2.1519 (1.09, 3.21) 0.03 2.5617 ( 1.18, 3.94 ) 0.02
C08 GSS 1.1348 (0.61, 1.66) 0.36 1.1513 ( 0.61, 1.70 ) 0.34
C09 GSTZ1 0.9577 (0.45, 1.46) 0.58 1.0105 ( 0.50, 1.52 ) 0.52
CIO GTF2I 1.3588 (0.67, 2.05) 0.21 1.628(0.75,2.51) 0.17
C ll KRT1 1.3098 (0.00001, 3.39) 0.27 3.1587(0.08,6.24) 0.05
C12 LPO 1.2799 (0.00001, 2.81) 0.80 2.5321 ( 0.00001, 5.17 ) 0.31
D01 MBL2 1.7289 (0.00001, 4.09) 0.33 2.4117 ( 0.11, 4.71 ) 0.46
D02 MGST3 0.9745 (0.41, 1.54) 0.60 0.8496 ( 0.36, 1.34 ) 0.75
D03 MPO 1.75 (0.20, 3.30) 0.27 1.6397 ( 0.48, 2.80 ) 0.20
D04 MPV17 1.1417 (0.59, 1.69) 0.35 1.0239(0.59, 1.46) 0.47
D05 MSRA 1.2396 (0.58, 1.90) 0.31 1.2218(0.65, 1.80) 0.29
D06 MT3 0.647 (0.00001, 1.36) 0.54 0.6572 ( 0.17, 1.15 ) 0.71
D07 MTL5 1.2307 (0.55, 1.92) 0.34 1.3221 ( 0.68, 1.97 ) 0.25
D08 NCF1 1.773 (0.51, 3.03) 0.23 2.0089 ( 0.77, 3.24 ) 0.16
D09 NCF2 1.574 (0.17, 2.97) 0.27 1.9353 ( 0.62, 3.25 ) 0.21
DIO NME5 1.5331 (0.72, 2.34) 0.21 1.3656 ( 0.78, 1.95 ) 0.22
192
D ll NOS2 1.0021 ( 0.31, 1.69 ) 0.51 1.2781 ( 0.57, 1.98 ) 0.24
D12 NOX5 1.0069 ( 0.22, 1.79 ) 0.84 1.4021 (0.14,2.67) 0.22
E01 NUDT1 1.1948 ( 0.61, 1.78 ) 0.33 1.0693 ( 0.55, 1.59 ) 0.43
E02 OXR1 1.1867 ( 0.54, 1.84 ) 0.30 1.2511 ( 0.56, 1.94 ) 0.29
E03 OXSR1 1.4271 ( 0.57, 2.28 ) 0.22 1.6217 ( 0.63, 2.61 ) 0.19
E04 PDLIM1 1.5253 ( 0.76, 2.29 ) 0.18 1.7638 ( 0.74, 2.79 ) 0.22
E05 IPCEF1 1.3406 ( 0.00001, 2.73 ) 0.28 2.0201 ( 0.61, 3.43 ) 0.22
E06 PNKP 1.3042 ( 0.52, 2.09 ) 0.27 1.7765 ( 0.61, 2.94 ) 0.12
E07 PRDX1 1.3351 ( 0.71, 1.96 ) 0.20 1.3653 ( 0.75, 1.98 ) 0.23
E08 PRDX2 1.2548 ( 0.55, 1.96 ) 0.33 1.0468 ( 0.43, 1.67 ) 0.45
E09 PRDX3 1.3641 ( 0.59, 2.14 ) 0.22 1.1413 ( 0.57, 1.71 ) 0.35
E10 PRDX4 1.492 ( 0.79, 2.19 ) 0.16 1.5539 (0.87,2.24) 0.16
E ll PRDX5 1.0794 ( 0.62, 1.54 ) 0.43 0.9967 ( 0.53, 1.47 ) 0.48
E12 PRDX6 1.0168 ( 0.55, 1.48 ) 0.58 0.9192 ( 0.37, 1.47 ) 0.52
F01 PREX1 1.2472 ( 0.34, 2.16 ) 0.33 1.8366 ( 0.54, 3.13 ) 0.22
F02 PRG3 0.9849 ( 0.00001, 2.09 ) 0.93 2.763 ( 0.07, 5.45 ) 0.27
F03 PRNP 1.8128 ( 0.07, 3.56 ) 0.38 1.373 ( 0.29, 2.45 ) 0.83
F04 PTGS1 1.3193 ( 0.62, 2.02 ) 0.25 1.2079 ( 0.59, 1.83 ) 0.27
F05 PTGS2 1.7331(0.00001,4.29) 0.29 1.7102 ( 0.00001, 3.76 ) 0.30
F06 PXDN 1.2418 ( 0.53, 1.95 ) 0.29 1.1421 ( 0.54, 1.74 ) 0.39
F07 PXDNL 0.7038 ( 0.00001, 1.46 ) 0.38 0.6323 ( 0.10, 1.16 ) 0.15
F08 RNF7 1.1085 ( 0.59, 1.63 ) 0.38 0.8882 ( 0.47, 1.31 ) 0.60
F09 SCARA3 1.4675 ( 0.57, 2.37 ) 0.23 2.0141 ( 0.61, 3.41 ) 0.15
F10 SELS 1.2514 ( 0.63, 1.87 ) 0.30 1.5521 ( 0.58, 2.52 ) 0.24
F l l SEPP1 1.1333 ( 0.46, 1.80) 0.35 1.3185 ( 0.66, 1.97 ) 0.30
F12 SFTPD 1.12 ( 0.28, 1.96 ) 0.60 1.3591 ( 0.40, 2.31 ) 0.29
G01 SGK2 1.1225 ( 0.19, 2.06 ) 0.70 1.4311 ( 0.15, 2.71 ) 0.37
G02 SIRT2 1.1415 ( 0.48, 1.81 ) 0.40 1.5681 ( 0.52, 2.62 ) 0.19
G03 SOD1 1.1593 ( 0.56, 1.76 ) 0.37 1.0501 ( 0.52, 1.58 ) 0.45
G04 SOD2 1.3707 ( 0.21, 2.53 ) 0.29 1.8217 ( 0.43, 3.21 ) 0.25
G05 SOD3 1.7483 ( 0.65, 2.84 ) 0.15 2.267 ( 0.53, 4.00 ) 0.14
G06 SRXN1 1.6644 ( 0.55, 2.78 ) 0.18 2.3422 (0.61,4.08) 0.13
G07 STK25 1.2846 ( 0.57, 2.00 ) 0.27 1.4982 ( 0.55, 2.45 ) 0.23
G08 TPO 1.9349 ( 0.66, 3.21 ) 0.09 2.6356 ( 0.82, 4.45 ) 0.06
G09 TTN 1.1465 ( 0.61, 1.68 ) 0.34 1.0769 ( 0.64, 1.51 ) 0.49
G10 TXNDC2 1.1822 ( 0.15, 2.22 ) 0.49 1.9383 ( 0.56, 3.32 ) 0.26
G i l TXNRD1 1.8751 ( 0.81, 2.94 ) 0.14 1.8898 ( 1.01, 2.77 ) 0.11
G12 TXNRD2 1.1818 ( 0.58, 1.78 ) 0.34 0.926 ( 0.49, 1.36 ) 0.62
Fold change gene expression in hVAT samples. Green text highlights down-regulation by more than 
2-fold. Red text highlights up-regulation by more than 2-fold
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APPENDIX 7
Raw data for relative gene expression analysis
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Mouse gene expression analysis
GSR
HiRh Glucose/No LPS (HG) v High Glucose/LPS (HGL)
ACT (HG) = 18.12 -  10.49 ACT (HGL) = 18.71 -  10.94
= 7.63 =7.77
AACT = HGL ACT -  HG ACT 
= 7 .77-7 .63
= 0.14
^ _ 2-aact
X = 0.91
Low Glucose/No LPS (LG) v Low Glucose/LPS (LGL)
ACT (LG) = 18.19 -  11.20 ACT (LGL) = 18.32 -10.65
= 6.99 = 7.67
AACT = LGL ACT-LG ACT 
= 7 .67-6 .99
=  0.68
^ _ 2-aact
X = 0.62
195
GPX1
High Glucose/No LPS (HG) v High Glucose/LPS (HGL)
ACT (HG) = 19.53 -  10.49 ACT (HGL) = 19.63 -  10.94
= 9.04 = 8.69
AACT = HGL ACT-HG ACT 
= 8 .69-9 .04  
= -0.35
^ _ 2-aac t 
X = 1.27
Low Glucose/No LPS (LG) v Low Glucose/LPS (LGL)
ACT (LG) = 19.04 -  11.20 ACT (LGL) = 20.08 -  10.65
= 7.84 = 9.43
AACT = LGL ACT-LG ACT 
= 9 .43-7 .84
= 1.59
^ _ 2-aact
X = 0.33
196
Human gene expression analysis
GSR
LvO
ACT (L) = 24.18 -  17.54 ACT (0) = 23.94 -  17.25
= 6.64 = 6.69
AACT = 0  ACT-L ACT 
= 6 .69-6 .64
= 0.05
^ _ 2-aact
X = 0.97
LvODM
ACT (L) = 24.18 -  17.54 ACT (ODM) = 22.89 -  17.44
= 6.64 = 5.45
AACT = ODM ACT-L ACT 
= 5 .45-6 .64
= -1.19
^  2*aact
X = 2.28
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0  vODM
ACT (0) = 23.94-17.25  
= 6.69
L v (O + ODM)
ACT (L) = 24.18 -17 .54  
= 6.64
(L + 0 )v  ODM 
ACT (L + 0) = 24.07-17.40  
= 6.67
ACT (ODM) = 22.89-17.44  
= 5.45
AACT = ODM ACT- 0  ACT 
= 5 .45-6 .69  
= -1.24
^ _ 2“Aact
X = 2.36
ACT (0 + ODM) = 23.40 -  17.35 
= 6.05
AACT = (O + ODM) ACT -  L ACT 
= 6 .05-6 .64  
= -0.59
^ _ 2-aact
X = 1.51
ACT (ODM) = 22.89-17.44  
= 5.45
AACT = ODM ACT -  (L + 0) ACT 
= 5 .45-6 .67
=  - 1.22
^ _ 2'AACT
X = 2.33
198
GPX1
LvO
ACT (L) = 19.15 -  17.54 ACT (O) = 18.70 -  17.25
= 1.61 = 1.45
AACT = O ACT-L ACT
= 1 .45-1.61
= -0.16 
^ _ 2-aact
X = 1.12
L v ODM
ACT (L) = 19.15 -  17.54 ACT (ODM) = 18.20 -  17.57
= 1.61 =0.63
AACT = ODM ACT-L ACT 
= 0 .63-1 .61
= -0.98
^ _ 2-aact
X = 1.97
0  vODM
ACT (O) = 18.70 -  17.25 ACT (ODM) = 18.20 -  17.57
= 1.45 = 0.63
AACT = ODM ACT- 0  ACT 
= 0.63 -1 .45
= -0.82
 ^_ 2-aac t
X = 1.77
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L v (0  + ODM)
ACT (L) = 19.15-17.54  
= 1.61
ACT (0 + ODM) = 18.45 -  17.41 
= 1.04
(L + 0) v ODM 
ACT (L + O) = 18.94 
= 1.54
AACT = (O + ODM) ACT -  L ACT
= 1.04-1.61
= -0.57 
^ _ 2-aact
X = 1.48
-17.40 ACT (ODM) = 18.20-
= 0.63
AACT = ODM ACT -  (L + O) ACT 
= 0 .63-1 .54
= -0.91
^ _ 2-aact
X = 1.88
17.57
200
IL-6
LvO
ACT (L) = 26.78 -  17.54 ACT (0) = 24.90 -  17.25
= 9.24 = 7.65
AACT = O ACT-L ACT 
= 7 .65-9 .24  
= -1.59
^ _ 2-AACT
X = 3.01
LvODM
ACT (L) = 26.78 -  17.54 ACT (ODM) = 25.66 -  17.44
= 9.24 = 8.22
AACT = ODM ACT-L ACT 
= 8 .22-9 .24
=  - 1.02
^    2-AACT
X = 2.03
0  vODM
ACT (0) = 24.90 -  17.25 ACT (ODM) = 25.66 -  17.44
= 7.65 = 8.22
AACT = ODM ACT-O ACT 
= 8.22-7 .65  
= 0.57
^  _  2 -AACT
X = 0.67
201
L v (O + ODM)
ACT (L) = 26.78 -  17.54 
= 9.24
ACT (0 + ODM) = 25.29 -  17.35 
= 7.94
(L + 0) v ODM 
ACT (L + 0) = 25.90 
= 8.50
AACT = (0 + ODM) ACT -  L ACT 
= 7 .94-9 .24  
= -1.30
^  _  2 -AACT
X = 2.46
-17.40 ACT (ODM) = 25.66 -17 .44
=  8.22
AACT = ODM ACT -  (L + 0) ACT 
= 8 .22-8 .50
= -0.28
^ _ 2_aact
X = 1.21
202
PPARv
LvO
ACT (L) = 20.42 -  17.54 ACT (O) = 20.76 -  17.25
= 2.88 =3.51
AACT = O ACT-L ACT 
= 3 .51-2 .88
= 0.63
^ _ 2-aact
X = 0.65
LvODM
ACT (L) = 20.42 -  17.54 ACT (ODM) = 20.91 -  17.44
= 2.88 = 3.47
AACT = ODM ACT-L ACT 
= 3 .47-2 .88  
= 0.59
^   2 "AACT
X = 0.66
O v ODM
ACT (0) = 20.76 -  17.25 ACT (ODM) = 20.91 -  17.44
= 3.51 = 3.47
AACT = ODM ACT-O ACT 
= 3 .47-3 .51  
= -0.04
^  _  2 -AACT
X = 1.03
203
L v (0  + ODM)
ACT (L) = 20.42 -  17.54 ACT (0  + ODM) = 20.84 -  17.35
= 2.88 = 3.49
AACT = (0 + ODM) ACT -  L ACT 
= 3 .49-2 .88
= 0.61
^ _ 2-aact
X = 0.66
(L + 0) v ODM
ACT (L + O) = 20.58 -  17.40 ACT (ODM) = 20.91 -  17.44
= 3.18 =3.47
AACT = ODM ACT -  (L + O) ACT 
= 3 .47-3 .18  
= 0.29
^ _ 2-AACT
X = 0.82
204
APPENDIX 8
List of published abstracts
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Jones DA, Prior SL, Baxter JN, Barry JD, Bain SC, Stephens JW (2013) Comet analysis 
of visceral fat samples from patients with obesity and Type 2 diabetes.
Diabetes UK APC 2013, Diab. Med. 2013, 30, Suppl 1, P63
5th International Congress on Prediabetes and the Metabolic Syndrome 2013
Jones DA, Prior SL, Baxter JN, Bain SC, Stephens JW (2012) Oxidative and RNA 
damage in visceral fat samples from patients with obesity and Type 2 diabetes.
Diabetes UK APC 2012. Diab. M ed . 2012, 29, Suppl 1, P70
Welsh Endocrine and Diabetes Society Meeting 2012
Jones DA, Prior SL, Baxter JN, Bain SC, Stephens JW (2011) Obesity-related type 2 
diabetes is associated with reduced gene expression of GPxl in visceral adipose 
tissue.
Diabetes UK APC 2011. Diab. Med. 2011, 28, Suppl 1, P47 
Welsh Endocrine and Diabetes Society Meeting 2011
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Company addresses
207
Company addresses
Ambion Inc.
http://www.invitrogen.com/site/us/en/home/brands/ambion. html?CID=fl-ambion
Bioline
https://www.bioline.eom/h uk.asp 
BioRad
http://www.bio-rad.com 
BMG Labtech 
http://www.bmglabtech.com 
Cambridge Bioscience 
http://www.bioscience.co.uk/home 
Cell Biolabs
http://www.cellbiolabs.com 
Eurofins MWG Operon 
http://www.eurofinsgenomics.eu 
Invitrogen
http://www.invitrogen.com/site/us/en/home.html
Millipore
http://www.millipore.com 
MP Biomedicals
http://www.mpbio.com/GB/Pages/Default.aspx
Qiagen
http://www.qiagen.com
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Sigma-Aldrich
http://www.sigmaaldrich.com/united-kingdom.html 
Source Bioscience 
http://www.sourcebioscience.com 
Thermo Scientific
http://www.thermoscientific.com/ecomm/servlet/home?storeld=11152
Zeiss
http://corporate.zeiss.com/countrv-page/en gb/home.html
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